HECTRE failed to produce a cdf for the PDF located at /Users/jan535/code/HECTRE/hectre/tests/test_data/292_bissonnette_2019.pdfdata
HECTRE Performance Evaluation Report¶
297_guttman_2019¶
Control rows matched by test output: 5 of 100
Literature data accuracy: 78.20%
Clinical data accuracy: 4.26%
Clinical data accuracy (drop unmatched): 85.13%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| upadacitinib | 30 | oncedaily | easi90 | 16 | 4 | c72t4 | test | Double-Blind | TRUE | Upadacitinib | Janus kinase inhibitor | 30 | mg | Oral | Once Daily | 42 | 42 | 21 | ITT | NRI | NRI | 16 | WK | EASI-90 | Percent | 50.0 | Percent | 52 | 39.9 | YR | |||||||||||||||||||||||||
| 30.0 | qd | easi90 | 16 | 72 | c72t4 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 21.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 90 | 50.0 | percent | 95%CI | 35.177 | 64.82300000000001 | 52.0 | 39.9 | YR | |||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 98 | 67 | 100 | 100 | 17 | 0 | 100 | 67 | 67 | 100 | 6 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | |||||||
| 15 | qd | easi75 | 16 | 0 | c57t0 | test | Double-Blind | TRUE | Upadacitinib | Janus kinase inhibitor | 15 | mg | Oral | QD | 42 | 42 | 32 | ITT | Cochran-Mantel-Haenszel test, adjusted for stratum (geographic region) | NRI | 16 | WK | EASI-75 | Percent | 76 | percent | 95% CI | 61 | 87 | 71 | 38.5 | YR | |||||||||||||||||||||||
| 15.0 | qd | easi75 | 16 | 57 | c57t0 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 22.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 75 | 52.4 | percent | 95%CI | 41.898 | 67.194 | 71.0 | 38.5 | YR | |||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 98 | 67 | 100 | 100 | 100 | 0 | 100 | 67 | 33 | 100 | 59 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 25 | 25 | 100 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | |||||||
| 30 | oncedaily | easi75 | 16 | 2 | c52t2 | test | Double-Blind | TRUE | Upadacitinib | Janus kinase inhibitor | 30 | mg | Oral | Once Daily | 42 | 42 | 32 | ITT | NRI | NRI | 16 | WK | EASI-75 | Percent | 76 | Percent | 95% CI | 61 | 87 | 52 | 39.9 | YR | |||||||||||||||||||||||
| 30.0 | qd | easi75 | 16 | 52 | c52t2 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 29.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 75 | 69.0 | percent | 95%CI | 55.336 | 83.4 | 52.0 | 39.9 | YR | |||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 98 | 67 | 100 | 100 | 17 | 0 | 100 | 67 | 33 | 100 | 6 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 33 | 100 | 100 | 100 | 25 | 33 | 100 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | |||||||
| 15 | qd | easi50 | 16 | 1 | c37t1 | test | Double-Blind | TRUE | Upadacitinib | Janus kinase inhibitor | 15 | mg | Oral | QD | 42 | 42 | 26 | ITT | Cochran-Mantel-Haenszel test, adjusted for stratum (geographic region) | NRI | 16 | WK | EASI-50 | Percent | 61.9 | Percent | 95% CI | 46.4 | 75.8 | 71 | 38.5 | YR | |||||||||||||||||||||||
| 15.0 | qd | easi50 | 16 | 37 | c37t1 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 30.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 50 | 71.4 | percent | 95%CI | 57.708 | 85.376 | 71.0 | 38.5 | YR | |||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 98 | 67 | 100 | 100 | 100 | 0 | 100 | 67 | 0 | 100 | 59 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 25 | 100 | 100 | 100 | 20 | 60 | 100 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | |||||||
| 30 | oncedaily | easi50 | 16 | 3 | c32t3 | test | Double-Blind | TRUE | Upadacitinib | Janus kinase inhibitor | 30 | mg | Oral | Once Daily | 42 | 42 | 30 | ITT | Cochran-Mantel-Haenszel test, adjusted for stratum (geographic region) | NRI | 16 | WK | EASI-50 | Percent | 71.4 | percent | 95% CI | 55.4 | 84.3 | 52 | 39.9 | YR | |||||||||||||||||||||||
| 30.0 | qd | easi50 | 16 | 32 | c32t3 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 35.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 50 | 83.3 | percent | 95%CI | 71.937 | 94.466 | 52.0 | 39.9 | YR | |||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 98 | 67 | 100 | 100 | 17 | 0 | 100 | 67 | 33 | 100 | 59 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 25 | 100 | 100 | 100 | 20 | 40 | 100 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | |||||||
| 7.5 | qd | scorad | 8 | 92 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 39.0 | ITT | ANCOVA | LOCF | 8 | WK | SCORAD | Mean | -35.4 | 5.53 | SE | 67.0 | 41.5 | YR | ||||||||||||||||||||||||||
| 16 | 93 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 39.0 | ITT | ANCOVA | LOCF | 16 | WK | SCORAD | Mean | -32.5 | 5.66 | SE | 67.0 | 41.5 | YR | |||||||||||||||||||||||||||||
| 0 | 91 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | ITT | ANCOVA | LOCF | 0 | WK | SCORAD | Mean | 0.0 | 67.0 | 41.5 | YR | |||||||||||||||||||||||||||||||
| easi90 | 8 | 80 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 4.0 | ITT | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 90 | 9.5 | percent | 95%CI | 0.198 | 17.985000000000003 | 67.0 | 41.5 | YR | ||||||||||||||||||||||||||
| 4 | 79 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 5.0 | ITT | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 90 | 11.759 | percent | 95%CI | 1.878 | 18.874 | 67.0 | 41.5 | YR | |||||||||||||||||||||||||||
| 2 | 78 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 2.0 | ITT | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 90 | 5.089 | percent | 95%CI | -0.84 | 11.018 | 67.0 | 41.5 | YR | |||||||||||||||||||||||||||
| 16 | 82 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 6.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 90 | 14.3 | percent | 95%CI | 4.095 | 24.505 | 67.0 | 41.5 | YR | |||||||||||||||||||||||||||
| 12 | 81 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 5.0 | ITT | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 90 | 11.56 | percent | 95%CI | 2.0749999999999997 | 21.443 | 67.0 | 41.5 | YR | |||||||||||||||||||||||||||
| easi75 | 8 | 60 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 13.0 | ITT | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 75 | 31.0 | percent | 95%CI | 16.996 | 44.664 | 67.0 | 41.5 | YR | ||||||||||||||||||||||||||
| 4 | 59 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 13.0 | ITT | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 75 | 30.83 | percent | 95%CI | 16.996 | 44.664 | 67.0 | 41.5 | YR | |||||||||||||||||||||||||||
| 2 | 58 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 6.0 | ITT | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 75 | 13.834 | percent | 95%CI | 6.720000000000001 | 19.368 | 67.0 | 41.5 | YR | |||||||||||||||||||||||||||
| 16 | 62 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 12.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 75 | 28.6 | percent | 95%CI | 18.578000000000003 | 37.155 | 67.0 | 41.5 | YR | |||||||||||||||||||||||||||
| 12 | 61 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 13.0 | ITT | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 75 | 30.435 | percent | 95%CI | 18.578000000000003 | 44.664 | 67.0 | 41.5 | YR | |||||||||||||||||||||||||||
| easi50 | 8 | 40 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 23.0 | ITT | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 50 | 54.8 | percent | 95%CI | 39.526 | 69.961 | 67.0 | 41.5 | YR | ||||||||||||||||||||||||||
| 4 | 39 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 22.0 | ITT | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 50 | 52.569 | percent | 95%CI | 37.154 | 67.589 | 67.0 | 41.5 | YR | |||||||||||||||||||||||||||
| 2 | 38 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 12.0 | ITT | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 50 | 28.063 | percent | 95%CI | 15.02 | 42.293 | 67.0 | 41.5 | YR | |||||||||||||||||||||||||||
| 16 | 42 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 21.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 50 | 50.0 | percent | 95%CI | 34.783 | 65.613 | 67.0 | 41.5 | YR | |||||||||||||||||||||||||||
| 12 | 41 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 20.0 | ITT | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 50 | 47.431 | percent | 95%CI | 32.411 | 62.846 | 67.0 | 41.5 | YR | |||||||||||||||||||||||||||
| easi100 | 16 | 1 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | 1.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 100 | 2.4 | percent | 95%CI | 0.0 | 6.819 | 67.0 | 41.5 | YR | ||||||||||||||||||||||||||
| easi | 8 | 19 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | ITT | ANCOVA | LOCF | 8 | WK | EASI | Mean | 31.4 | 0-72 score | 15.8 | SD | Mean | -43.7 | 6.09 | SE | 67.0 | 41.5 | YR | |||||||||||||||||||||||
| 4 | 18 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | ITT | ANCOVA | LOCF | 4 | WK | EASI | Mean | 31.4 | 0-72 score | 15.8 | SD | Mean | -51.053 | 5.527 | SE | 67.0 | 41.5 | YR | |||||||||||||||||||||||||
| 2 | 17 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | ITT | ANCOVA | LOCF | 2 | WK | EASI | Mean | 31.4 | 0-72 score | 15.8 | SD | Mean | -39.474 | 5.264 | SE | 67.0 | 41.5 | YR | ||||||||||||||||||||||||
| 16 | 21 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | ITT | ANCOVA | LOCF | 16 | WK | EASI | Mean | 31.4 | 0-72 score | 15.8 | SD | Mean | -39.4 | 6.24 | SE | 67.0 | 41.5 | YR | ||||||||||||||||||||||||
| 12 | 20 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | ITT | ANCOVA | LOCF | 12 | WK | EASI | Mean | 31.4 | 0-72 score | 15.8 | SD | Mean | -40.527 | 6.316000000000001 | SE | 67.0 | 41.5 | YR | |||||||||||||||||||||||||
| 0 | 16 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 7.5 | MG | ORAL | QD | TAB | 42 | 42.0 | ITT | ANCOVA | LOCF | 0 | WK | EASI | Mean | 31.4 | 0-72 score | 15.8 | SD | Mean | 0.0 | 67.0 | 41.5 | YR | ||||||||||||||||||||||||||
| 30.0 | qd | scorad | 8 | 98 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 40.0 | ITT | ANCOVA | LOCF | 8 | WK | SCORAD | Mean | -65.3 | 5.52 | SE | 52.0 | 39.9 | YR | ||||||||||||||||||||||||||
| 16 | 99 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 40.0 | ITT | ANCOVA | LOCF | 16 | WK | SCORAD | Mean | -60.4 | 5.65 | SE | 52.0 | 39.9 | YR | |||||||||||||||||||||||||||||
| 0 | 97 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | ITT | ANCOVA | LOCF | 0 | WK | SCORAD | Mean | 0.0 | 52.0 | 39.9 | YR | |||||||||||||||||||||||||||||||
| easi90 | 8 | 70 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 19.0 | ITT | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 90 | 45.2 | percent | 95%CI | 30.238 | 59.881 | 52.0 | 39.9 | YR | ||||||||||||||||||||||||||
| 4 | 69 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 14.0 | ITT | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 90 | 33.498999999999995 | percent | 95%CI | 21.641 | 47.727 | 52.0 | 39.9 | YR | |||||||||||||||||||||||||||
| 2 | 68 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 4.0 | ITT | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 90 | 9.437 | percent | 95%CI | 0.742 | 18.132 | 52.0 | 39.9 | YR | |||||||||||||||||||||||||||
| 12 | 71 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 19.0 | ITT | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 90 | 45.157 | percent | 95%CI | 29.744 | 60.178 | 52.0 | 39.9 | YR | |||||||||||||||||||||||||||
| easi75 | 8 | 50 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 34.0 | ITT | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 75 | 81.0 | percent | 95%CI | 69.17 | 92.886 | 52.0 | 39.9 | YR | ||||||||||||||||||||||||||
| 4 | 49 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 33.0 | ITT | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 75 | 78.65700000000001 | percent | 95%CI | 66.00800000000001 | 91.305 | 52.0 | 39.9 | YR | |||||||||||||||||||||||||||
| 2 | 48 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 14.0 | ITT | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 75 | 33.202 | percent | 95%CI | 24.111 | 47.431 | 52.0 | 39.9 | YR | |||||||||||||||||||||||||||
| 12 | 51 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 32.0 | ITT | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 75 | 75.89 | percent | 95%CI | 65.218 | 89.32900000000001 | 52.0 | 39.9 | YR | |||||||||||||||||||||||||||
| easi50 | 8 | 30 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 39.0 | ITT | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 50 | 92.9 | percent | 95%CI | 85.376 | 100.0 | 52.0 | 39.9 | YR | ||||||||||||||||||||||||||
| 4 | 29 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 36.0 | ITT | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 50 | 85.376 | percent | 95%CI | 75.099 | 96.443 | 52.0 | 39.9 | YR | |||||||||||||||||||||||||||
| 2 | 28 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 25.0 | ITT | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 50 | 59.289 | percent | 95%CI | 45.059 | 74.308 | 52.0 | 39.9 | YR | |||||||||||||||||||||||||||
| 12 | 31 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 39.0 | ITT | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 50 | 92.885 | percent | 95%CI | 85.376 | 100.0 | 52.0 | 39.9 | YR | |||||||||||||||||||||||||||
| easi100 | 16 | 3 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 10.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 100 | 24.0 | percent | 95%CI | 10.607 | 36.742999999999995 | 52.0 | 39.9 | YR | ||||||||||||||||||||||||||
| easi | 8 | 7 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | ITT | ANCOVA | LOCF | 8 | WK | EASI | Mean | 28.2 | 0-72 score | 11.6 | SD | Mean | -82.8 | 5.98 | SE | 52.0 | 39.9 | YR | |||||||||||||||||||||||
| 4 | 6 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | ITT | ANCOVA | LOCF | 4 | WK | EASI | Mean | 28.2 | 0-72 score | 11.6 | SD | Mean | -77.895 | 5.264 | SE | 52.0 | 39.9 | YR | |||||||||||||||||||||||||
| 2 | 5 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | ITT | ANCOVA | LOCF | 2 | WK | EASI | Mean | 28.2 | 0-72 score | 11.6 | SD | Mean | -58.948 | 4.737 | SE | 52.0 | 39.9 | YR | |||||||||||||||||||||||||
| 16 | 9 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | ITT | ANCOVA | LOCF | 16 | WK | EASI | Mean | 28.2 | 0-72 score | 11.6 | SD | Mean | -74.4 | 6.13 | SE | 52.0 | 39.9 | YR | ||||||||||||||||||||||||
| 12 | 8 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | ITT | ANCOVA | LOCF | 12 | WK | EASI | Mean | 28.2 | 0-72 score | 11.6 | SD | Mean | -82.632 | 6.316000000000001 | SE | 52.0 | 39.9 | YR | |||||||||||||||||||||||||
| 0 | 4 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 42 | 42.0 | ITT | ANCOVA | LOCF | 0 | WK | EASI | Mean | 28.2 | 0-72 score | 11.6 | SD | Mean | 0.0 | 52.0 | 39.9 | YR | ||||||||||||||||||||||||||
| 15.0 | qd | scorad | 8 | 95 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 36.0 | ITT | ANCOVA | LOCF | 8 | WK | SCORAD | Mean | -44.1 | 5.69 | SE | 71.0 | 38.5 | YR | ||||||||||||||||||||||||||
| 16 | 96 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 36.0 | ITT | ANCOVA | LOCF | 16 | WK | SCORAD | Mean | -46.9 | 5.82 | SE | 71.0 | 38.5 | YR | |||||||||||||||||||||||||||||
| 0 | 94 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | ITT | ANCOVA | LOCF | 0 | WK | SCORAD | Mean | 0.0 | 71.0 | 38.5 | YR | |||||||||||||||||||||||||||||||
| easi90 | 8 | 75 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 11.0 | ITT | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 90 | 26.2 | percent | 95%CI | 12.846 | 39.328 | 71.0 | 38.5 | YR | ||||||||||||||||||||||||||
| 4 | 74 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 10.0 | ITT | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 90 | 23.617 | percent | 95%CI | 11.76 | 36.66 | 71.0 | 38.5 | YR | |||||||||||||||||||||||||||
| 2 | 73 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 2.0 | ITT | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 90 | 4.694 | percent | 95%CI | -1.63 | 11.018 | 71.0 | 38.5 | YR | |||||||||||||||||||||||||||
| 16 | 77 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 11.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 90 | 26.2 | percent | 95%CI | 13.27 | 39.129999999999995 | 71.0 | 38.5 | YR | |||||||||||||||||||||||||||
| 12 | 76 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 13.0 | ITT | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 90 | 32.114999999999995 | percent | 95%CI | 19.071 | 47.53 | 71.0 | 38.5 | YR | |||||||||||||||||||||||||||
| easi75 | 8 | 55 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 22.0 | ITT | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 75 | 52.4 | percent | 95%CI | 37.155 | 67.589 | 71.0 | 38.5 | YR | ||||||||||||||||||||||||||
| 4 | 54 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 18.0 | ITT | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 75 | 42.293 | percent | 95%CI | 27.668 | 57.708 | 71.0 | 38.5 | YR | |||||||||||||||||||||||||||
| 2 | 53 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 11.0 | ITT | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 75 | 25.297 | percent | 95%CI | 19.368 | 39.131 | 71.0 | 38.5 | YR | |||||||||||||||||||||||||||
| 12 | 56 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 21.0 | ITT | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 75 | 49.803 | percent | 95%CI | 34.782999999999994 | 63.242 | 71.0 | 38.5 | YR | |||||||||||||||||||||||||||
| easi50 | 8 | 35 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 30.0 | ITT | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 50 | 71.4 | percent | 95%CI | 58.103 | 85.376 | 71.0 | 38.5 | YR | ||||||||||||||||||||||||||
| 4 | 34 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 31.0 | ITT | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 50 | 72.727 | percent | 95%CI | 60.474 | 83.795 | 71.0 | 38.5 | YR | |||||||||||||||||||||||||||
| 2 | 33 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 24.0 | ITT | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 50 | 56.127 | percent | 95%CI | 44.664 | 72.332 | 71.0 | 38.5 | YR | |||||||||||||||||||||||||||
| 12 | 36 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 33.0 | ITT | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 50 | 78.656 | percent | 95%CI | 66.008 | 85.771 | 71.0 | 38.5 | YR | |||||||||||||||||||||||||||
| easi100 | 16 | 2 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | 4.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 100 | 9.5 | percent | 95%CI | 0.379 | 18.182 | 71.0 | 38.5 | YR | ||||||||||||||||||||||||||
| easi | 8 | 13 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | ITT | ANCOVA | LOCF | 8 | WK | EASI | Mean | 31.4 | 0-72 score | 12.3 | SD | Mean | -65.4 | 5.97 | SE | 71.0 | 38.5 | YR | |||||||||||||||||||||||
| 4 | 12 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | ITT | ANCOVA | LOCF | 4 | WK | EASI | Mean | 31.4 | 0-72 score | 12.3 | SD | Mean | -65.264 | 5.0 | SE | 71.0 | 38.5 | YR | |||||||||||||||||||||||||
| 2 | 11 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | ITT | ANCOVA | LOCF | 2 | WK | EASI | Mean | 31.4 | 0-72 score | 12.3 | SD | Mean | -54.737 | 5.0 | SE | 71.0 | 38.5 | YR | |||||||||||||||||||||||||
| 16 | 15 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | ITT | ANCOVA | LOCF | 16 | WK | EASI | Mean | 31.4 | 0-72 score | 12.3 | SD | Mean | -61.7 | 6.12 | SE | 71.0 | 38.5 | YR | |||||||||||||||||||||||||
| 12 | 14 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | ITT | ANCOVA | LOCF | 12 | WK | EASI | Mean | 31.4 | 0-72 score | 12.3 | SD | Mean | -66.843 | 6.053 | SE | 71.0 | 38.5 | YR | |||||||||||||||||||||||||
| 0 | 10 | control | Double-Blind | True | upadacitinib | Janus kinase inhibitors | 15.0 | MG | ORAL | QD | TAB | 42 | 42.0 | ITT | ANCOVA | LOCF | 0 | WK | EASI | Mean | 31.4 | 0-72 score | 12.3 | SD | Mean | 0.0 | 71.0 | 38.5 | YR | ||||||||||||||||||||||||||
| placebo | 0.0 | qd | scorad | 8 | 89 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 33.0 | ITT | ANCOVA | LOCF | 8 | WK | SCORAD | Mean | -7.0 | 5.84 | SE | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||
| 16 | 90 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 33.0 | ITT | ANCOVA | LOCF | 16 | WK | SCORAD | Mean | -12.4 | 5.97 | SE | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||||||
| 0 | 88 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | ITT | ANCOVA | LOCF | 0 | WK | SCORAD | Mean | 0.0 | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||||||||
| easi90 | 8 | 85 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 0.0 | ITT | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 90 | 0.0 | percent | 95%CI | -13.24 | 13.24 | 59.0 | 39.9 | YR | |||||||||||||||||||||||||||
| 4 | 84 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 0.0 | ITT | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 90 | 0.296 | percent | 95%CI | -9.188 | 9.78 | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||||
| 2 | 83 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 0.0 | ITT | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 90 | 0.346 | percent | 59.0 | 39.9 | YR | |||||||||||||||||||||||||||||||
| 16 | 87 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 1.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 90 | 2.4 | percent | 95%CI | -2.32 | 7.12 | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||||
| 12 | 86 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 2.0 | ITT | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 90 | 4.8420000000000005 | percent | 59.0 | 39.9 | YR | |||||||||||||||||||||||||||||||
| easi75 | 8 | 65 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 3.0 | ITT | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 75 | 7.3 | percent | 95%CI | -1.974999999999998 | 15.415 | 59.0 | 39.9 | YR | |||||||||||||||||||||||||||
| 4 | 64 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 0.0 | ITT | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 75 | 0.0 | percent | 59.0 | 39.9 | YR | |||||||||||||||||||||||||||||||
| 2 | 63 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 1.0 | ITT | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 75 | 1.977 | percent | 95%CI | -2.7660000000000005 | 6.720000000000001 | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||||
| 16 | 67 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 4.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 75 | 9.8 | percent | 95%CI | 4.975 | 14.625 | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||||
| 12 | 66 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 4.0 | ITT | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 75 | 9.882 | percent | 95%CI | 0.791 | 16.996 | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||||
| easi50 | 8 | 45 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 9.0 | ITT | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 50 | 22.0 | percent | 95%CI | 9.091 | 34.783 | 59.0 | 39.9 | YR | |||||||||||||||||||||||||||
| 4 | 44 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 3.0 | ITT | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 50 | 7.115 | percent | 95%CI | -1.1849999999999987 | 15.415 | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||||
| 2 | 43 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 3.0 | ITT | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 50 | 7.115 | percent | 95%CI | -0.7899999999999991 | 15.02 | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||||
| 16 | 47 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 9.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 50 | 22.0 | percent | 95%CI | 9.486 | 34.783 | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||||
| 12 | 46 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 8.0 | ITT | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 50 | 19.368 | percent | 95%CI | 7.51 | 31.621 | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||||
| easi100 | 16 | 0 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | 0.0 | ITT | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 100 | 0.0 | percent | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||||||
| easi | 8 | 25 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 39.0 | ITT | ANCOVA | LOCF | 8 | WK | EASI | Mean | 32.6 | 0-72 score | 14.5 | SD | Mean | -17.5 | 6.27 | SE | 59.0 | 39.9 | YR | ||||||||||||||||||||||||
| 4 | 24 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | ITT | ANCOVA | LOCF | 4 | WK | EASI | Mean | 32.6 | 0-72 score | 14.5 | SD | Mean | -11.579 | 5.527 | SE | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||
| 2 | 23 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | ITT | ANCOVA | LOCF | 2 | WK | EASI | Mean | 32.6 | 0-72 score | 14.5 | SD | Mean | -8.948 | 5.527 | SE | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||
| 16 | 27 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 39.0 | ITT | ANCOVA | LOCF | 16 | WK | EASI | Mean | 32.6 | 0-72 score | 14.5 | SD | Mean | -23.0 | 6.42 | SE | 59.0 | 39.9 | YR | |||||||||||||||||||||||||
| 12 | 26 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | ITT | ANCOVA | LOCF | 12 | WK | EASI | Mean | 32.6 | 0-72 score | 14.5 | SD | Mean | -21.053 | 6.316000000000001 | SE | 59.0 | 39.9 | YR | ||||||||||||||||||||||||||
| 0 | 22 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 41 | 41.0 | ITT | ANCOVA | LOCF | 0 | WK | EASI | Mean | 32.6 | 0-72 score | 14.5 | SD | Mean | 0.0 | 59.0 | 39.9 | YR |
299_gooderham_2019¶
Control rows matched by test output: 9 of 240
Literature data accuracy: 87.20%
Clinical data accuracy: 2.98%
Clinical data accuracy (drop unmatched): 79.57%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| abrocitinib | 200 | oncedaily | easi50 | 12 | 3 | c96t3 | test | Double-Blind | TRUE | Abrocitinib | Janus Kinase 1 Inhibitor | 200 | mg | Oral | Once Daily | 48 | 54 | 38 | FAS | Logistic regression model | NRI | 12 | WK | EASI-50 | Observed response | 79.2 | percent | 50.9 | 38.7 | YR | |||||||||||||||||||||||||
| 200.0 | qd | easi50 | 12 | 96 | c96t3 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 48.0 | 38.0 | FAS | 12 | WK | EASI 50 | 79.2 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 94 | 75 | 100 | 100 | 17 | 0 | 0 | 33 | 67 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 30mg | oncedaily | easi50 | 12 | 5 | c78t5 | test | Double-Blind | TRUE | Abrocitinib | Janus Kinase 1 Inhibitor | 30 mg | mg | Oral | Once Daily | 51 | 45 | 15 | FAS | Logistic regression model | NRI | 12 | WK | EASI-50 | Odds ratio | 1.36 | 90% CI | 0.65 | 2.82 | 43.1 | 37.6 | YR | ||||||||||||||||||||||||
| 30.0 | qd | easi50 | 12 | 78 | c78t5 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 45.0 | 15.0 | FAS | 12 | WK | EASI 50 | 33.3 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 94 | 44 | 100 | 100 | 17 | 0 | 100 | 67 | 67 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 50 | 0 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 100mg | oncedaily | easi50 | 12 | 7 | c69t7 | test | Double-Blind | TRUE | Abrocitinib | Janus Kinase 1 Inhibitor | 100 mg | mg | Oral | Once Daily | 54 | 54 | 30 | FAS | Logistic regression model | NRI | 12 | WK | EASI-50 | Odds ratio | 3.28 | 90% CI | 1.66 | 6.48 | 55.4 | 41.1 | YR | ||||||||||||||||||||||||
| 10.0 | qd | easi50 | 12 | 69 | c69t7 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 46.0 | 12.0 | FAS | 12 | WK | EASI 50 | 26.1 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 94 | 40 | 100 | 100 | 17 | 0 | 50 | 33 | 33 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 25 | 0 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 50 | 50 | 100 | |||||||
| placebo | oncedaily | easi50 | 12 | 1 | c60t1 | test | Double-Blind | TRUE | Placebo | Oral | Once Daily | 52 | 52 | 14 | FAS | Logistic regression model | NRI | 12 | WK | EASI-50 | Odds ratio | 0.96 | 90% CI | 0.45 | 2.03 | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||
| 0.0 | qd | easi50 | 12 | 60 | c60t1 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 52.0 | 14.0 | FAS | 12 | WK | EASI 50 | 26.9 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 100 | 50 | 67 | 67 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 50 | 0 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| abrocitinib | 200 | oncedaily | easi90 | 12 | 4 | c186t4 | test | Double-Blind | TRUE | Abrocitinib | Janus Kinase 1 Inhibitor | 200 | mg | Oral | Once Daily | 48 | 48 | 21 | FAS | Logistic regression model | NRI | 12 | WK | EASI-90 | Observed response, No. (%) | 21 (52.1) | percent | 50.9 | 38.7 | YR | |||||||||||||||||||||||||
| 200.0 | qd | easi90 | 12 | 186 | c186t4 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 48.0 | 25.0 | FAS | 12 | WK | EASI 90 | 52.1 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 94 | 75 | 100 | 100 | 17 | 0 | 0 | 67 | 33 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 73 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 100mg | oncedaily | easi90 | 12 | 8 | c159t8 | test | Double-Blind | TRUE | Abrocitinib | Janus Kinase 1 Inhibitor | 100 mg | mg | Oral | Once Daily | 54 | 54 | 14 | FAS | Logistic regression model | NRI | 12 | WK | EASI-90 | Odds ratio | 3.18 | 90% CI | 1.29 | 7.86 | 55.4 | 41.1 | YR | ||||||||||||||||||||||||
| 10.0 | qd | easi90 | 12 | 159 | c159t8 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 46.0 | 5.0 | FAS | 12 | WK | EASI 90 | 10.9 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 94 | 40 | 100 | 100 | 17 | 0 | 50 | 33 | 0 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 50 | 0 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 50 | 50 | 100 | |||||||
| 200 | oncedaily | easi75 | 12 | 2 | c141t2 | test | Double-Blind | TRUE | Abrocitinib | Janus Kinase 1 Inhibitor | 200 | mg | Oral | Once Daily | 48 | 48 | 31 | FAS | Logistic regression model | NRI | 12 | WK | EASI-75 | Observed response | 64.6 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||
| 200.0 | qd | easi75 | 12 | 141 | c141t2 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 48.0 | 31.0 | FAS | 12 | WK | EASI 75 | 64.6 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 94 | 75 | 100 | 100 | 17 | 0 | 0 | 67 | 67 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 100mg | oncedaily | easi75 | 12 | 6 | c114t6 | test | Double-Blind | TRUE | Abrocitinib | Janus Kinase 1 Inhibitor | 100 mg | mg | Oral | Once Daily | 54 | 54 | 22 | FAS | Logistic regression model | NRI | 12 | WK | EASI-75 | Observed response | 40.7 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||
| 10.0 | qd | easi75 | 12 | 114 | c114t6 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 46.0 | 8.0 | FAS | 12 | WK | EASI 75 | 17.4 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 94 | 40 | 100 | 100 | 17 | 0 | 50 | 33 | 0 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 25 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 50 | 50 | 100 | |||||||
| placebo | oncedaily | easi75 | 12 | 0 | c105t0 | test | Double-Blind | TRUE | Placebo | Oral | Once Daily | 52 | 52 | 8 | FAS | Logistic regression | NRI | 12 | WK | EASI-75 | Observed response | 15.4 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||
| 0.0 | qd | easi75 | 12 | 105 | c105t0 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 52.0 | 8.0 | FAS | 12 | WK | EASI 75 | 15.4 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 100 | 50 | 67 | 50 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| scorad | 8 | 195 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | 41.0 | FAS | MMRM | 8 | WK | SCORAD | Mean | 65.0 | 0-103 score | 12.1 | SD | Mean | -19.052 | 0-103 score | 18.574 | SD | Mean | -29.624 | 30.563 | SD | 37.5 | 42.6 | YR | ||||||||||||||||||||
| 6 | 194 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | 44.0 | FAS | MMRM | 6 | WK | SCORAD | Mean | 65.0 | 0-103 score | 12.1 | SD | Mean | -19.527 | 0-103 score | 16.787 | SD | Mean | -30.789 | 27.942 | SD | 37.5 | 42.6 | YR | |||||||||||||||||||||
| 4 | 193 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | 50.0 | FAS | MMRM | 4 | WK | SCORAD | Mean | 65.0 | 0-103 score | 12.1 | SD | Mean | -14.555 | 0-103 score | 16.641 | SD | Mean | -22.476 | 26.516 | SD | 37.5 | 42.6 | YR | |||||||||||||||||||||
| 2 | 192 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | 55.0 | FAS | MMRM | 2 | WK | SCORAD | Mean | 65.0 | 0-103 score | 12.1 | SD | Mean | -10.905 | 0-103 score | 15.416 | SD | Mean | -16.488 | 23.001 | SD | 37.5 | 42.6 | YR | |||||||||||||||||||||
| 16 | 199 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | 28.0 | FAS | MMRM | 16 | WK | SCORAD | Mean | 65.0 | 0-103 score | 12.1 | SD | Mean | -19.408 | 0-103 score | 22.174 | SD | Mean | -31.972 | 36.506 | SD | 37.5 | 42.6 | YR | |||||||||||||||||||||
| 14 | 198 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | 32.0 | FAS | MMRM | 14 | WK | SCORAD | Mean | 65.0 | 0-103 score | 12.1 | SD | Mean | -17.987 | 0-103 score | 22.089 | SD | Mean | -29.393 | 36.664 | SD | 37.5 | 42.6 | YR | |||||||||||||||||||||
| 13 | 197 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | 30.0 | FAS | MMRM | 13 | WK | SCORAD | Mean | 65.0 | 0-103 score | 12.1 | SD | Mean | -16.603 | 0-103 score | 21.385 | SD | Mean | -26.794 | 34.338 | SD | 37.5 | 42.6 | YR | |||||||||||||||||||||
| 12 | 196 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | 35.0 | FAS | MMRM | 12 | WK | SCORAD | Mean | 65.0 | 0-103 score | 12.1 | SD | Mean | -18.647 | 0-103 score | 20.019 | SD | Mean | -29.379 | 31.908 | SD | 37.5 | 42.6 | YR | |||||||||||||||||||||
| 50 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | 52.0 | FAS | MMRM | 12 | WK | SCORAD | Mean | 65.0 | 0-103 score | 12.1 | SD | LS Mean | -29.0 | 95%CI | -36.6 | -21.3 | 37.5 | 42.6 | YR | ||||||||||||||||||||||||||
| 1 | 191 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | 54.0 | FAS | MMRM | 1 | WK | SCORAD | Mean | 65.0 | 0-103 score | 12.1 | SD | Mean | -7.91 | 0-103 score | 12.463 | SD | Mean | -11.547 | 19.713 | SD | 37.5 | 42.6 | YR | |||||||||||||||||||||
| 0 | 190 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | 55.0 | FAS | MMRM | 0 | WK | SCORAD | Mean | 65.0 | 0-103 score | 12.1 | SD | Mean | 0.0 | 0-103 score | Mean | 0.0 | 37.5 | 42.6 | YR | |||||||||||||||||||||||||
| easi90 | 8 | 149 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 55.0 | 3.0 | FAS | 8 | WK | EASI 90 | 5.5 | percent | 37.5 | 42.6 | YR | ||||||||||||||||||||||||||||||||
| 6 | 148 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 55.0 | 4.0 | FAS | 6 | WK | EASI 90 | 7.3 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 4 | 147 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 55.0 | 1.0 | FAS | 4 | WK | EASI 90 | 1.8 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 2 | 146 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 55.0 | 0.0 | FAS | 2 | WK | EASI 90 | 0.0 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 16 | 153 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 28.0 | 4.0 | FAS | 16 | WK | EASI 90 | 14.3 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 14 | 152 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 32.0 | 5.0 | FAS | 14 | WK | EASI 90 | 15.6 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 13 | 151 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 30.0 | 3.0 | FAS | 13 | WK | EASI 90 | 10.0 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 12 | 150 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 52.0 | 5.0 | FAS | 12 | WK | EASI 90 | 9.6 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 1 | 145 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 54.0 | 0.0 | FAS | 1 | WK | EASI 90 | 0.0 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| easi75 | 8 | 104 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 55.0 | 11.0 | FAS | 8 | WK | EASI 75 | 20.0 | percent | 37.5 | 42.6 | YR | ||||||||||||||||||||||||||||||||
| 6 | 103 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 55.0 | 9.0 | FAS | 6 | WK | EASI 75 | 16.4 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 4 | 102 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 55.0 | 6.0 | FAS | 4 | WK | EASI 75 | 10.9 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 2 | 101 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 55.0 | 3.0 | FAS | 2 | WK | EASI 75 | 5.5 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 16 | 108 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 28.0 | 9.0 | FAS | 16 | WK | EASI 75 | 32.1 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 14 | 107 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 32.0 | 10.0 | FAS | 14 | WK | EASI 75 | 31.3 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 13 | 106 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 30.0 | 8.0 | FAS | 13 | WK | EASI 75 | 26.7 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 1 | 100 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 54.0 | 2.0 | FAS | 1 | WK | EASI 75 | 3.7 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| easi50 | 8 | 59 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 55.0 | 17.0 | FAS | 8 | WK | EASI 50 | 30.9 | percent | 37.5 | 42.6 | YR | ||||||||||||||||||||||||||||||||
| 6 | 58 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 55.0 | 20.0 | FAS | 6 | WK | EASI 50 | 36.4 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 4 | 57 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 55.0 | 15.0 | FAS | 4 | WK | EASI 50 | 27.3 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 2 | 56 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 55.0 | 15.0 | FAS | 2 | WK | EASI 50 | 27.3 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 16 | 63 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 28.0 | 12.0 | FAS | 16 | WK | EASI 50 | 42.9 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 14 | 62 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 32.0 | 12.0 | FAS | 14 | WK | EASI 50 | 37.5 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 13 | 61 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 30.0 | 13.0 | FAS | 13 | WK | EASI 50 | 43.3 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| 1 | 55 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 56 | 54.0 | 5.0 | FAS | 1 | WK | EASI 50 | 9.3 | percent | 37.5 | 42.6 | YR | |||||||||||||||||||||||||||||||||
| easi | 8 | 5 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | FAS | MMRM | 8 | WK | EASI | Mean | 25.4 | 0-72 score | 12.9 | SD | LS Mean | -32.5532 | 90%CI | -43.404 | -21.702 | 37.5 | 42.6 | YR | |||||||||||||||||||||||||
| 6 | 4 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | FAS | MMRM | 6 | WK | EASI | Mean | 25.4 | 0-72 score | 12.9 | SD | LS Mean | -35.3191 | 90%CI | -45.106 | -25.532 | 37.5 | 42.6 | YR | ||||||||||||||||||||||||||
| 4 | 3 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | FAS | MMRM | 4 | WK | EASI | Mean | 25.4 | 0-72 score | 12.9 | SD | LS Mean | -22.766 | 90%CI | -30.851 | -14.255 | 37.5 | 42.6 | YR | ||||||||||||||||||||||||||
| 2 | 2 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | FAS | MMRM | 2 | WK | EASI | Mean | 25.4 | 0-72 score | 12.9 | SD | LS Mean | -23.4043 | 90%CI | -31.277 | -16.17 | 37.5 | 42.6 | YR | ||||||||||||||||||||||||||
| 16 | 9 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | FAS | MMRM | 16 | WK | EASI | Mean | 25.4 | 0-72 score | 12.9 | SD | LS Mean | -32.5532 | 90%CI | -46.17 | -18.298 | 37.5 | 42.6 | YR | ||||||||||||||||||||||||||
| 14 | 8 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | FAS | MMRM | 14 | WK | EASI | Mean | 25.4 | 0-72 score | 12.9 | SD | LS Mean | -29.5745 | 90%CI | -42.979 | -16.809 | 37.5 | 42.6 | YR | ||||||||||||||||||||||||||
| 13 | 7 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | FAS | MMRM | 13 | WK | EASI | Mean | 25.4 | 0-72 score | 12.9 | SD | LS Mean | -22.766 | 90%CI | -34.681 | -10.638 | 37.5 | 42.6 | YR | ||||||||||||||||||||||||||
| 12 | 6 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | 52.0 | FAS | MMRM | 12 | WK | EASI | Mean | 25.4 | 0-72 score | 12.9 | SD | LS Mean | -35.2 | 90%CI | -46.1 | -24.4 | 37.5 | 42.6 | YR | |||||||||||||||||||||||||
| 1 | 1 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | FAS | MMRM | 1 | WK | EASI | Mean | 25.4 | 0-72 score | 12.9 | SD | LS Mean | -12.9787 | 90%CI | -19.787 | -6.17 | 37.5 | 42.6 | YR | ||||||||||||||||||||||||||
| 0 | 0 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | ORAL | QD | 55 | 55.0 | FAS | MMRM | 0 | WK | EASI | Mean | 25.4 | 0-72 score | 12.9 | SD | LS Mean | 0.0 | 37.5 | 42.6 | YR | ||||||||||||||||||||||||||||
| abrocitinib | 30.0 | qd | scorad | 8 | 215 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | 43.0 | FAS | MMRM | 8 | WK | SCORAD | Mean | 62.4 | 0-103 score | 13.0 | SD | Mean | -19.534 | 0-103 score | 18.71 | SD | Mean | -30.48 | 29.474 | SD | 43.1 | 37.6 | YR | ||||||||||||||||
| 6 | 214 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | 43.0 | FAS | MMRM | 6 | WK | SCORAD | Mean | 62.4 | 0-103 score | 13.0 | SD | Mean | -19.93 | 0-103 score | 17.597 | SD | Mean | -31.276 | 29.652 | SD | 43.1 | 37.6 | YR | ||||||||||||||||||||
| 4 | 213 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | 47.0 | FAS | MMRM | 4 | WK | SCORAD | Mean | 62.4 | 0-103 score | 13.0 | SD | Mean | -15.496 | 0-103 score | 16.48 | SD | Mean | -24.866 | 25.376 | SD | 43.1 | 37.6 | YR | ||||||||||||||||||||
| 2 | 212 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | 47.0 | FAS | MMRM | 2 | WK | SCORAD | Mean | 62.4 | 0-103 score | 13.0 | SD | Mean | -13.266 | 0-103 score | 14.527 | SD | Mean | -20.613 | 21.028 | SD | 43.1 | 37.6 | YR | ||||||||||||||||||||
| 16 | 219 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | 27.0 | FAS | MMRM | 16 | WK | SCORAD | Mean | 62.4 | 0-103 score | 13.0 | SD | Mean | -12.716 | 0-103 score | 15.939 | SD | Mean | -19.794 | 25.055 | SD | 43.1 | 37.6 | YR | ||||||||||||||||||||
| 14 | 218 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | 29.0 | FAS | MMRM | 14 | WK | SCORAD | Mean | 62.4 | 0-103 score | 13.0 | SD | Mean | -12.768 | 0-103 score | 13.691 | SD | Mean | -20.072 | 21.74 | SD | 43.1 | 37.6 | YR | ||||||||||||||||||||
| 13 | 217 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | 31.0 | FAS | MMRM | 13 | WK | SCORAD | Mean | 62.4 | 0-103 score | 13.0 | SD | Mean | -15.023 | 0-103 score | 16.157 | SD | Mean | -24.232 | 26.246 | SD | 43.1 | 37.6 | YR | ||||||||||||||||||||
| 12 | 216 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | 30.0 | FAS | MMRM | 12 | WK | SCORAD | Mean | 62.4 | 0-103 score | 13.0 | SD | Mean | -21.211 | 0-103 score | 17.677 | SD | Mean | -32.535 | 25.271 | SD | 43.1 | 37.6 | YR | ||||||||||||||||||||
| 52 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | 45.0 | FAS | MMRM | 12 | WK | SCORAD | Mean | 62.4 | 0-103 score | 13.0 | SD | LS Mean | -30.1 | 95%CI | -38.1 | -22.1 | 43.1 | 37.6 | YR | |||||||||||||||||||||||||
| 1 | 211 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | 49.0 | FAS | MMRM | 1 | WK | SCORAD | Mean | 62.4 | 0-103 score | 13.0 | SD | Mean | -8.388 | 0-103 score | 14.632 | SD | Mean | -13.068 | 21.075 | SD | 43.1 | 37.6 | YR | ||||||||||||||||||||
| 0 | 210 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | 50.0 | FAS | MMRM | 0 | WK | SCORAD | Mean | 62.4 | 0-103 score | 13.0 | SD | Mean | 0.0 | 0-103 score | Mean | 0.0 | 43.1 | 37.6 | YR | ||||||||||||||||||||||||
| easi90 | 8 | 167 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 4.0 | FAS | 8 | WK | EASI 90 | 8.0 | percent | 43.1 | 37.6 | YR | |||||||||||||||||||||||||||||||
| 6 | 166 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 7.0 | FAS | 6 | WK | EASI 90 | 14.0 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 4 | 165 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 4.0 | FAS | 4 | WK | EASI 90 | 8.0 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 2 | 164 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 2.0 | FAS | 2 | WK | EASI 90 | 4.0 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 16 | 171 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 27.0 | 1.0 | FAS | 16 | WK | EASI 90 | 3.7 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 14 | 170 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 29.0 | 0.0 | FAS | 14 | WK | EASI 90 | 0.0 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 13 | 169 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 31.0 | 1.0 | FAS | 13 | WK | EASI 90 | 3.2 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 12 | 168 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 45.0 | 0.0 | FAS | 12 | WK | EASI 90 | 0.0 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 1 | 163 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 2.0 | FAS | 1 | WK | EASI 90 | 4.0 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| easi75 | 8 | 122 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 11.0 | FAS | 8 | WK | EASI 75 | 22.0 | percent | 43.1 | 37.6 | YR | |||||||||||||||||||||||||||||||
| 6 | 121 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 9.0 | FAS | 6 | WK | EASI 75 | 18.0 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 4 | 120 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 10.0 | FAS | 4 | WK | EASI 75 | 20.0 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 2 | 119 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 3.0 | FAS | 2 | WK | EASI 75 | 6.0 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 16 | 126 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 27.0 | 1.0 | FAS | 16 | WK | EASI 75 | 3.7 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 14 | 125 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 29.0 | 2.0 | FAS | 14 | WK | EASI 75 | 6.9 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 13 | 124 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 31.0 | 4.0 | FAS | 13 | WK | EASI 75 | 12.9 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 12 | 123 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 45.0 | 6.0 | FAS | 12 | WK | EASI 75 | 13.3 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 1 | 118 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 3.0 | FAS | 1 | WK | EASI 75 | 6.0 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| easi50 | 8 | 77 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 20.0 | FAS | 8 | WK | EASI 50 | 40.0 | percent | 43.1 | 37.6 | YR | |||||||||||||||||||||||||||||||
| 6 | 76 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 20.0 | FAS | 6 | WK | EASI 50 | 40.0 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 4 | 75 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 18.0 | FAS | 4 | WK | EASI 50 | 36.0 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 2 | 74 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 12.0 | FAS | 2 | WK | EASI 50 | 24.0 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 16 | 81 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 27.0 | 9.0 | FAS | 16 | WK | EASI 50 | 33.3 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 14 | 80 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 29.0 | 11.0 | FAS | 14 | WK | EASI 50 | 37.9 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 13 | 79 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 31.0 | 14.0 | FAS | 13 | WK | EASI 50 | 45.2 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| 1 | 73 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 51 | 50.0 | 7.0 | FAS | 1 | WK | EASI 50 | 14.0 | percent | 43.1 | 37.6 | YR | ||||||||||||||||||||||||||||||||
| easi | 8 | 25 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | FAS | MMRM | 8 | WK | EASI | Mean | 22.1 | 0-72 score | 10.7 | SD | LS Mean | -35.9574 | 90%CI | -46.383 | -22.979 | 43.1 | 37.6 | YR | ||||||||||||||||||||||||
| 6 | 24 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | FAS | MMRM | 6 | WK | EASI | Mean | 22.1 | 0-72 score | 10.7 | SD | LS Mean | -39.7872 | 90%CI | -49.149 | -26.809 | 43.1 | 37.6 | YR | |||||||||||||||||||||||||
| 4 | 23 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | FAS | MMRM | 4 | WK | EASI | Mean | 22.1 | 0-72 score | 10.7 | SD | LS Mean | -32.9787 | 90%CI | -41.277 | -20.0 | 43.1 | 37.6 | YR | |||||||||||||||||||||||||
| 2 | 22 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | FAS | MMRM | 2 | WK | EASI | Mean | 22.1 | 0-72 score | 10.7 | SD | LS Mean | -25.3191 | 90%CI | -33.617 | -17.234 | 43.1 | 37.6 | YR | |||||||||||||||||||||||||
| 16 | 29 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | FAS | MMRM | 16 | WK | EASI | Mean | 22.1 | 0-72 score | 10.7 | SD | LS Mean | -15.7447 | 90%CI | -29.575 | -2.766 | 43.1 | 37.6 | YR | |||||||||||||||||||||||||
| 14 | 28 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | FAS | MMRM | 14 | WK | EASI | Mean | 22.1 | 0-72 score | 10.7 | SD | LS Mean | -24.2553 | 90%CI | -37.021 | -11.064 | 43.1 | 37.6 | YR | |||||||||||||||||||||||||
| 13 | 27 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | FAS | MMRM | 13 | WK | EASI | Mean | 22.1 | 0-72 score | 10.7 | SD | LS Mean | -33.1915 | 90%CI | -44.894 | -20.0 | 43.1 | 37.6 | YR | |||||||||||||||||||||||||
| 12 | 26 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | 45.0 | FAS | MMRM | 12 | WK | EASI | Mean | 22.1 | 0-72 score | 10.7 | SD | LS Mean | -40.7 | 90%CI | -52.0 | -29.5 | 43.1 | 37.6 | YR | ||||||||||||||||||||||||
| 1 | 21 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | FAS | MMRM | 1 | WK | EASI | Mean | 22.1 | 0-72 score | 10.7 | SD | LS Mean | -14.8936 | 90%CI | -21.489 | -7.234 | 43.1 | 37.6 | YR | |||||||||||||||||||||||||
| 0 | 20 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 30.0 | MG | ORAL | QD | TAB | 50 | 50.0 | FAS | MMRM | 0 | WK | EASI | Mean | 22.1 | 0-72 score | 10.7 | SD | LS Mean | 0.0 | 43.1 | 37.6 | YR | |||||||||||||||||||||||||||
| 200.0 | qd | scorad | 8 | 235 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | 49.0 | FAS | MMRM | 8 | WK | SCORAD | Mean | 62.7 | 0-103 score | 13.7 | SD | Mean | -42.604 | 0-103 score | 13.977 | SD | Mean | -69.736 | 21.44 | SD | 50.9 | 38.7 | YR | |||||||||||||||||
| 6 | 234 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | 52.0 | FAS | MMRM | 6 | WK | SCORAD | Mean | 62.7 | 0-103 score | 13.7 | SD | Mean | -41.458 | 0-103 score | 14.394 | SD | Mean | -66.971 | 22.434 | SD | 50.9 | 38.7 | YR | ||||||||||||||||||||
| 4 | 233 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | 52.0 | FAS | MMRM | 4 | WK | SCORAD | Mean | 62.7 | 0-103 score | 13.7 | SD | Mean | -39.567 | 0-103 score | 14.733 | SD | Mean | -63.97 | 21.67 | SD | 50.9 | 38.7 | YR | ||||||||||||||||||||
| 2 | 232 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | 50.0 | FAS | MMRM | 2 | WK | SCORAD | Mean | 62.7 | 0-103 score | 13.7 | SD | Mean | -32.152 | 0-103 score | 14.435 | SD | Mean | -51.384 | 21.358 | SD | 50.9 | 38.7 | YR | ||||||||||||||||||||
| 16 | 239 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | 38.0 | FAS | MMRM | 16 | WK | SCORAD | Mean | 62.7 | 0-103 score | 13.7 | SD | Mean | -21.024 | 0-103 score | 18.158 | SD | Mean | -34.995 | 27.5 | SD | 50.9 | 38.7 | YR | ||||||||||||||||||||
| 14 | 238 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | 44.0 | FAS | MMRM | 14 | WK | SCORAD | Mean | 62.7 | 0-103 score | 13.7 | SD | Mean | -21.292 | 0-103 score | 17.778 | SD | Mean | -36.519 | 28.54 | SD | 50.9 | 38.7 | YR | ||||||||||||||||||||
| 13 | 237 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | 45.0 | FAS | MMRM | 13 | WK | SCORAD | Mean | 62.7 | 0-103 score | 13.7 | SD | Mean | -29.884 | 0-103 score | 19.15 | SD | Mean | -48.428 | 30.113 | SD | 50.9 | 38.7 | YR | ||||||||||||||||||||
| 12 | 236 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | 42.0 | FAS | MMRM | 12 | WK | SCORAD | Mean | 62.7 | 0-103 score | 13.7 | SD | Mean | -41.384 | 0-103 score | 15.436 | SD | Mean | -68.537 | 24.239 | SD | 50.9 | 38.7 | YR | ||||||||||||||||||||
| 54 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | 48.0 | FAS | MMRM | 12 | WK | SCORAD | Mean | 62.7 | 0-103 score | 13.7 | SD | LS Mean | -69.7 | 95%CI | -76.9 | -62.5 | 50.9 | 38.7 | YR | |||||||||||||||||||||||||
| 1 | 231 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | 53.0 | FAS | MMRM | 1 | WK | SCORAD | Mean | 62.7 | 0-103 score | 13.7 | SD | Mean | -21.326 | 0-103 score | 15.887 | SD | Mean | -34.66 | 25.084 | SD | 50.9 | 38.7 | YR | ||||||||||||||||||||
| 0 | 230 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | 54.0 | FAS | MMRM | 0 | WK | SCORAD | Mean | 62.7 | 0-103 score | 13.7 | SD | Mean | 0.0 | 0-103 score | Mean | 0.0 | 50.9 | 38.7 | YR | ||||||||||||||||||||||||
| easi90 | 8 | 185 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 53.0 | 23.0 | FAS | 8 | WK | EASI 90 | 43.4 | percent | 50.9 | 38.7 | YR | |||||||||||||||||||||||||||||||
| 6 | 184 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 54.0 | 24.0 | FAS | 6 | WK | EASI 90 | 44.4 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 4 | 183 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 54.0 | 21.0 | FAS | 4 | WK | EASI 90 | 38.9 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 2 | 182 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 52.0 | 10.0 | FAS | 2 | WK | EASI 90 | 19.2 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 16 | 189 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 38.0 | 4.0 | FAS | 16 | WK | EASI 90 | 10.5 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 14 | 188 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 44.0 | 8.0 | FAS | 14 | WK | EASI 90 | 18.2 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 13 | 187 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 45.0 | 14.0 | FAS | 13 | WK | EASI 90 | 31.1 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 1 | 181 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 54.0 | 4.0 | FAS | 1 | WK | EASI 90 | 7.4 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| easi75 | 8 | 140 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 53.0 | 39.0 | FAS | 8 | WK | EASI 75 | 73.6 | percent | 50.9 | 38.7 | YR | |||||||||||||||||||||||||||||||
| 6 | 139 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 54.0 | 37.0 | FAS | 6 | WK | EASI 75 | 68.5 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 4 | 138 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 54.0 | 31.0 | FAS | 4 | WK | EASI 75 | 57.4 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 2 | 137 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 52.0 | 19.0 | FAS | 2 | WK | EASI 75 | 36.5 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 16 | 144 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 38.0 | 14.0 | FAS | 16 | WK | EASI 75 | 36.8 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 14 | 143 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 44.0 | 20.0 | FAS | 14 | WK | EASI 75 | 45.5 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 13 | 142 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 45.0 | 25.0 | FAS | 13 | WK | EASI 75 | 55.6 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 1 | 136 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 54.0 | 9.0 | FAS | 1 | WK | EASI 75 | 16.7 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| easi50 | 8 | 95 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 53.0 | 48.0 | FAS | 8 | WK | EASI 50 | 90.6 | percent | 50.9 | 38.7 | YR | |||||||||||||||||||||||||||||||
| 6 | 94 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 54.0 | 49.0 | FAS | 6 | WK | EASI 50 | 90.7 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 4 | 93 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 54.0 | 46.0 | FAS | 4 | WK | EASI 50 | 85.2 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 2 | 92 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 52.0 | 34.0 | FAS | 2 | WK | EASI 50 | 65.4 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 16 | 99 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 38.0 | 26.0 | FAS | 16 | WK | EASI 50 | 68.4 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 14 | 98 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 44.0 | 29.0 | FAS | 14 | WK | EASI 50 | 65.9 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 13 | 97 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 45.0 | 34.0 | FAS | 13 | WK | EASI 50 | 75.6 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| 1 | 91 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 55 | 54.0 | 22.0 | FAS | 1 | WK | EASI 50 | 40.7 | percent | 50.9 | 38.7 | YR | ||||||||||||||||||||||||||||||||
| easi | 8 | 45 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | FAS | MMRM | 8 | WK | EASI | Mean | 24.6 | 0-72 score | 13.5 | SD | LS Mean | -81.9149 | 90%CI | -92.128 | -72.128 | 50.9 | 38.7 | YR | ||||||||||||||||||||||||
| 6 | 44 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | FAS | MMRM | 6 | WK | EASI | Mean | 24.6 | 0-72 score | 13.5 | SD | LS Mean | -82.1277 | 90%CI | -91.277 | -72.766 | 50.9 | 38.7 | YR | |||||||||||||||||||||||||
| 4 | 43 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | FAS | MMRM | 4 | WK | EASI | Mean | 24.6 | 0-72 score | 13.5 | SD | LS Mean | -77.234 | 90%CI | -85.319 | -69.149 | 50.9 | 38.7 | YR | |||||||||||||||||||||||||
| 2 | 42 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | FAS | MMRM | 2 | WK | EASI | Mean | 24.6 | 0-72 score | 13.5 | SD | LS Mean | -62.1277 | 90%CI | -70.213 | -54.043 | 50.9 | 38.7 | YR | |||||||||||||||||||||||||
| 16 | 49 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | FAS | MMRM | 16 | WK | EASI | Mean | 24.6 | 0-72 score | 13.5 | SD | LS Mean | -51.0638 | 90%CI | -63.192 | -38.723 | 50.9 | 38.7 | YR | |||||||||||||||||||||||||
| 14 | 48 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | FAS | MMRM | 14 | WK | EASI | Mean | 24.6 | 0-72 score | 13.5 | SD | LS Mean | -55.1064 | 90%CI | -66.383 | -42.979 | 50.9 | 38.7 | YR | |||||||||||||||||||||||||
| 13 | 47 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | FAS | MMRM | 13 | WK | EASI | Mean | 24.6 | 0-72 score | 13.5 | SD | LS Mean | -65.1064 | 90%CI | -76.383 | -54.468 | 50.9 | 38.7 | YR | |||||||||||||||||||||||||
| 12 | 46 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | 48.0 | FAS | MMRM | 12 | WK | EASI | Mean | 24.6 | 0-72 score | 13.5 | SD | LS Mean | -82.6 | 90%CI | -92.8 | -72.4 | 50.9 | 38.7 | YR | ||||||||||||||||||||||||
| 1 | 41 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | FAS | MMRM | 1 | WK | EASI | Mean | 24.6 | 0-72 score | 13.5 | SD | LS Mean | -41.4894 | 90%CI | -48.085 | -34.255 | 50.9 | 38.7 | YR | |||||||||||||||||||||||||
| 0 | 40 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 54 | 54.0 | FAS | MMRM | 0 | WK | EASI | Mean | 24.6 | 0-72 score | 13.5 | SD | LS Mean | 0.0 | 50.9 | 38.7 | YR | |||||||||||||||||||||||||||
| 100.0 | qd | scorad | 8 | 225 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | 47.0 | FAS | MMRM | 8 | WK | SCORAD | Mean | 65.4 | 0-103 score | 13.7 | SD | Mean | -30.148 | 0-103 score | 20.789 | SD | Mean | -46.187 | 32.789 | SD | 55.4 | 41.1 | YR | |||||||||||||||||
| 6 | 224 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | 48.0 | FAS | MMRM | 6 | WK | SCORAD | Mean | 65.4 | 0-103 score | 13.7 | SD | Mean | -29.729 | 0-103 score | 21.612 | SD | Mean | -45.27 | 34.389 | SD | 55.4 | 41.1 | YR | ||||||||||||||||||||
| 4 | 223 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | 52.0 | FAS | MMRM | 4 | WK | SCORAD | Mean | 65.4 | 0-103 score | 13.7 | SD | Mean | -28.058 | 0-103 score | 16.678 | SD | Mean | -43.846 | 26.2 | SD | 55.4 | 41.1 | YR | ||||||||||||||||||||
| 2 | 222 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | 53.0 | FAS | MMRM | 2 | WK | SCORAD | Mean | 65.4 | 0-103 score | 13.7 | SD | Mean | -20.286 | 0-103 score | 15.24 | SD | Mean | -31.025 | 23.988 | SD | 55.4 | 41.1 | YR | ||||||||||||||||||||
| 16 | 229 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | 36.0 | FAS | MMRM | 16 | WK | SCORAD | Mean | 65.4 | 0-103 score | 13.7 | SD | Mean | -17.753 | 0-103 score | 19.184 | SD | Mean | -29.13 | 33.187 | SD | 55.4 | 41.1 | YR | ||||||||||||||||||||
| 14 | 228 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | 40.0 | FAS | MMRM | 14 | WK | SCORAD | Mean | 65.4 | 0-103 score | 13.7 | SD | Mean | -20.211 | 0-103 score | 20.292 | SD | Mean | -31.521 | 34.127 | SD | 55.4 | 41.1 | YR | ||||||||||||||||||||
| 13 | 227 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | 38.0 | FAS | MMRM | 13 | WK | SCORAD | Mean | 65.4 | 0-103 score | 13.7 | SD | Mean | -24.261 | 0-103 score | 19.491 | SD | Mean | -38.193 | 32.346 | SD | 55.4 | 41.1 | YR | ||||||||||||||||||||
| 12 | 226 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | 43.0 | FAS | MMRM | 12 | WK | SCORAD | Mean | 65.4 | 0-103 score | 13.7 | SD | Mean | -33.145 | 0-103 score | 21.422 | SD | Mean | -51.624 | 33.011 | SD | 55.4 | 41.1 | YR | ||||||||||||||||||||
| 53 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | 54.0 | FAS | MMRM | 12 | WK | SCORAD | Mean | 65.4 | 0-103 score | 13.7 | SD | LS Mean | -49.2 | 95%CI | -56.4 | -42.0 | 55.4 | 41.1 | YR | |||||||||||||||||||||||||
| 1 | 221 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | 55.0 | FAS | MMRM | 1 | WK | SCORAD | Mean | 65.4 | 0-103 score | 13.7 | SD | Mean | -12.024 | 0-103 score | 12.405 | SD | Mean | -19.185 | 20.009 | SD | 55.4 | 41.1 | YR | ||||||||||||||||||||
| 0 | 220 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | 55.0 | FAS | MMRM | 0 | WK | SCORAD | Mean | 65.4 | 0-103 score | 13.7 | SD | Mean | 0.0 | 0-103 score | Mean | 0.0 | 55.4 | 41.1 | YR | ||||||||||||||||||||||||
| easi90 | 8 | 176 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 13.0 | FAS | 8 | WK | EASI 90 | 23.6 | percent | 55.4 | 41.1 | YR | |||||||||||||||||||||||||||||||
| 6 | 175 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 9.0 | FAS | 6 | WK | EASI 90 | 16.4 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 4 | 174 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 6.0 | FAS | 4 | WK | EASI 90 | 10.9 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 2 | 173 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 3.0 | FAS | 2 | WK | EASI 90 | 5.5 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 16 | 180 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 36.0 | 3.0 | FAS | 16 | WK | EASI 90 | 8.3 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 14 | 179 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 40.0 | 7.0 | FAS | 14 | WK | EASI 90 | 17.5 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 13 | 178 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 38.0 | 9.0 | FAS | 13 | WK | EASI 90 | 23.7 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 12 | 177 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 54.0 | 14.0 | FAS | 12 | WK | EASI 90 | 25.9 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 1 | 172 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 0.0 | FAS | 1 | WK | EASI 90 | 0.0 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| easi75 | 8 | 131 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 22.0 | FAS | 8 | WK | EASI 75 | 40.0 | percent | 55.4 | 41.1 | YR | |||||||||||||||||||||||||||||||
| 6 | 130 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 21.0 | FAS | 6 | WK | EASI 75 | 38.2 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 4 | 129 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 15.0 | FAS | 4 | WK | EASI 75 | 27.3 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 2 | 128 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 7.0 | FAS | 2 | WK | EASI 75 | 12.7 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 16 | 135 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 36.0 | 9.0 | FAS | 16 | WK | EASI 75 | 25.0 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 14 | 134 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 40.0 | 14.0 | FAS | 14 | WK | EASI 75 | 35.0 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 13 | 133 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 38.0 | 14.0 | FAS | 13 | WK | EASI 75 | 36.8 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 12 | 132 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 54.0 | 22.0 | FAS | 12 | WK | EASI 75 | 40.7 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 1 | 127 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 2.0 | FAS | 1 | WK | EASI 75 | 3.6 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| easi50 | 8 | 86 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 33.0 | FAS | 8 | WK | EASI 50 | 60.0 | percent | 55.4 | 41.1 | YR | |||||||||||||||||||||||||||||||
| 6 | 85 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 33.0 | FAS | 6 | WK | EASI 50 | 60.0 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 4 | 84 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 32.0 | FAS | 4 | WK | EASI 50 | 58.2 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 2 | 83 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 20.0 | FAS | 2 | WK | EASI 50 | 36.4 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 16 | 90 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 36.0 | 15.0 | FAS | 16 | WK | EASI 50 | 41.7 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 14 | 89 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 40.0 | 20.0 | FAS | 14 | WK | EASI 50 | 50.0 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 13 | 88 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 38.0 | 21.0 | FAS | 13 | WK | EASI 50 | 55.3 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 12 | 87 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 54.0 | 30.0 | FAS | 12 | WK | EASI 50 | 55.6 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| 1 | 82 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 56 | 55.0 | 7.0 | FAS | 1 | WK | EASI 50 | 12.7 | percent | 55.4 | 41.1 | YR | ||||||||||||||||||||||||||||||||
| easi | 8 | 35 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | FAS | MMRM | 8 | WK | EASI | Mean | 26.7 | 0-72 score | 11.8 | SD | LS Mean | -51.7021 | 90%CI | -62.34 | -41.489 | 55.4 | 41.1 | YR | ||||||||||||||||||||||||
| 6 | 34 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | FAS | MMRM | 6 | WK | EASI | Mean | 26.7 | 0-72 score | 11.8 | SD | LS Mean | -52.3404 | 90%CI | -61.489 | -42.979 | 55.4 | 41.1 | YR | |||||||||||||||||||||||||
| 4 | 33 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | FAS | MMRM | 4 | WK | EASI | Mean | 26.7 | 0-72 score | 11.8 | SD | LS Mean | -53.1915 | 90%CI | -61.489 | -45.106 | 55.4 | 41.1 | YR | |||||||||||||||||||||||||
| 2 | 32 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | FAS | MMRM | 2 | WK | EASI | Mean | 26.7 | 0-72 score | 11.8 | SD | LS Mean | -38.0851 | 90%CI | -45.957 | -30.638 | 55.4 | 41.1 | YR | |||||||||||||||||||||||||
| 16 | 39 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | FAS | MMRM | 16 | WK | EASI | Mean | 26.7 | 0-72 score | 11.8 | SD | LS Mean | -18.7234 | 90%CI | -31.915 | -6.596 | 55.4 | 41.1 | YR | |||||||||||||||||||||||||
| 14 | 38 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | FAS | MMRM | 14 | WK | EASI | Mean | 26.7 | 0-72 score | 11.8 | SD | LS Mean | -34.0426 | 90%CI | -46.596 | -22.128 | 55.4 | 41.1 | YR | |||||||||||||||||||||||||
| 13 | 37 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | FAS | MMRM | 13 | WK | EASI | Mean | 26.7 | 0-72 score | 11.8 | SD | LS Mean | -46.383 | 90%CI | -58.298 | -35.532 | 55.4 | 41.1 | YR | |||||||||||||||||||||||||
| 12 | 36 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | 54.0 | FAS | MMRM | 12 | WK | EASI | Mean | 26.7 | 0-72 score | 11.8 | SD | LS Mean | -59.0 | 90%CI | -69.3 | -48.8 | 55.4 | 41.1 | YR | ||||||||||||||||||||||||
| 1 | 31 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | FAS | MMRM | 1 | WK | EASI | Mean | 26.7 | 0-72 score | 11.8 | SD | LS Mean | -20.0 | 90%CI | -26.383 | -13.192 | 55.4 | 41.1 | YR | |||||||||||||||||||||||||
| 0 | 30 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 55 | 55.0 | FAS | MMRM | 0 | WK | EASI | Mean | 26.7 | 0-72 score | 11.8 | SD | LS Mean | 0.0 | 55.4 | 41.1 | YR | |||||||||||||||||||||||||||
| 10.0 | qd | scorad | 8 | 205 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 36.0 | FAS | MMRM | 8 | WK | SCORAD | Mean | 65.3 | 0-103 score | 13.2 | SD | Mean | -18.853 | 0-103 score | 21.795 | SD | Mean | -28.599 | 33.146 | SD | 42.9 | 44.3 | YR | |||||||||||||||||
| 6 | 204 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 38.0 | FAS | MMRM | 6 | WK | SCORAD | Mean | 65.3 | 0-103 score | 13.2 | SD | Mean | -16.667 | 0-103 score | 21.858 | SD | Mean | -25.851 | 34.295 | SD | 42.9 | 44.3 | YR | ||||||||||||||||||||
| 4 | 203 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 45.0 | FAS | MMRM | 4 | WK | SCORAD | Mean | 65.3 | 0-103 score | 13.2 | SD | Mean | -14.116 | 0-103 score | 19.164 | SD | Mean | -20.751 | 29.085 | SD | 42.9 | 44.3 | YR | ||||||||||||||||||||
| 2 | 202 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 48.0 | FAS | MMRM | 2 | WK | SCORAD | Mean | 65.3 | 0-103 score | 13.2 | SD | Mean | -8.795 | 0-103 score | 16.388 | SD | Mean | -12.98 | 25.52 | SD | 42.9 | 44.3 | YR | ||||||||||||||||||||
| 16 | 209 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 26.0 | FAS | MMRM | 16 | WK | SCORAD | Mean | 65.3 | 0-103 score | 13.2 | SD | Mean | -18.925 | 0-103 score | 21.546 | SD | Mean | -30.135 | 34.236 | SD | 42.9 | 44.3 | YR | ||||||||||||||||||||
| 14 | 208 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 28.0 | FAS | MMRM | 14 | WK | SCORAD | Mean | 65.3 | 0-103 score | 13.2 | SD | Mean | -15.842 | 0-103 score | 19.5 | SD | Mean | -25.511 | 31.199 | SD | 42.9 | 44.3 | YR | ||||||||||||||||||||
| 13 | 207 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 29.0 | FAS | MMRM | 13 | WK | SCORAD | Mean | 65.3 | 0-103 score | 13.2 | SD | Mean | -16.895 | 0-103 score | 22.113 | SD | Mean | -26.905 | 34.188 | SD | 42.9 | 44.3 | YR | ||||||||||||||||||||
| 12 | 206 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 29.0 | FAS | MMRM | 12 | WK | SCORAD | Mean | 65.3 | 0-103 score | 13.2 | SD | Mean | -17.986 | 0-103 score | 23.195 | SD | Mean | -27.607 | 36.502 | SD | 42.9 | 44.3 | YR | ||||||||||||||||||||
| 51 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 46.0 | FAS | MMRM | 12 | WK | SCORAD | Mean | 65.3 | 0-103 score | 13.2 | SD | LS Mean | -26.7 | 95%CI | -35.0 | -18.4 | 42.9 | 44.3 | YR | |||||||||||||||||||||||||
| 1 | 201 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 48.0 | FAS | MMRM | 1 | WK | SCORAD | Mean | 65.3 | 0-103 score | 13.2 | SD | Mean | -5.0 | 0-103 score | 13.331 | SD | Mean | -7.287 | 20.64 | SD | 42.9 | 44.3 | YR | ||||||||||||||||||||
| 0 | 200 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 49.0 | FAS | MMRM | 0 | WK | SCORAD | Mean | 65.3 | 0-103 score | 13.2 | SD | Mean | 0.0 | 0-103 score | Mean | 0.0 | 42.9 | 44.3 | YR | ||||||||||||||||||||||||
| easi90 | 8 | 158 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 49.0 | 6.0 | FAS | 8 | WK | EASI 90 | 12.2 | percent | 42.9 | 44.3 | YR | |||||||||||||||||||||||||||||||
| 6 | 157 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 49.0 | 7.0 | FAS | 6 | WK | EASI 90 | 14.3 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 4 | 156 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 49.0 | 4.0 | FAS | 4 | WK | EASI 90 | 8.2 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 2 | 155 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 49.0 | 3.0 | FAS | 2 | WK | EASI 90 | 6.1 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 16 | 162 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 26.0 | 6.0 | FAS | 16 | WK | EASI 90 | 23.1 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 14 | 161 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 28.0 | 4.0 | FAS | 14 | WK | EASI 90 | 14.3 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 13 | 160 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 29.0 | 4.0 | FAS | 13 | WK | EASI 90 | 13.8 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 1 | 154 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 48.0 | 1.0 | FAS | 1 | WK | EASI 90 | 2.1 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| easi75 | 8 | 113 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 49.0 | 11.0 | FAS | 8 | WK | EASI 75 | 22.4 | percent | 42.9 | 44.3 | YR | |||||||||||||||||||||||||||||||
| 6 | 112 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 49.0 | 9.0 | FAS | 6 | WK | EASI 75 | 18.4 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 4 | 111 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 49.0 | 9.0 | FAS | 4 | WK | EASI 75 | 18.4 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 2 | 110 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 49.0 | 6.0 | FAS | 2 | WK | EASI 75 | 12.2 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 16 | 117 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 26.0 | 10.0 | FAS | 16 | WK | EASI 75 | 38.5 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 14 | 116 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 28.0 | 7.0 | FAS | 14 | WK | EASI 75 | 25.0 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 13 | 115 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 29.0 | 8.0 | FAS | 13 | WK | EASI 75 | 27.6 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 1 | 109 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 48.0 | 1.0 | FAS | 1 | WK | EASI 75 | 2.1 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| easi50 | 8 | 68 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 49.0 | 18.0 | FAS | 8 | WK | EASI 50 | 36.7 | percent | 42.9 | 44.3 | YR | |||||||||||||||||||||||||||||||
| 6 | 67 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 49.0 | 15.0 | FAS | 6 | WK | EASI 50 | 30.6 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 4 | 66 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 49.0 | 15.0 | FAS | 4 | WK | EASI 50 | 30.6 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 2 | 65 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 49.0 | 8.0 | FAS | 2 | WK | EASI 50 | 16.3 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 16 | 72 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 26.0 | 11.0 | FAS | 16 | WK | EASI 50 | 42.3 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 14 | 71 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 28.0 | 12.0 | FAS | 14 | WK | EASI 50 | 42.9 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 13 | 70 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 29.0 | 12.0 | FAS | 13 | WK | EASI 50 | 41.4 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| 1 | 64 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 48.0 | 4.0 | FAS | 1 | WK | EASI 50 | 8.3 | percent | 42.9 | 44.3 | YR | ||||||||||||||||||||||||||||||||
| easi | 8 | 15 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | FAS | MMRM | 8 | WK | EASI | Mean | 28.1 | 0-72 score | 13.1 | SD | LS Mean | -33.1915 | 90%CI | -44.681 | -22.128 | 42.9 | 44.3 | YR | ||||||||||||||||||||||||
| 6 | 14 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | FAS | MMRM | 6 | WK | EASI | Mean | 28.1 | 0-72 score | 13.1 | SD | LS Mean | -29.7872 | 90%CI | -40.426 | -19.362 | 42.9 | 44.3 | YR | |||||||||||||||||||||||||
| 4 | 13 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | FAS | MMRM | 4 | WK | EASI | Mean | 28.1 | 0-72 score | 13.1 | SD | LS Mean | -28.9362 | 90%CI | -38.085 | -20.213 | 42.9 | 44.3 | YR | |||||||||||||||||||||||||
| 2 | 12 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | FAS | MMRM | 2 | WK | EASI | Mean | 28.1 | 0-72 score | 13.1 | SD | LS Mean | -15.3191 | 90%CI | -23.404 | -7.234 | 42.9 | 44.3 | YR | |||||||||||||||||||||||||
| 16 | 19 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | FAS | MMRM | 16 | WK | EASI | Mean | 28.1 | 0-72 score | 13.1 | SD | LS Mean | -32.9787 | 90%CI | -47.447 | -17.872 | 42.9 | 44.3 | YR | |||||||||||||||||||||||||
| 14 | 18 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | FAS | MMRM | 14 | WK | EASI | Mean | 28.1 | 0-72 score | 13.1 | SD | LS Mean | -29.5745 | 90%CI | -43.83 | -15.106 | 42.9 | 44.3 | YR | |||||||||||||||||||||||||
| 13 | 17 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | FAS | MMRM | 13 | WK | EASI | Mean | 28.1 | 0-72 score | 13.1 | SD | LS Mean | -35.7447 | 90%CI | -48.298 | -22.766 | 42.9 | 44.3 | YR | |||||||||||||||||||||||||
| 12 | 16 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 46.0 | FAS | MMRM | 12 | WK | EASI | Mean | 28.1 | 0-72 score | 13.1 | SD | LS Mean | -31.1 | 90%CI | -42.8 | -19.4 | 42.9 | 44.3 | YR | ||||||||||||||||||||||||
| 1 | 11 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | FAS | MMRM | 1 | WK | EASI | Mean | 28.1 | 0-72 score | 13.1 | SD | LS Mean | -14.2553 | 90%CI | -21.277 | -7.234 | 42.9 | 44.3 | YR | |||||||||||||||||||||||||
| 0 | 10 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 10.0 | MG | ORAL | QD | TAB | 49 | 49.0 | FAS | MMRM | 0 | WK | EASI | Mean | 28.1 | 0-72 score | 13.1 | SD | LS Mean | 0.0 | 42.9 | 44.3 | YR |
290_reich_2020¶
Control rows matched by test output: 4 of 66
Literature data accuracy: 83.33%
Clinical data accuracy: 4.96%
Clinical data accuracy (drop unmatched): 81.89%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| baricitinib | 4 | oncedaily | easi90 | 16 | 1 | c65t1 | test | Double-Blind | TRUE | Baricitinib | Janus kinase (JAK) 1/JAK2 inhibitor | 4 | mg | Oral | Once daily | 111 | 111 | 27 | ITT | Logistic regression | NRI | 16 | WK | EASI-90 | Percent | 24 | Percent | 66 | 33.9 | YR | |||||||||||||||||||||||||
| 4.0 | qd | easi90 | 16 | 65 | c65t1 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | 27.0 | ITT | Logistic Regression Model | NRI | 16 | WK | EASI 90 | 24.0 | percent | 95%CI | 17.435 | 33.554 | 68.0 | 33.9 | YR | |||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 79 | 50 | 100 | 100 | 17 | 0 | 100 | 75 | 67 | 100 | 86 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 67 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 33 | 100 | 100 | |||||||
| placebo | easi75 | 16 | 3 | c5t3 | test | Double-Blind | TRUE | Placebo | Topical Corticosteroids | 109 | 109 | 25 | ITT | Logistic regression | NRI | 16 | WK | EASI-75 | Percent | 23 | Percent | 65 | 33.7 | YR | |||||||||||||||||||||||||||||||
| 0.0 | qd | easi75 | 16 | 5 | c5t3 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | 25.0 | ITT | Logistic Regression Model | NRI | 16 | WK | EASI 75 | 23.0 | percent | 95%CI | 15.918 | 31.429 | 65.0 | 33.7 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 20 | 0 | 0 | 0 | 0 | 100 | 100 | 75 | 67 | 100 | 86 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 67 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | |||||||
| baricitinib | 4 | oncedaily | easi75 | 16 | 0 | c17t0 | test | Double-Blind | TRUE | Baricitinib | Janus kinase (JAK) 1/JAK2 inhibitor | 4 | mg | Oral | Once daily | 111 | 111 | 53 | ITT | Logistic regression | NRI | 16 | WK | EASI-75 | Percent | 48 | Percent | 66 | 33.9 | YR | |||||||||||||||||||||||||
| 4.0 | qd | easi75 | 16 | 17 | c17t0 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | 53.0 | ITT | Logistic Regression Model | NRI | 16 | WK | EASI 75 | 48.0 | percent | 95%CI | 38.367 | 56.735 | 68.0 | 33.9 | YR | |||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 79 | 50 | 100 | 100 | 17 | 0 | 100 | 75 | 67 | 100 | 86 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 67 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 33 | 100 | 100 | |||||||
| 2mgofbaricitinib | 2 | oncedaily | easi75 | 16 | 2 | c11t2 | test | Double-Blind | TRUE | 2 mg of Baricitinib | Janus kinase (JAK) inhibitor | 2 | mg | Oral | Once daily | 109 | 109 | 47 | ITT | Logistic regression | NRI | 16 | WK | EASI-75 | Percent | 43 | Percent | 64 | 33.8 | YR | |||||||||||||||||||||||||
| baricitinib | 2.0 | qd | easi75 | 16 | 11 | c11t2 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | 47.0 | ITT | Logistic Regression Model | NRI | 16 | WK | EASI 75 | 43.0 | percent | 95%CI | 34.286 | 52.245 | 64.0 | 33.8 | YR | ||||||||||||||||||||||
| similarity | 100 | 100 | 73 | 90 | 50 | 100 | 100 | 17 | 0 | 100 | 75 | 67 | 100 | 86 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 67 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | |||||||
| placebo | 0.0 | qd | scorad | 16 | 24 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | ITT | MMRM | 16 | WK | SCORAD | Mean | 66.6 | 0-103 score | 13.8 | SD | LS Mean | -21.4 | 0-103 score | 1.9 | SE | 65.0 | 33.7 | YR | |||||||||||||||||||||
| 0 | 21 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | ITT | MMRM | 0 | WK | SCORAD | Mean | 66.6 | 0-103 score | 13.8 | SD | LS Mean | 0.0 | 0-103 score | 65.0 | 33.7 | YR | |||||||||||||||||||||||||||
| easi90 | 8 | 51 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | 5.0 | ITT | Logistic Regression Model | NRI | 8 | WK | EASI 90 | 4.441 | percent | 95%CI | 2.139 | 10.691 | 65.0 | 33.7 | YR | |||||||||||||||||||||||||||
| 4 | 50 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | 6.0 | ITT | Logistic Regression Model | NRI | 4 | WK | EASI 90 | 5.345 | percent | 95%CI | 2.385 | 11.596 | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||||
| 2 | 49 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | 5.0 | ITT | Logistic Regression Model | NRI | 2 | WK | EASI 90 | 4.317 | percent | 65.0 | 33.7 | YR | |||||||||||||||||||||||||||||||
| 16 | 53 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | 15.0 | ITT | Logistic Regression Model | NRI | 16 | WK | EASI 90 | 14.0 | percent | 95%CI | 8.553 | 21.711 | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||||
| 12 | 52 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | 9.0 | ITT | Logistic Regression Model | NRI | 12 | WK | EASI 90 | 8.47 | percent | 95%CI | 4.523 | 15.708 | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||||
| 1 | 48 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | 2.0 | ITT | Logistic Regression Model | NRI | 1 | WK | EASI 90 | 1.995 | percent | 95%CI | -2.281 | 6.271 | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||||
| easi75 | 8 | 3 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | 16.0 | ITT | Logistic Regression Model | NRI | 8 | WK | EASI 75 | 14.694 | percent | 95%CI | 9.388 | 22.449 | 65.0 | 33.7 | YR | |||||||||||||||||||||||||||
| 4 | 2 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | 13.0 | ITT | Logistic Regression Model | NRI | 4 | WK | EASI 75 | 11.837 | percent | 95%CI | 6.939 | 19.592 | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||||
| 2 | 1 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | 9.0 | ITT | Logistic Regression Model | NRI | 2 | WK | EASI 75 | 8.163 | percent | 95%CI | 4.49 | 15.102 | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||||
| 12 | 4 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | 22.0 | ITT | Logistic Regression Model | NRI | 12 | WK | EASI 75 | 20.0 | percent | 95%CI | 13.469 | 28.571 | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||||
| 1 | 0 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | 8.0 | ITT | Logistic Regression Model | NRI | 1 | WK | EASI 75 | 6.939 | percent | 95%CI | 3.673 | 13.878 | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||||
| easi50 | 16 | 18 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | 45.0 | ITT | Logistic Regression Model | NRI | 16 | WK | EASI 50 | 41.0 | percent | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||||||
| easi | 8 | 31 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | ITT | MMRM | 8 | WK | EASI | Mean | 28.5 | 0-72 score | 12.3 | SD | LS Mean | -42.632 | 3.026 | SE | 65.0 | 33.7 | YR | |||||||||||||||||||||||||
| 4 | 30 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | ITT | MMRM | 4 | WK | EASI | Mean | 28.5 | 0-72 score | 12.3 | SD | LS Mean | -36.842 | 2.763 | SE | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||
| 2 | 29 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | ITT | MMRM | 2 | WK | EASI | Mean | 28.5 | 0-72 score | 12.3 | SD | LS Mean | -34.474 | 2.763 | SE | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||
| 16 | 33 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | ITT | MMRM | 16 | WK | EASI | Mean | 28.5 | 0-72 score | 12.3 | SD | LS Mean | -45.1 | 3.8 | SE | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||
| 12 | 32 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | ITT | MMRM | 12 | WK | EASI | Mean | 28.5 | 0-72 score | 12.3 | SD | LS Mean | -45.263 | 3.421 | SE | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||
| 1 | 28 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | ITT | MMRM | 1 | WK | EASI | Mean | 28.5 | 0-72 score | 12.3 | SD | LS Mean | -22.632 | 2.632 | SE | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||
| 0 | 27 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 109 | 109.0 | ITT | MMRM | 0 | WK | EASI | Mean | 28.5 | 0-72 score | 12.3 | SD | LS Mean | 0.0 | 65.0 | 33.7 | YR | ||||||||||||||||||||||||||||
| baricitinib | 4.0 | qd | scorad | 16 | 26 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | ITT | MMRM | 16 | WK | SCORAD | Mean | 68.3 | 0-103 score | 13.2 | SD | LS Mean | -35.8 | 0-103 score | 1.8 | SE | 68.0 | 33.9 | YR | ||||||||||||||||||||
| 0 | 23 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | ITT | MMRM | 0 | WK | SCORAD | Mean | 68.3 | 0-103 score | 13.2 | SD | LS Mean | 0.0 | 0-103 score | 68.0 | 33.9 | YR | ||||||||||||||||||||||||||
| easi90 | 8 | 63 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | 20.0 | ITT | Logistic Regression Model | NRI | 8 | WK | EASI 90 | 18.257 | percent | 95%CI | 12.007 | 26.481 | 68.0 | 33.9 | YR | ||||||||||||||||||||||||||
| 4 | 62 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | 18.0 | ITT | Logistic Regression Model | NRI | 4 | WK | EASI 90 | 16.201 | percent | 95%CI | 10.279 | 24.096 | 68.0 | 33.9 | YR | |||||||||||||||||||||||||||
| 2 | 61 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | 7.0 | ITT | Logistic Regression Model | NRI | 2 | WK | EASI 90 | 6.62 | percent | 95%CI | 3.001 | 12.213 | 68.0 | 33.9 | YR | |||||||||||||||||||||||||||
| 12 | 64 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | 24.0 | ITT | Logistic Regression Model | NRI | 12 | WK | EASI 90 | 21.627 | percent | 95%CI | 15.05 | 30.511 | 68.0 | 33.9 | YR | |||||||||||||||||||||||||||
| 1 | 60 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | 4.0 | ITT | Logistic Regression Model | NRI | 1 | WK | EASI 90 | 3.639 | percent | 95%CI | -1.624 | 8.902 | 68.0 | 33.9 | YR | |||||||||||||||||||||||||||
| easi75 | 8 | 15 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | 45.0 | ITT | Logistic Regression Model | NRI | 8 | WK | EASI 75 | 40.816 | percent | 95%CI | 32.653 | 50.612 | 68.0 | 33.9 | YR | ||||||||||||||||||||||||||
| 4 | 14 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | 43.0 | ITT | Logistic Regression Model | NRI | 4 | WK | EASI 75 | 38.367 | percent | 95%CI | 30.204 | 47.755 | 68.0 | 33.9 | YR | |||||||||||||||||||||||||||
| 2 | 13 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | 29.0 | ITT | Logistic Regression Model | NRI | 2 | WK | EASI 75 | 26.531 | percent | 95%CI | 18.776 | 35.102 | 68.0 | 33.9 | YR | |||||||||||||||||||||||||||
| 12 | 16 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | 53.0 | ITT | Logistic Regression Model | NRI | 12 | WK | EASI 75 | 47.755 | percent | 95%CI | 38.367 | 56.735 | 68.0 | 33.9 | YR | |||||||||||||||||||||||||||
| 1 | 12 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | 10.0 | ITT | Logistic Regression Model | NRI | 1 | WK | EASI 75 | 8.98 | percent | 95%CI | 4.898 | 15.918 | 68.0 | 33.9 | YR | |||||||||||||||||||||||||||
| easi50 | 16 | 20 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | 78.0 | ITT | Logistic Regression Model | NRI | 16 | WK | EASI 50 | 70.0 | percent | 68.0 | 33.9 | YR | |||||||||||||||||||||||||||||
| easi | 8 | 45 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | ITT | MMRM | 8 | WK | EASI | Mean | 30.9 | 0-72 score | 12.6 | SD | LS Mean | -67.105 | 2.895 | SE | 68.0 | 33.9 | YR | ||||||||||||||||||||||||
| 4 | 44 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | ITT | MMRM | 4 | WK | EASI | Mean | 30.9 | 0-72 score | 12.6 | SD | LS Mean | -67.105 | 2.763 | SE | 68.0 | 33.9 | YR | |||||||||||||||||||||||||
| 2 | 43 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | ITT | MMRM | 2 | WK | EASI | Mean | 30.9 | 0-72 score | 12.6 | SD | LS Mean | -56.842 | 2.632 | SE | 68.0 | 33.9 | YR | |||||||||||||||||||||||||
| 16 | 47 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | ITT | MMRM | 16 | WK | EASI | Mean | 30.9 | 0-72 score | 12.6 | SD | LS Mean | -67.2 | 3.7 | SE | 68.0 | 33.9 | YR | |||||||||||||||||||||||||
| 12 | 46 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | ITT | MMRM | 12 | WK | EASI | Mean | 30.9 | 0-72 score | 12.6 | SD | LS Mean | -68.158 | 3.289 | SE | 68.0 | 33.9 | YR | |||||||||||||||||||||||||
| 1 | 42 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | ITT | MMRM | 1 | WK | EASI | Mean | 30.9 | 0-72 score | 12.6 | SD | LS Mean | -38.947 | 2.632 | SE | 68.0 | 33.9 | YR | |||||||||||||||||||||||||
| 0 | 41 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 4.0 | MG | ORAL | QD | TAB | 111 | 111.0 | ITT | MMRM | 0 | WK | EASI | Mean | 30.9 | 0-72 score | 12.6 | SD | LS Mean | 0.0 | 68.0 | 33.9 | YR | |||||||||||||||||||||||||||
| 2.0 | qd | scorad | 16 | 25 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | ITT | MMRM | 16 | WK | SCORAD | Mean | 66.8 | 0-103 score | 14.0 | SD | LS Mean | -29.9 | 0-103 score | 1.9 | SE | 64.0 | 33.8 | YR | |||||||||||||||||||||
| 0 | 22 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | ITT | MMRM | 0 | WK | SCORAD | Mean | 66.8 | 0-103 score | 14.0 | SD | LS Mean | 0.0 | 0-103 score | 64.0 | 33.8 | YR | ||||||||||||||||||||||||||
| easi90 | 8 | 57 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | 17.0 | ITT | Logistic Regression Model | NRI | 8 | WK | EASI 90 | 15.954 | percent | 95%CI | 10.033 | 23.52 | 64.0 | 33.8 | YR | ||||||||||||||||||||||||||
| 4 | 56 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | 11.0 | ITT | Logistic Regression Model | NRI | 4 | WK | EASI 90 | 10.28 | percent | 95%CI | 5.674 | 17.189 | 64.0 | 33.8 | YR | |||||||||||||||||||||||||||
| 2 | 55 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | 5.0 | ITT | Logistic Regression Model | NRI | 2 | WK | EASI 90 | 4.647 | percent | 95%CI | 1.686 | 10.239 | 64.0 | 33.8 | YR | |||||||||||||||||||||||||||
| 16 | 59 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | 19.0 | ITT | Logistic Regression Model | NRI | 16 | WK | EASI 90 | 17.0 | percent | 95%CI | 10.855 | 24.674 | 64.0 | 33.8 | YR | |||||||||||||||||||||||||||
| 12 | 58 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | 20.0 | ITT | Logistic Regression Model | NRI | 12 | WK | EASI 90 | 18.339 | percent | 95%CI | 12.418 | 26.892 | 64.0 | 33.8 | YR | |||||||||||||||||||||||||||
| 1 | 54 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | 0.0 | ITT | Logistic Regression Model | NRI | 1 | WK | EASI 90 | 0.02 | percent | 95%CI | -3.271 | 3.311 | 64.0 | 33.8 | YR | |||||||||||||||||||||||||||
| easi75 | 8 | 9 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | 37.0 | ITT | Logistic Regression Model | NRI | 8 | WK | EASI 75 | 33.878 | percent | 95%CI | 25.714 | 42.857 | 64.0 | 33.8 | YR | ||||||||||||||||||||||||||
| 4 | 8 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | 29.0 | ITT | Logistic Regression Model | NRI | 4 | WK | EASI 75 | 26.531 | percent | 95%CI | 18.776 | 35.51 | 64.0 | 33.8 | YR | |||||||||||||||||||||||||||
| 2 | 7 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | 21.0 | ITT | Logistic Regression Model | NRI | 2 | WK | EASI 75 | 19.184 | percent | 95%CI | 13.061 | 27.755 | 64.0 | 33.8 | YR | |||||||||||||||||||||||||||
| 12 | 10 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | 44.0 | ITT | Logistic Regression Model | NRI | 12 | WK | EASI 75 | 40.0 | percent | 95%CI | 31.429 | 49.388 | 64.0 | 33.8 | YR | |||||||||||||||||||||||||||
| 1 | 6 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | 5.0 | ITT | Logistic Regression Model | NRI | 1 | WK | EASI 75 | 4.49 | percent | 95%CI | 1.633 | 10.204 | 64.0 | 33.8 | YR | |||||||||||||||||||||||||||
| easi50 | 16 | 19 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | 70.0 | ITT | Logistic Regression Model | NRI | 16 | WK | EASI 50 | 64.0 | percent | 64.0 | 33.8 | YR | |||||||||||||||||||||||||||||
| easi | 8 | 38 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | ITT | MMRM | 8 | WK | EASI | Mean | 29.3 | 0-72 score | 11.9 | SD | LS Mean | -60.526 | 2.895 | SE | 64.0 | 33.8 | YR | ||||||||||||||||||||||||
| 4 | 37 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | ITT | MMRM | 4 | WK | EASI | Mean | 29.3 | 0-72 score | 11.9 | SD | LS Mean | -57.895 | 2.763 | SE | 64.0 | 33.8 | YR | |||||||||||||||||||||||||
| 2 | 36 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | ITT | MMRM | 2 | WK | EASI | Mean | 29.3 | 0-72 score | 11.9 | SD | LS Mean | -48.158 | 2.763 | SE | 64.0 | 33.8 | YR | |||||||||||||||||||||||||
| 16 | 40 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | ITT | MMRM | 16 | WK | EASI | Mean | 29.3 | 0-72 score | 11.9 | SD | LS Mean | -58.2 | 3.7 | SE | 64.0 | 33.8 | YR | |||||||||||||||||||||||||
| 12 | 39 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | ITT | MMRM | 12 | WK | EASI | Mean | 29.3 | 0-72 score | 11.9 | SD | LS Mean | -62.895 | 3.29 | SE | 64.0 | 33.8 | YR | |||||||||||||||||||||||||
| 1 | 35 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | ITT | MMRM | 1 | WK | EASI | Mean | 29.3 | 0-72 score | 11.9 | SD | LS Mean | -33.947 | 2.5 | SE | 64.0 | 33.8 | YR | |||||||||||||||||||||||||
| 0 | 34 | control | Double-Blind | True | baricitinib | Janus kinase inhibitors | 2.0 | MG | ORAL | QD | TAB | 109 | 109.0 | ITT | MMRM | 0 | WK | EASI | Mean | 29.3 | 0-72 score | 11.9 | SD | LS Mean | 0.0 | 64.0 | 33.8 | YR |
291_silverberg_2020¶
Control rows matched by test output: 34 of 111
Literature data accuracy: 91.33%
Clinical data accuracy: 24.69%
Clinical data accuracy (drop unmatched): 80.61%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| abrocitinib | 200 | oncedaily | easi75 | 2 | 23 | c9t23 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 200 | mg | oral | once-daily | 155 | 152 | 37 | PPAS | Cochran-Mantel-Haenszel test | 2 | WK | EASI-75 | Percentage | 24.3 | percent | 56.8 | 33.5 | YR | ||||||||||||||||||||||||||
| 200.0 | qd | easi75 | 4 | 9 | c9t23 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 153.0 | 78.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 75 | 51.0 | percent | 95%CI | 43.1 | 58.9 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 75 | 100 | 100 | 17 | 0 | 100 | 50 | 33 | 57 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 25 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 200 | oncedaily | easi75 | 2 | 22 | c8t22 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 200 | mg | oral | once-daily | 155 | 152 | 37 | FAS | Cochran-Mantel-Haenszel test | 2 | WK | EASI-75 | Percentage | 24.3 | percent | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||
| 200.0 | qd | easi75 | 2 | 8 | c8t22 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 152.0 | 37.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 75 | 24.3 | percent | 95%CI | 17.5 | 31.2 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 75 | 100 | 100 | 17 | 0 | 100 | 75 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 200 | oncedaily | easi75 | 12 | 25 | c80t25 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 200 | mg | oral | once-daily | 155 | 130 | 81 | PPAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-75 | Percent | 62.3 | Percent | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||
| 200.0 | qd | easi75 | 12 | 80 | c80t25 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 130 | 130.0 | 81.0 | PP | 12 | WK | EASI 75 | 62.3 | percent | 95%CI | 54.0 | 70.6 | 56.8 | 33.5 | YR | |||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 75 | 100 | 100 | 17 | 0 | 33 | 75 | 67 | 67 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 100mg | oncedaily | easi75 | 12 | 2 | c7t2 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 100 mg | mg | oral | once-daily | 158 | 155 | 69 | FAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-75 | Percentage | 44.5 | percent | 95% CI | 37.1 | 53.3 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||
| 100.0 | qd | easi75 | 12 | 7 | c7t2 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 155.0 | 69.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 75 | 44.5 | percent | 95%CI | 36.7 | 52.3 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 55 | 100 | 100 | 17 | 0 | 100 | 75 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 50 | 75 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 100mg | oncedaily | easi75 | 12 | 3 | c79t3 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 100 mg | mg | oral | once-daily | 158 | 128 | 63 | PPAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-75 | Percent | 49.2 | Percent | 40.0 | 60.9 | 59.5 | 37.4 | YR | |||||||||||||||||||||||||
| 100.0 | qd | easi75 | 12 | 79 | c79t3 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 128 | 128.0 | 63.0 | PP | 12 | WK | EASI 75 | 49.2 | percent | 95%CI | 40.6 | 57.9 | 59.5 | 37.4 | YR | |||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 55 | 100 | 100 | 17 | 0 | 67 | 75 | 67 | 67 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 50 | 50 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | oncedaily | easi75 | 12 | 15 | c78t15 | test | Double-Blind | TRUE | Placebo | Oral | Once-daily | 78 | 52 | 7 | PPAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-75 | Percentage | 10.4 | percent | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||||
| 0.0 | qd | easi75 | 12 | 78 | c78t15 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 52 | 52.0 | 7.0 | PP | 12 | WK | EASI 75 | 13.5 | percent | 95%CI | 4.2 | 22.7 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 100 | 0 | 67 | 50 | 67 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 50 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| abrocitinib | 200 | oncedaily | easi90 | 12 | 33 | c62t33 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 200 | mg | oral | once-daily | 155 | 130 | 58 | PPAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-90 | Percentage | 37.7 | percent | 56.8 | 33.5 | YR | ||||||||||||||||||||||||||
| 200.0 | qd | easi | 12 | 62 | c62t33 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 12 | WK | EASI | Mean | 29.0 | 0-72 score | 12.4 | SD | LS Mean | -73.3 | 95%CI | -79.7 | -66.9 | 56.8 | 33.5 | YR | ||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 75 | 100 | 100 | 17 | 0 | 100 | 25 | 0 | 57 | 12 | 100 | 100 | 100 | 73 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | |||||||
| 100mg | oncedaily | easi75 | 2 | 1 | c5t1 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 100 mg | mg | oral | once-daily | 158 | 157 | 56 | PPAS | Cochran-Mantel-Haenszel test | 2 | WK | EASI-75 | Percentage | 35.7 | percent | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||
| 100.0 | qd | easi75 | 4 | 5 | c5t1 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 155.0 | 41.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 75 | 26.5 | percent | 95%CI | 19.5 | 33.4 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 55 | 100 | 100 | 17 | 0 | 100 | 50 | 0 | 57 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 25 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 100mg | oncedaily | easi50 | 12 | 9 | c57t9 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 100 mg | mg | oral | once-daily | 158 | 128 | 106 | PPAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-50 | Percentage | 68.4 | percent | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||
| 100.0 | qd | easi | 12 | 57 | c57t9 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 12 | WK | EASI | Mean | 28.4 | 0-72 score | 11.2 | SD | LS Mean | -60.0 | 95%CI | -66.5 | -53.6 | 59.5 | 37.4 | YR | ||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 55 | 100 | 100 | 17 | 0 | 100 | 50 | 0 | 57 | 12 | 100 | 100 | 100 | 73 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | |||||||
| 100mg | oncedaily | easi50 | 2 | 7 | c53t7 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 100 mg | mg | oral | once-daily | 158 | 157 | 56 | PPAS | Cochran-Mantel-Haenszel test | 2 | WK | EASI-50 | Percentage | 35.7 | percent | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||
| 100.0 | qd | easi | 0 | 53 | c53t7 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 0 | WK | EASI | Mean | 28.4 | 0-72 score | 11.2 | SD | LS Mean | 0.0 | 59.5 | 37.4 | YR | |||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 55 | 100 | 100 | 17 | 0 | 100 | 50 | 0 | 57 | 12 | 100 | 0 | 100 | 73 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 100mg | oncedaily | easi75 | 2 | 0 | c4t0 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 100 mg | mg | oral | once-daily | 158 | 157 | 16 | FAS | Cochran-Mantel-Haenszel test | 2 | WK | EASI-75 | Percentage | 10.2 | percent | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||
| 100.0 | qd | easi75 | 2 | 4 | c4t0 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 157.0 | 16.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 75 | 10.2 | percent | 95%CI | 5.5 | 14.9 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 55 | 100 | 100 | 17 | 0 | 100 | 75 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 200 | oncedaily | easi50 | 12 | 29 | c47t29 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 200 | mg | oral | once-daily | 155 | 130 | 123 | PPAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-50 | Percentage | 79.9 | percent | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||
| 200.0 | qd | easi100 | 12 | 47 | c47t29 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 154.0 | 11.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 100 | 7.1 | percent | 95%CI | 3.1 | 11.2 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 75 | 100 | 100 | 17 | 0 | 100 | 25 | 29 | 57 | 100 | 100 | 100 | 100 | 80 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 29 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | oncedaily | easi75 | 12 | 14 | c3t14 | test | Double-Blind | TRUE | Placebo | Oral | Once-daily | 78 | 77 | 8 | FAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-75 | Percentage | 10.4 | percent | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||||
| 0.0 | qd | easi75 | 12 | 3 | c3t14 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 77.0 | 8.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 75 | 10.4 | percent | 95%CI | 3.6 | 17.2 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 100 | 100 | 67 | 50 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| oncedaily | easi50 | 12 | 19 | c39t19 | test | Double-Blind | TRUE | Placebo | Oral | Once-daily | 78 | 52 | 15 | PPAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-50 | Percentage | 19.5 | percent | 60.3 | 33.4 | YR | |||||||||||||||||||||||||||||||
| 0.0 | qd | easi100 | 12 | 39 | c39t19 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 77.0 | 0.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 100 | 0.0 | percent | 95%CI | 0.0 | 4.7 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 100 | 100 | 0 | 0 | 57 | 100 | 100 | 100 | 100 | 80 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 29 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| abrocitinib | 200 | oncedaily | easi90 | 12 | 32 | c35t32 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 200 | mg | oral | once-daily | 155 | 154 | 58 | FAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-90 | Percentage | 37.7 | percent | 56.8 | 33.5 | YR | ||||||||||||||||||||||||||
| 200.0 | qd | easi90 | 12 | 35 | c35t32 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 154.0 | 58.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 90 | 37.7 | percent | 95%CI | 30.0 | 45.3 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 75 | 100 | 100 | 17 | 0 | 100 | 75 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 200 | oncedaily | easi90 | 2 | 31 | c33t31 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 200 | mg | oral | once-daily | 155 | 152 | 14 | PPAS | Cochran-Mantel-Haenszel test | 2 | WK | EASI-90 | Percentage | 9.2 | percent | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||
| 200.0 | qd | easi90 | 4 | 33 | c33t31 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 153.0 | 35.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 90 | 22.9 | percent | 95%CI | 16.2 | 29.5 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 75 | 100 | 100 | 17 | 0 | 100 | 50 | 0 | 57 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 86 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 200 | oncedaily | easi90 | 2 | 30 | c32t30 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 200 | mg | oral | once-daily | 155 | 152 | 14 | FAS | Cochran-Mantel-Haenszel test | 2 | WK | EASI-90 | Percentage | 9.2 | percent | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||
| 200.0 | qd | easi90 | 2 | 32 | c32t30 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 152.0 | 14.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 90 | 9.2 | percent | 95%CI | 4.6 | 13.8 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 75 | 100 | 100 | 17 | 0 | 100 | 75 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 100mg | oncedaily | easi90 | 12 | 10 | c31t10 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 100 mg | mg | oral | once-daily | 158 | 155 | 37 | FAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-90 | Percentage | 23.9 | percent | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||
| 100.0 | qd | easi90 | 12 | 31 | c31t10 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 155.0 | 37.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 90 | 23.9 | percent | 95%CI | 17.2 | 30.6 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 55 | 100 | 100 | 17 | 0 | 100 | 75 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 100mg | oncedaily | easi90 | 12 | 11 | c28t11 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 100 mg | mg | oral | once-daily | 158 | 128 | 37 | PPAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-90 | Percentage | 23.9 | percent | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||
| 100.0 | qd | easi90 | 2 | 28 | c28t11 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 157.0 | 4.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 90 | 2.5 | percent | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 55 | 100 | 100 | 17 | 0 | 100 | 25 | 0 | 57 | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 57 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | oncedaily | easi90 | 12 | 20 | c27t20 | test | Double-Blind | TRUE | Placebo | Oral | Once-daily | 78 | 77 | 3 | FAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-90 | Percentage | 3.9 | percent | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||||
| 0.0 | qd | easi90 | 12 | 27 | c27t20 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 77.0 | 3.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 90 | 3.9 | percent | 95%CI | 0.0 | 8.2 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 100 | 100 | 67 | 50 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| oncedaily | easi90 | 12 | 21 | c24t21 | test | Double-Blind | TRUE | Placebo | Oral | Once-daily | 78 | 52 | 3 | PPAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-90 | Percentage | 3.9 | percent | 60.3 | 33.4 | YR | |||||||||||||||||||||||||||||||
| 0.0 | qd | easi90 | 2 | 24 | c24t21 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 76.0 | 0.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 90 | 0.0 | percent | 95%CI | -4.7 | 4.7 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 100 | 100 | 0 | 0 | 57 | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 33 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| abrocitinib | 200 | oncedaily | easi50 | 12 | 28 | c23t28 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 200 | mg | oral | once-daily | 155 | 154 | 123 | FAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-50 | Percentage | 79.9 | percent | 56.8 | 33.5 | YR | ||||||||||||||||||||||||||
| 200.0 | qd | easi50 | 12 | 23 | c23t28 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 154.0 | 123.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 50 | 79.9 | percent | 95%CI | 73.5 | 86.2 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 75 | 100 | 100 | 17 | 0 | 100 | 75 | 75 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 200 | oncedaily | easi50 | 2 | 27 | c21t27 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 200 | mg | oral | once-daily | 155 | 152 | 84 | PPAS | Cochran-Mantel-Haenszel test | 2 | WK | EASI-50 | Percentage | 55.3 | percent | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||
| 200.0 | qd | easi50 | 4 | 21 | c21t27 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 153.0 | 120.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 50 | 78.4 | percent | 95%CI | 71.9 | 84.9 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 75 | 100 | 100 | 17 | 0 | 100 | 50 | 0 | 57 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 25 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 200 | oncedaily | easi50 | 2 | 26 | c20t26 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 200 | mg | oral | once-daily | 155 | 152 | 84 | FAS | Cochran-Mantel-Haenszel test | 2 | WK | EASI-50 | Percentage | 55.3 | percent | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||
| 200.0 | qd | easi50 | 2 | 20 | c20t26 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 152.0 | 84.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 50 | 55.3 | percent | 95%CI | 47.4 | 63.2 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 75 | 100 | 100 | 17 | 0 | 100 | 75 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | oncedaily | easi75 | 2 | 13 | c1t13 | test | Double-Blind | TRUE | Placebo | Oral | Once-daily | 78 | 76 | 1 | PPAS | Cochran-Mantel-Haenszel test | 2 | WK | EASI-75 | Percentage | 1.3 | percent | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||||
| 0.0 | qd | easi75 | 4 | 1 | c1t13 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 77.0 | 5.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 75 | 6.5 | percent | 95%CI | 1.0 | 12.0 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 100 | 100 | 33 | 0 | 57 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 33 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| abrocitinib | 100mg | oncedaily | easi50 | 12 | 8 | c19t8 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 100 mg | mg | oral | once-daily | 158 | 155 | 106 | FAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-50 | Percentage | 68.4 | percent | 59.5 | 37.4 | YR | ||||||||||||||||||||||||||
| 100.0 | qd | easi50 | 12 | 19 | c19t8 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 155.0 | 106.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 50 | 68.4 | percent | 95%CI | 61.1 | 75.7 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 55 | 100 | 100 | 17 | 0 | 100 | 75 | 75 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 100mg | oncedaily | easi50 | 4 | 5 | c18t5 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 100 mg | mg | oral | once-daily | 158 | 157 | 56 | PPAS | Cochran-Mantel-Haenszel test | 4 | WK | EASI-50 | Percentage | 35.7 | percent | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||
| 100.0 | qd | easi50 | 8 | 18 | c18t5 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 157.0 | 104.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 50 | 66.2 | percent | 95%CI | 58.8 | 73.6 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 55 | 100 | 100 | 17 | 0 | 100 | 75 | 0 | 57 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 25 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 100mg | oncedaily | easi50 | 4 | 4 | c17t4 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 100 mg | mg | oral | once-daily | 158 | 157 | 56 | FAS | Cochran-Mantel-Haenszel test | 4 | WK | EASI-50 | Percentage | 35.7 | percent | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||
| 100.0 | qd | easi50 | 4 | 17 | c17t4 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 155.0 | 91.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 50 | 58.7 | percent | 95%CI | 51.0 | 66.5 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 55 | 100 | 100 | 17 | 0 | 100 | 50 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 75 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 100mg | oncedaily | easi50 | 2 | 6 | c16t6 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 100 mg | mg | oral | once-daily | 158 | 157 | 56 | FAS | Cochran-Mantel-Haenszel test | 2 | WK | EASI-50 | Percentage | 35.7 | percent | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||
| 100.0 | qd | easi50 | 2 | 16 | c16t6 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 157.0 | 56.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 50 | 35.7 | percent | 95%CI | 28.2 | 43.2 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 55 | 100 | 100 | 17 | 0 | 100 | 75 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | oncedaily | easi50 | 12 | 18 | c15t18 | test | Double-Blind | TRUE | Placebo | Oral | Once-daily | 78 | 77 | 15 | FAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-50 | Percentage | 19.5 | percent | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||||
| 0.0 | qd | easi50 | 12 | 15 | c15t18 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 77.0 | 15.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 50 | 19.5 | percent | 95%CI | 10.6 | 28.3 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 100 | 100 | 67 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| oncedaily | easi50 | 2 | 17 | c13t17 | test | Double-Blind | TRUE | Placebo | Oral | Once-daily | 78 | 76 | 8 | PPAS | Cochran-Mantel-Haenszel test | 2 | WK | EASI-50 | Percentage | 10.5 | percent | 60.3 | 33.4 | YR | |||||||||||||||||||||||||||||||
| 0.0 | qd | easi50 | 4 | 13 | c13t17 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 77.0 | 22.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 50 | 28.6 | percent | 95%CI | 18.5 | 38.7 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 100 | 100 | 33 | 0 | 57 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 25 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| oncedaily | easi50 | 2 | 16 | c12t16 | test | Double-Blind | TRUE | Placebo | Oral | Once-daily | 78 | 76 | 8 | FAS | Cochran-Mantel-Haenszel test | 2 | WK | EASI-50 | Percentage | 10.5 | percent | 60.3 | 33.4 | YR | |||||||||||||||||||||||||||||||
| 0.0 | qd | easi50 | 2 | 12 | c12t16 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 76.0 | 8.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 50 | 10.5 | percent | 95%CI | 3.6 | 17.4 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 100 | 100 | 67 | 50 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| abrocitinib | 200 | oncedaily | easi75 | 12 | 24 | c11t24 | test | Double-Blind | TRUE | abrocitinib | Janus kinase 1 selective inhibitor | 200 | mg | oral | once-daily | 155 | 154 | 94 | FAS | Cochran-Mantel-Haenszel test | 12 | WK | EASI-75 | Percentage | 61.0 | percent | 95% CI | 40.0 | 60.9 | 56.8 | 33.5 | YR | |||||||||||||||||||||||
| 200.0 | qd | easi75 | 12 | 11 | c11t24 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 154.0 | 94.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 75 | 61.0 | percent | 95%CI | 53.3 | 68.7 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 77 | 75 | 100 | 100 | 17 | 0 | 100 | 75 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 25 | 50 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | oncedaily | easi75 | 2 | 12 | c0t12 | test | Double-Blind | TRUE | Placebo | Oral | Once-daily | 78 | 76 | 1 | FAS | Cochran-Mantel-Haenszel test | 2 | WK | EASI-75 | Percentage | 1.3 | percent | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||||
| 0.0 | qd | easi75 | 2 | 0 | c0t12 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 76.0 | 1.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 75 | 1.3 | percent | 95%CI | 0.0 | 3.9 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 100 | 100 | 67 | 50 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| scorad | 8 | 99 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 8 | WK | SCORAD | LS Mean | -1.5 | 0-103 score | 95%CI | -2.1 | -0.9 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||
| 84 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 8 | WK | SCORAD | LS Mean | -1.8 | 0-103 score | 95%CI | -2.4 | -1.2 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||||
| 66 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 8 | WK | SCORAD | Mean | 64.3 | 0-103 pt scale | 12.4 | SD | LS Mean | -23.1 | 95%CI | -29.2 | -17.1 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||
| 4 | 98 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 4 | WK | SCORAD | LS Mean | -1.0 | 0-103 score | 95%CI | -1.5 | -0.5 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||||||
| 83 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 4 | WK | SCORAD | LS Mean | -1.2 | 0-103 score | 95%CI | -1.7 | -0.6 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||||
| 65 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 4 | WK | SCORAD | Mean | 64.3 | 0-103 pt scale | 12.4 | SD | LS Mean | -17.2 | 95%CI | -22.5 | -12.0 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||
| 2 | 97 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 2 | WK | SCORAD | LS Mean | -0.5 | 0-103 score | 95%CI | -1.0 | 0.0 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||||||
| 82 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 2 | WK | SCORAD | LS Mean | -0.6 | 0-103 score | 95%CI | -1.1 | -0.1 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||||
| 64 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 2 | WK | SCORAD | Mean | 64.3 | 0-103 pt scale | 12.4 | SD | LS Mean | -6.3 | 95%CI | -11.0 | -1.6 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||
| 12 | 100 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 12 | WK | SCORAD | LS Mean | -2.1 | 0-103 score | 95%CI | -2.7 | -1.5 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||||||
| 85 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 12 | WK | SCORAD | LS Mean | -2.1 | 0-103 score | 95%CI | -2.7 | -1.4 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||||
| 67 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 12 | WK | SCORAD | Mean | 64.3 | 0-103 pt scale | 12.4 | SD | LS Mean | -22.7 | 95%CI | -30.4 | -15.1 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||
| 0 | 96 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 0 | WK | SCORAD | LS Mean | 0.0 | 0-103 score | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||||||
| 81 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 0 | WK | SCORAD | LS Mean | 0.0 | 0-103 score | 60.3 | 33.4 | YR | |||||||||||||||||||||||||||||||||
| 63 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 0 | WK | SCORAD | Mean | 64.3 | 0-103 pt scale | 12.4 | SD | LS Mean | 0.0 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||||||
| easi90 | 8 | 26 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | 2.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 90 | 2.6 | percent | 95%CI | 0.0 | 6.1 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||
| 4 | 25 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 77.0 | 0.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 90 | 0.0 | percent | 95%CI | -4.7 | 4.7 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||||||
| easi75 | 8 | 2 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | 10.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 75 | 12.8 | percent | 95%CI | 5.4 | 20.2 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||
| easi50 | 8 | 14 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | 27.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 50 | 34.6 | percent | 95%CI | 24.1 | 45.2 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||
| easi100 | 8 | 38 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | 0.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 100 | 0.0 | percent | 95%CI | 0.0 | 4.6 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||
| 4 | 37 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 77.0 | 0.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 100 | 0.0 | percent | 95%CI | 0.0 | 4.7 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||||||
| 2 | 36 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 76.0 | 0.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 100 | 0.0 | percent | 95%CI | 0.0 | 4.7 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||||||
| easi | 8 | 51 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 8 | WK | EASI | Mean | 28.0 | 0-72 score | 10.2 | SD | LS Mean | -33.0 | 95%CI | -41.1 | -25.0 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||
| 4 | 50 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 4 | WK | EASI | Mean | 28.0 | 0-72 score | 10.2 | SD | LS Mean | -24.4 | 95%CI | -31.1 | -17.7 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||
| 2 | 49 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 2 | WK | EASI | Mean | 28.0 | 0-72 score | 10.2 | SD | LS Mean | -9.0 | 95%CI | -15.4 | -2.5 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||
| 12 | 52 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 12 | WK | EASI | Mean | 28.0 | 0-72 score | 10.2 | SD | LS Mean | -28.6 | 95%CI | -38.4 | -18.8 | 60.3 | 33.4 | YR | |||||||||||||||||||||||||
| 0 | 48 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | 78 | 78.0 | FAS | MMRM | 0 | WK | EASI | Mean | 28.0 | 0-72 score | 10.2 | SD | LS Mean | 0.0 | 60.3 | 33.4 | YR | ||||||||||||||||||||||||||||
| abrocitinib | 200.0 | qd | scorad | 8 | 109 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 8 | WK | SCORAD | LS Mean | -3.9 | 0-103 score | 95%CI | -4.3 | -3.5 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||
| 94 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 8 | WK | SCORAD | LS Mean | -4.3 | 0-103 score | 95%CI | -4.7 | -4.0 | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||||
| 76 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 8 | WK | SCORAD | Mean | 64.1 | 0-103 pt scale | 13.1 | SD | LS Mean | -56.7 | 95%CI | -60.9 | -52.6 | 56.8 | 33.5 | YR | |||||||||||||||||||||||||
| 4 | 108 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 4 | WK | SCORAD | LS Mean | -3.9 | 0-103 score | 95%CI | -4.3 | -3.6 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||||||
| 93 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 4 | WK | SCORAD | LS Mean | -4.3 | 0-103 score | 95%CI | -4.6 | -3.9 | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||||
| 75 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 4 | WK | SCORAD | Mean | 64.1 | 0-103 pt scale | 13.1 | SD | LS Mean | -53.1 | 95%CI | -56.9 | -49.4 | 56.8 | 33.5 | YR | |||||||||||||||||||||||||
| 2 | 107 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 2 | WK | SCORAD | LS Mean | -2.9 | 0-103 score | 95%CI | -3.3 | -2.5 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||||||
| 92 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 2 | WK | SCORAD | LS Mean | -3.5 | 0-103 score | 95%CI | -3.8 | -3.1 | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||||
| 74 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 2 | WK | SCORAD | Mean | 64.1 | 0-103 pt scale | 13.1 | SD | LS Mean | -38.5 | 95%CI | -41.8 | -35.1 | 56.8 | 33.5 | YR | |||||||||||||||||||||||||
| 12 | 110 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 12 | WK | SCORAD | LS Mean | -3.8 | 0-103 score | 95%CI | -4.2 | -3.4 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||||||
| 95 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 12 | WK | SCORAD | LS Mean | -4.2 | 0-103 score | 95%CI | -4.7 | -3.8 | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||||
| 77 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 12 | WK | SCORAD | Mean | 64.1 | 0-103 pt scale | 13.1 | SD | LS Mean | -56.2 | 95%CI | -61.2 | -51.1 | 56.8 | 33.5 | YR | |||||||||||||||||||||||||
| 0 | 106 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 0 | WK | SCORAD | LS Mean | 0.0 | 0-103 score | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||||||
| 91 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 0 | WK | SCORAD | LS Mean | 0.0 | 0-103 score | 56.8 | 33.5 | YR | ||||||||||||||||||||||||||||||||
| 73 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 0 | WK | SCORAD | Mean | 64.1 | 0-103 pt scale | 13.1 | SD | LS Mean | 0.0 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||||||
| easi90 | 8 | 34 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 154.0 | 53.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 90 | 34.4 | percent | 95%CI | 26.9 | 41.9 | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||
| easi75 | 8 | 10 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 154.0 | 93.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 75 | 60.4 | percent | 95%CI | 52.7 | 68.1 | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||
| easi50 | 8 | 22 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 154.0 | 127.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 50 | 82.5 | percent | 95%CI | 76.5 | 88.5 | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||
| easi100 | 8 | 46 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 154.0 | 6.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 100 | 3.9 | percent | 95%CI | 0.8 | 7.0 | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||
| 4 | 45 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 153.0 | 6.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 100 | 3.9 | percent | 95%CI | 0.8 | 7.0 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||||||
| 2 | 44 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 152.0 | 2.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 100 | 1.3 | percent | 95%CI | 0.0 | 3.1 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||||||
| easi | 8 | 61 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 8 | WK | EASI | Mean | 29.0 | 0-72 score | 12.4 | SD | LS Mean | -73.2 | 95%CI | -78.7 | -67.7 | 56.8 | 33.5 | YR | |||||||||||||||||||||||
| 4 | 60 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 4 | WK | EASI | Mean | 29.0 | 0-72 score | 12.4 | SD | LS Mean | -69.0 | 95%CI | -73.7 | -64.2 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||
| 2 | 59 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 2 | WK | EASI | Mean | 29.0 | 0-72 score | 12.4 | SD | LS Mean | -51.3 | 95%CI | -55.9 | -46.7 | 56.8 | 33.5 | YR | ||||||||||||||||||||||||
| 0 | 58 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 200.0 | MG | ORAL | QD | TAB | 155 | 155.0 | FAS | MMRM | 0 | WK | EASI | Mean | 29.0 | 0-72 score | 12.4 | SD | LS Mean | 0.0 | 56.8 | 33.5 | YR | |||||||||||||||||||||||||||
| 100.0 | qd | scorad | 8 | 104 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 8 | WK | SCORAD | LS Mean | -3.1 | 0-103 score | 95%CI | -3.5 | -2.7 | 59.5 | 37.4 | YR | |||||||||||||||||||||||||
| 89 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 8 | WK | SCORAD | LS Mean | -3.4 | 0-103 score | 95%CI | -3.8 | -3.0 | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||||
| 71 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 8 | WK | SCORAD | Mean | 63.8 | 0-103 pt scale | 11.4 | SD | LS Mean | -42.6 | 95%CI | -46.7 | -38.4 | 59.5 | 37.4 | YR | |||||||||||||||||||||||||
| 4 | 103 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 4 | WK | SCORAD | LS Mean | -2.8 | 0-103 score | 95%CI | -3.1 | -2.4 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||||||
| 88 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 4 | WK | SCORAD | LS Mean | -3.1 | 0-103 score | 95%CI | -3.5 | -2.7 | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||||
| 70 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 4 | WK | SCORAD | Mean | 63.8 | 0-103 pt scale | 11.4 | SD | LS Mean | -38.798 | 95%CI | -42.6 | -35.1 | 59.5 | 37.4 | YR | |||||||||||||||||||||||||
| 2 | 102 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 2 | WK | SCORAD | LS Mean | -1.9 | 0-103 score | 95%CI | -2.2 | -1.5 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||||||
| 87 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 2 | WK | SCORAD | LS Mean | -2.3 | 0-103 score | 95%CI | -2.7 | -2.0 | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||||
| 69 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 2 | WK | SCORAD | Mean | 63.8 | 0-103 pt scale | 11.4 | SD | LS Mean | -27.2 | 95%CI | -30.5 | -23.9 | 59.5 | 37.4 | YR | |||||||||||||||||||||||||
| 12 | 105 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 12 | WK | SCORAD | LS Mean | -3.0 | 0-103 score | 95%CI | -3.4 | -2.6 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||||||
| 90 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 12 | WK | SCORAD | LS Mean | -3.5 | 0-103 score | 95%CI | -3.9 | -3.1 | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||||
| 72 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 12 | WK | SCORAD | Mean | 63.8 | 0-103 pt scale | 11.4 | SD | LS Mean | -45.8 | 95%CI | -50.9 | -40.7 | 59.5 | 37.4 | YR | |||||||||||||||||||||||||
| 0 | 101 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 0 | WK | SCORAD | LS Mean | 0.0 | 0-103 score | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||||||
| 86 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 0 | WK | SCORAD | LS Mean | 0.0 | 0-103 score | 59.5 | 37.4 | YR | ||||||||||||||||||||||||||||||||
| 68 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 0 | WK | SCORAD | Mean | 63.8 | 0-103 pt scale | 11.4 | SD | LS Mean | 0.0 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||||||
| easi90 | 8 | 30 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 157.0 | 27.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 90 | 17.2 | percent | 95%CI | 11.3 | 23.1 | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||
| 4 | 29 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 155.0 | 15.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 90 | 9.7 | percent | 95%CI | 5.0 | 14.3 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||||||
| easi75 | 8 | 6 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 157.0 | 68.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 75 | 43.3 | percent | 95%CI | 35.6 | 51.1 | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||
| easi100 | 8 | 42 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 157.0 | 2.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 100 | 1.3 | percent | 95%CI | 0.0 | 3.0 | 59.5 | 37.4 | YR | |||||||||||||||||||||||||||
| 4 | 41 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 155.0 | 2.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 100 | 1.3 | percent | 95%CI | 0.0 | 3.1 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||||||
| 2 | 40 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 157.0 | 0.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 100 | 0.0 | percent | 95%CI | 0.0 | 2.3 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||||||
| 12 | 43 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 155.0 | 8.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 100 | 5.2 | percent | 95%CI | 1.7 | 8.6 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||||||
| easi | 8 | 56 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 8 | WK | EASI | Mean | 28.4 | 0-72 score | 11.2 | SD | LS Mean | -59.5 | 95%CI | -65.0 | -54.0 | 59.5 | 37.4 | YR | |||||||||||||||||||||||
| 4 | 55 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 4 | WK | EASI | Mean | 28.4 | 0-72 score | 11.2 | SD | LS Mean | -54.3 | 95%CI | -59.1 | -49.5 | 59.5 | 37.4 | YR | ||||||||||||||||||||||||
| 2 | 54 | control | Double-Blind | True | abrocitinib | Janus kinase inhibitors | 100.0 | MG | ORAL | QD | TAB | 158 | 158.0 | FAS | MMRM | 2 | WK | EASI | Mean | 28.4 | 0-72 score | 11.2 | SD | LS Mean | -39.2 | 95%CI | -43.8 | -34.7 | 59.5 | 37.4 | YR |
287_silverberg_2021¶
Control rows matched by test output: 9 of 84
Literature data accuracy: 84.93%
Clinical data accuracy: 9.05%
Clinical data accuracy (drop unmatched): 84.43%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| tralokinumab | 300 | q2w | easi90 | 16 | 2 | c83t2 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 253 | 252 | 83 | FAS | NRI | 16 | WK | EASI-90 | n(%) | 32.9 | percent | 95% CI (2.1-20.7) | 2.1 | 20.7 | 49.4 | 37.0 | YR | |||||||||||||||||||||||
| 300.0 | q2w | easi90 | 16 | 83 | c83t2 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 83.0 | FAS | NRI | 16 | WK | EASI 90 | 32.9 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 67 | 75 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 300 | q2w | easi90 | 16 | 5 | c78t5 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 252 | 252 | 83 | FAS | Cochran-Mantel-Haenszel test | NRI | 16 | WK | EASI-90 | Percent | 32.9 | Percent | 95% CI | 2.1 | 20.7 | 49.4 | 37.0 | YR | |||||||||||||||||||||||
| 300.0 | q2w | easi90 | 6 | 78 | c78t5 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 41.0 | FAS | NRI | 6 | WK | EASI 90 | 16.1444 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 100 | 75 | 0 | 100 | 0 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 18 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 300 | q2w | easi50 | 16 | 1 | c67t1 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 253 | 252 | 200 | FAS | Cochran-Mantel-Haenszel test | NRI | 16 | WK | EASI-50 | Percent | 79.4 | Percent | 11.3 | 31.3 | 49.4 | 37.0 | YR | ||||||||||||||||||||||||
| 300.0 | q2w | easi50 | 16 | 67 | c67t1 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 200.0 | FAS | NRI | 16 | WK | EASI 50 | 79.4 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 67 | 75 | 75 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 300 | q2w | easi50 | 16 | 4 | c62t4 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 252 | 252 | 200 | FAS | Cochran-Mantel-Haenszel test | NRI | 16 | WK | EASI-50 | Percent | 79.4 | Percent | 11.3 | 31.3 | 49.4 | 37.0 | YR | ||||||||||||||||||||||||
| 300.0 | q2w | easi50 | 6 | 62 | c62t4 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 177.0 | FAS | NRI | 6 | WK | EASI 50 | 70.1333 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 100 | 75 | 25 | 100 | 0 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 36 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | q2w | easi50 | 16 | 8 | c59t8 | test | Double-Blind | TRUE | Placebo | Placebo | SC | Q2W | 126 | 126 | 73 | FAS | Cochran-Mantel-Haenszel test | NRI | 16 | WK | EASI-50 | Percent | 57.9 | Percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||
| 0.0 | q2w | easi50 | 16 | 59 | c59t8 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 73.0 | FAS | NRI | 16 | WK | EASI 50 | 57.9 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 75 | 67 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| tralokinumab | 300 | q2w | easi75 | 16 | 0 | c33t0 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 253 | 252 | 141 | FAS | Cochran-Mantel-Haenszel test | NRI | 16 | WK | EASI-75 | Percent | 56.0 | Percent | 95% CI | 9.8 | 30.6 | 49.4 | 37.0 | YR | ||||||||||||||||||||||
| 300.0 | q2w | easi75 | 16 | 33 | c33t0 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 141.0 | FAS | NRI | 16 | WK | EASI 75 | 56.0 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 67 | 75 | 75 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 300 | q2w | easi75 | 16 | 3 | c28t3 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 252 | 252 | 141 | FAS | Cochran-Mantel-Haenszel test | NRI | 16 | WK | EASI-75 | Percent | 56.0 | Percent | 95% CI | 9.8 | 30.6 | 49.4 | 37.0 | YR | |||||||||||||||||||||||
| 300.0 | q2w | easi75 | 6 | 28 | c28t3 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 105.0 | FAS | NRI | 6 | WK | EASI 75 | 41.679 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 100 | 75 | 25 | 100 | 0 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 40 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 300 | every4weeks | easi75 | 32 | 6 | c26t6 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Every 4 weeks | 69 | 69 | 63 | FAS | Cochran-Mantel-Haenszel test | NRI | 32 | WK | EASI-75 | Percent | 90.8 | percent | 95% CI | 81.3 | 95.7 | ||||||||||||||||||||||||||
| 300.0 | q2w | easi75 | 2 | 26 | c26t6 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 42.0 | FAS | NRI | 2 | WK | EASI 75 | 16.641 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 12 | 100 | 0 | 0 | 0 | 100 | 0 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 20 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| placebo | q2w | easi75 | 16 | 7 | c25t7 | test | Double-Blind | TRUE | Placebo | Placebo | SC | Q2W | 126 | 126 | 45 | FAS | Cochran-Mantel-Haenszel test | NRI | 16 | WK | EASI-75 | Percent | 35.7 | Percent | 95% CI | 27.3 | 44.9 | 66.1 | 34.0 | YR | |||||||||||||||||||||||||
| 0.0 | q2w | easi75 | 16 | 25 | c25t7 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 45.0 | FAS | NRI | 16 | WK | EASI 75 | 35.7 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 75 | 67 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| tralokinumab | 600.0 | q2w | scorad | 0 | 43 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 600.0 | MG | SC | Q2W | 252 | 252.0 | FAS | MMRM | OC | 0 | WK | SCORAD | Mean | 67.0 | 0-103 pt scale | 13.3 | SD | LS Mean | 0.0 | 0-103 pt scale | Mean | 67.0 | 0-103 pt scale | 13.3 | SD | 49.4 | 37.0 | YR | |||||||||||||||||
| easi | 0 | 9 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 600.0 | MG | SC | Q2W | 252 | 252.0 | FAS | MMRM | OC | 0 | WK | EASI | Median | 24.7 | 0-72 score | 12.963 | SD | LS Mean | 0.0 | 0-72 score | Mean | 0.0 | 49.4 | 37.0 | YR | |||||||||||||||||||||||
| 300.0 | q2w | scorad | 8 | 47 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 243.0 | FAS | MMRM | OC | 8 | WK | SCORAD | Mean | 67.0 | 0-103 pt scale | 13.3 | SD | LS Mean | -34.0 | 0-103 pt scale | 1.03 | SE | Mean | 32.7 | 0-103 pt scale | 16.2 | SD | 49.4 | 37.0 | YR | ||||||||||||||||
| 6 | 46 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 247.0 | FAS | MMRM | OC | 6 | WK | SCORAD | Mean | 67.0 | 0-103 pt scale | 13.3 | SD | LS Mean | -31.1 | 0-103 pt scale | 1.03 | SE | Mean | 35.7 | 0-103 pt scale | 16.2 | SD | 49.4 | 37.0 | YR | |||||||||||||||||||
| 4 | 45 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 246.0 | FAS | MMRM | OC | 4 | WK | SCORAD | Mean | 67.0 | 0-103 pt scale | 13.3 | SD | LS Mean | -26.9 | 0-103 pt scale | 1.02 | SE | Mean | 40.1 | 0-103 pt scale | 16.7 | SD | 49.4 | 37.0 | YR | |||||||||||||||||||
| 2 | 44 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 249.0 | FAS | MMRM | OC | 2 | WK | SCORAD | Mean | 67.0 | 0-103 pt scale | 13.3 | SD | LS Mean | -20.6 | 0-103 pt scale | 0.93 | SE | Mean | 46.5 | 0-103 pt scale | 16.7 | SD | 49.4 | 37.0 | YR | |||||||||||||||||||
| 16 | 51 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 235.0 | FAS | MMRM | OC | 16 | WK | SCORAD | Mean | 67.0 | 0-103 pt scale | 13.3 | SD | LS Mean | -37.7 | 0-103 pt scale | 1.25 | SE | Mean | 29.2 | 0-103 pt scale | 18.7 | SD | 49.4 | 37.0 | YR | |||||||||||||||||||
| 14 | 50 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 235.0 | FAS | MMRM | OC | 14 | WK | SCORAD | Mean | 67.0 | 0-103 pt scale | 13.3 | SD | LS Mean | -38.2 | 0-103 pt scale | 1.21 | SE | Mean | 28.5 | 0-103 pt scale | 18.2 | SD | 49.4 | 37.0 | YR | |||||||||||||||||||
| 12 | 49 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 238.0 | FAS | MMRM | OC | 12 | WK | SCORAD | Mean | 67.0 | 0-103 pt scale | 13.3 | SD | LS Mean | -37.6 | 0-103 pt scale | 1.16 | SE | Mean | 29.4 | 0-103 pt scale | 17.2 | SD | 49.4 | 37.0 | YR | |||||||||||||||||||
| 10 | 48 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 236.0 | FAS | MMRM | OC | 10 | WK | SCORAD | Mean | 67.0 | 0-103 pt scale | 13.3 | SD | LS Mean | -36.4 | 0-103 pt scale | 1.1 | SE | Mean | 30.2 | 0-103 pt scale | 16.8 | SD | 49.4 | 37.0 | YR | |||||||||||||||||||
| easi90 | 8 | 79 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 54.0 | FAS | NRI | 8 | WK | EASI 90 | 21.6202 | percent | 49.4 | 37.0 | YR | |||||||||||||||||||||||||||||||
| 4 | 77 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 25.0 | FAS | NRI | 4 | WK | EASI 90 | 10.1056 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 76 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 8.0 | FAS | NRI | 2 | WK | EASI 90 | 3.08109 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 14 | 82 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 85.0 | FAS | NRI | 14 | WK | EASI 90 | 33.5392 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 81 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 77.0 | FAS | NRI | 12 | WK | EASI 90 | 30.7398 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 10 | 80 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 71.0 | FAS | NRI | 10 | WK | EASI 90 | 28.363 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| easi75 | 8 | 29 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 119.0 | FAS | NRI | 8 | WK | EASI 75 | 47.328 | percent | 49.4 | 37.0 | YR | |||||||||||||||||||||||||||||||
| 4 | 27 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 73.0 | FAS | NRI | 4 | WK | EASI 75 | 29.008 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 14 | 32 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 142.0 | FAS | NRI | 14 | WK | EASI 75 | 56.336 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 31 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 139.0 | FAS | NRI | 12 | WK | EASI 75 | 55.267 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 10 | 30 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 135.0 | FAS | NRI | 10 | WK | EASI 75 | 53.435 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| easi50 | 8 | 63 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 185.0 | FAS | NRI | 8 | WK | EASI 50 | 73.3333 | percent | 49.4 | 37.0 | YR | |||||||||||||||||||||||||||||||
| 4 | 61 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 148.0 | FAS | NRI | 4 | WK | EASI 50 | 58.6667 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 60 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 97.0 | FAS | NRI | 2 | WK | EASI 50 | 38.6667 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 14 | 66 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 199.0 | FAS | NRI | 14 | WK | EASI 50 | 78.9333 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 65 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 199.0 | FAS | NRI | 12 | WK | EASI 50 | 78.9333 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 10 | 64 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 252.0 | 190.0 | FAS | NRI | 10 | WK | EASI 50 | 75.4667 | percent | 49.4 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| easi | 8 | 13 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 243.0 | FAS | MMRM | OC | 8 | WK | EASI | Median | 24.7 | 0-72 score | 12.963 | SD | Mean | -68.0 | 26.3 | SD | 49.4 | 37.0 | YR | ||||||||||||||||||||||||
| 6 | 12 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 247.0 | FAS | MMRM | OC | 6 | WK | EASI | Median | 24.7 | 0-72 score | 12.963 | SD | Mean | -62.8 | 27.5 | SD | 49.4 | 37.0 | YR | |||||||||||||||||||||||||
| 4 | 11 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 247.0 | FAS | MMRM | OC | 4 | WK | EASI | Median | 24.7 | 0-72 score | 12.963 | SD | Mean | -54.0 | 31.0 | SD | 49.4 | 37.0 | YR | |||||||||||||||||||||||||
| 2 | 10 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 250.0 | FAS | MMRM | OC | 2 | WK | EASI | Median | 24.7 | 0-72 score | 12.963 | SD | Mean | -40.2 | 30.6 | SD | 49.4 | 37.0 | YR | |||||||||||||||||||||||||
| 16 | 17 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 235.0 | FAS | MMRM | OC | 16 | WK | EASI | Median | 24.7 | 0-72 score | 12.963 | SD | LS Mean | -21.0 | 0-72 score | 0.67 | SE | Mean | -72.3 | 30.5 | SD | 49.4 | 37.0 | YR | ||||||||||||||||||||
| 14 | 16 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 235.0 | FAS | MMRM | OC | 14 | WK | EASI | Median | 24.7 | 0-72 score | 12.963 | SD | Mean | -73.5 | 30.9 | SD | 49.4 | 37.0 | YR | |||||||||||||||||||||||||
| 12 | 15 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 238.0 | FAS | MMRM | OC | 12 | WK | EASI | Median | 24.7 | 0-72 score | 12.963 | SD | Mean | -72.3 | 30.6 | SD | 49.4 | 37.0 | YR | |||||||||||||||||||||||||
| 10 | 14 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 252 | 237.0 | FAS | MMRM | OC | 10 | WK | EASI | Median | 24.7 | 0-72 score | 12.963 | SD | Mean | -70.9 | 26.8 | SD | 49.4 | 37.0 | YR | |||||||||||||||||||||||||
| placebo | 0.0 | q2w | scorad | 8 | 38 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 122.0 | FAS | MMRM | OC | 8 | WK | SCORAD | Mean | 68.9 | 0-103 pt scale | 13.2 | SD | LS Mean | -25.2 | 0-103 pt scale | 1.47 | SE | Mean | 41.9 | 0-103 pt scale | 19.2 | SD | 66.1 | 34.0 | YR | |||||||||||||||
| 6 | 37 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 125.0 | FAS | MMRM | OC | 6 | WK | SCORAD | Mean | 68.9 | 0-103 pt scale | 13.2 | SD | LS Mean | -24.0 | 0-103 pt scale | 1.48 | SE | Mean | 43.6 | 0-103 pt scale | 20.5 | SD | 66.1 | 34.0 | YR | |||||||||||||||||||
| 4 | 36 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | FAS | MMRM | OC | 4 | WK | SCORAD | Mean | 68.9 | 0-103 pt scale | 13.2 | SD | LS Mean | -21.9 | 0-103 pt scale | 1.44 | SE | Mean | 46.6 | 0-103 pt scale | 20.2 | SD | 66.1 | 34.0 | YR | |||||||||||||||||||
| 2 | 35 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 124.0 | FAS | MMRM | OC | 2 | WK | SCORAD | Mean | 68.9 | 0-103 pt scale | 13.2 | SD | LS Mean | -16.4 | 0-103 pt scale | 1.33 | SE | Mean | 51.4 | 0-103 pt scale | 17.1 | SD | 66.1 | 34.0 | YR | |||||||||||||||||||
| 16 | 42 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 119.0 | FAS | MMRM | OC | 16 | WK | SCORAD | Mean | 68.9 | 0-103 pt scale | 13.2 | SD | LS Mean | -26.8 | 0-103 pt scale | 1.8 | SE | Mean | 40.9 | 0-103 pt scale | 23.7 | SD | 66.1 | 34.0 | YR | |||||||||||||||||||
| 14 | 41 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 118.0 | FAS | MMRM | OC | 14 | WK | SCORAD | Mean | 68.9 | 0-103 pt scale | 13.2 | SD | LS Mean | -28.3 | 0-103 pt scale | 1.75 | SE | Mean | 38.8 | 0-103 pt scale | 22.4 | SD | 66.1 | 34.0 | YR | |||||||||||||||||||
| 12 | 40 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 119.0 | FAS | MMRM | OC | 12 | WK | SCORAD | Mean | 68.9 | 0-103 pt scale | 13.2 | SD | LS Mean | -27.3 | 0-103 pt scale | 1.67 | SE | Mean | 39.6 | 0-103 pt scale | 21.6 | SD | 66.1 | 34.0 | YR | |||||||||||||||||||
| 10 | 39 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 118.0 | FAS | MMRM | OC | 10 | WK | SCORAD | Mean | 68.9 | 0-103 pt scale | 13.2 | SD | LS Mean | -27.2 | 0-103 pt scale | 1.58 | SE | Mean | 40.4 | 0-103 pt scale | 20.5 | SD | 66.1 | 34.0 | YR | |||||||||||||||||||
| 0 | 34 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | FAS | MMRM | OC | 0 | WK | SCORAD | Mean | 68.9 | 0-103 pt scale | 13.2 | SD | LS Mean | 0.0 | 0-103 pt scale | Mean | 68.9 | 0-103 pt scale | 13.2 | SD | 66.1 | 34.0 | YR | |||||||||||||||||||||
| easi90 | 8 | 71 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 15.0 | FAS | NRI | 8 | WK | EASI 90 | 11.7603 | percent | 66.1 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 6 | 70 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 14.0 | FAS | NRI | 6 | WK | EASI 90 | 11.2148 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 4 | 69 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 9.0 | FAS | NRI | 4 | WK | EASI 90 | 7.00694 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 68 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 3.0 | FAS | NRI | 2 | WK | EASI 90 | 2.37686 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 16 | 75 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 27.0 | FAS | NRI | 16 | WK | EASI 90 | 21.4 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 14 | 74 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 23.0 | FAS | NRI | 14 | WK | EASI 90 | 17.9053 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 73 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 21.0 | FAS | NRI | 12 | WK | EASI 90 | 16.5144 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 10 | 72 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 21.0 | FAS | NRI | 10 | WK | EASI 90 | 16.5319 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| easi75 | 8 | 21 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 40.0 | FAS | NRI | 8 | WK | EASI 75 | 31.603 | percent | 66.1 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 6 | 20 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 36.0 | FAS | NRI | 6 | WK | EASI 75 | 28.55 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 4 | 19 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 30.0 | FAS | NRI | 4 | WK | EASI 75 | 23.512 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 18 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 14.0 | FAS | NRI | 2 | WK | EASI 75 | 10.84 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 14 | 24 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 45.0 | FAS | NRI | 14 | WK | EASI 75 | 35.725 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 23 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 44.0 | FAS | NRI | 12 | WK | EASI 75 | 34.809 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 10 | 22 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 40.0 | FAS | NRI | 10 | WK | EASI 75 | 31.603 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| easi50 | 8 | 55 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 74.0 | FAS | NRI | 8 | WK | EASI 50 | 58.9333 | percent | 66.1 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 6 | 54 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 64.0 | FAS | NRI | 6 | WK | EASI 50 | 50.6667 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 4 | 53 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 60.0 | FAS | NRI | 4 | WK | EASI 50 | 47.7333 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 52 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 43.0 | FAS | NRI | 2 | WK | EASI 50 | 34.4 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 14 | 58 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 76.0 | FAS | NRI | 14 | WK | EASI 50 | 60.5333 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 57 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 74.0 | FAS | NRI | 12 | WK | EASI 50 | 58.9333 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| 10 | 56 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | 77.0 | FAS | NRI | 10 | WK | EASI 50 | 61.3333 | percent | 66.1 | 34.0 | YR | ||||||||||||||||||||||||||||||||
| easi | 8 | 4 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 122.0 | FAS | MMRM | OC | 8 | WK | EASI | Median | 26.5 | 0-72 score | 14.37 | SD | Mean | -56.7 | 32.1 | SD | 66.1 | 34.0 | YR | ||||||||||||||||||||||||
| 6 | 3 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 125.0 | FAS | MMRM | OC | 6 | WK | EASI | Median | 26.5 | 0-72 score | 14.37 | SD | Mean | -51.3 | 33.7 | SD | 66.1 | 34.0 | YR | |||||||||||||||||||||||||
| 4 | 2 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | FAS | MMRM | OC | 4 | WK | EASI | Median | 26.5 | 0-72 score | 14.37 | SD | Mean | -44.8 | 37.7 | SD | 66.1 | 34.0 | YR | |||||||||||||||||||||||||
| 2 | 1 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 124.0 | FAS | MMRM | OC | 2 | WK | EASI | Median | 26.5 | 0-72 score | 14.37 | SD | Mean | -33.6 | 32.3 | SD | 66.1 | 34.0 | YR | |||||||||||||||||||||||||
| 16 | 8 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 120.0 | FAS | MMRM | OC | 16 | WK | EASI | Median | 26.5 | 0-72 score | 14.37 | SD | LS Mean | -15.6 | 0-72 score | 0.96 | SE | Mean | -54.9 | 41.3 | SD | 66.1 | 34.0 | YR | ||||||||||||||||||||
| 14 | 7 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 118.0 | FAS | MMRM | OC | 14 | WK | EASI | Median | 26.5 | 0-72 score | 14.37 | SD | Mean | -57.5 | 39.4 | SD | 66.1 | 34.0 | YR | |||||||||||||||||||||||||
| 12 | 6 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 119.0 | FAS | MMRM | OC | 12 | WK | EASI | Median | 26.5 | 0-72 score | 14.37 | SD | Mean | -58.9 | 32.5 | SD | 66.1 | 34.0 | YR | |||||||||||||||||||||||||
| 10 | 5 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 118.0 | FAS | MMRM | OC | 10 | WK | EASI | Median | 26.5 | 0-72 score | 14.37 | SD | Mean | -56.4 | 34.5 | SD | 66.1 | 34.0 | YR | |||||||||||||||||||||||||
| 0 | 0 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 126 | 126.0 | FAS | MMRM | OC | 0 | WK | EASI | Median | 26.5 | 0-72 score | 14.37 | SD | LS Mean | 0.0 | 0-72 score | Mean | 0.0 | 66.1 | 34.0 | YR |
289_guttman_2020¶
Control rows matched by test output: 11 of 68
Literature data accuracy: 82.73%
Clinical data accuracy: 14.33%
Clinical data accuracy (drop unmatched): 88.60%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| lebrikizumab | 250 | every4weeks | easi50 | 16 | 1 | c7t1 | test | Double-Blind | TRUE | lebrikizumab | Interleukin-13 Inhibitor | 250 | mg | SC | Every 4 weeks | 80 | 80 | 62 | mITT | Cochran-Mantel-Haenszel tests | MCMC | 16 | WK | EASI-50 | Percent | 77.0 | Percent | 41.2 | 40.2 | YR | |||||||||||||||||||||||||
| 125.0 | q4w | easi50 | 16 | 7 | c7t1 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | 48.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 16 | WK | EASI 50 | 66.4 | percent | 37.0 | 36.7 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 98 | 50 | 100 | 100 | 25 | 100 | 0 | 33 | 0 | 100 | 98 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 25 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 25 | 25 | 100 | |||||||
| 125 | every4weeks | easi50 | 16 | 9 | c6t9 | test | Double-Blind | TRUE | lebrikizumab | Interleukin-13 Inhibitor | 125 | mg | SC | Every 4 weeks | 73 | 73 | 48 | mITT | Pairwise Cochran-Mantel-Haenszel tests | MI | 16 | wk | EASI-50 | Percent | 66.4 | Percent | pvalue | 37.0 | 36.7 | YR | |||||||||||||||||||||||||
| 125.0 | q4w | easi50 | 12 | 6 | c6t9 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | 50.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 12 | WK | EASI 50 | 68.153 | percent | 37.0 | 36.7 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 98 | 75 | 100 | 100 | 25 | 100 | 100 | 67 | 0 | 100 | 85 | 33 | 50 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 40 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 250 | q2w | easi90 | 16 | 5 | c47t5 | test | Double-Blind | TRUE | lebrikizumab | Interleukin-13 Inhibitor | 250 | mg | SC | Q2W | 75 | 75 | 33 | mITT | Pairwise Cochran-Mantel-Haenszel tests | MCMC | 16 | wk | EASI-90 | Percent | 44.0 | percent | pvalue <.001 | 34.7 | 38.9 | YR | |||||||||||||||||||||||||
| 250.0 | q2w | easi90 | 16 | 47 | c47t5 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | 33.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 16 | WK | EASI 90 | 44.0 | percent | 34.7 | 38.9 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 98 | 75 | 100 | 100 | 100 | 100 | 100 | 67 | 67 | 100 | 85 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | q2w | easi50 | 16 | 7 | c3t7 | test | Double-Blind | TRUE | Placebo | SC | Q2W | 52 | 52 | 24 | mITT | Cochran-Mantel-Haenszel tests | MCMC | 16 | wk | EASI-50 | Percent | 45.8 | percent | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||||
| 0.0 | q2w | easi50 | 16 | 3 | c3t7 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | 24.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 16 | WK | EASI 50 | 45.8 | percent | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 67 | 67 | 100 | 98 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| lebrikizumab | 250 | every4weeks | easi90 | 16 | 2 | c39t2 | test | Double-Blind | TRUE | lebrikizumab | Interleukin-13 Inhibitor | 250 | mg | SC | Every 4 weeks | 80 | 80 | 29 | mITT | Pairwise Cochran-Mantel-Haenszel tests | MCMC | 16 | wk | EASI-90 | Percent | 36.1 | Percent | pvalue two-sided | 41.2 | 40.2 | YR | ||||||||||||||||||||||||
| 125.0 | q4w | easi90 | 16 | 39 | c39t2 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | 19.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 16 | WK | EASI 90 | 26.1 | percent | 37.0 | 36.7 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 98 | 50 | 100 | 100 | 25 | 100 | 0 | 33 | 33 | 100 | 85 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 75 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 25 | 25 | 100 | |||||||
| 125 | every4weeks | easi90 | 16 | 10 | c38t10 | test | Double-Blind | TRUE | lebrikizumab | Interleukin-13 Inhibitor | 125 | mg | SC | Every 4 weeks | 73 | 73 | 19 | mITT | Pairwise Cochran-Mantel-Haenszel tests | MCMC | 16 | wk | EASI-90 | Percent | 26.1 | percent | pvalue two-sided | 37.0 | 36.7 | YR | |||||||||||||||||||||||||
| 125.0 | q4w | easi90 | 12 | 38 | c38t10 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | 15.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 12 | WK | EASI 90 | 20.383 | percent | 37.0 | 36.7 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 98 | 75 | 100 | 100 | 25 | 100 | 100 | 67 | 33 | 100 | 85 | 100 | 50 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 20 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 250 | q2w | easi75 | 16 | 3 | c31t3 | test | Double-Blind | TRUE | lebrikizumab | Interleukin-13 Inhibitor | 250 | mg | SC | Q2W | 75 | 75 | 45 | mITT | Pairwise Cochran-Mantel-Haenszel tests | MCMC | 16 | WK | EASI-75 | Percent | 60.6 | Percent | pvalue <.001 | 34.7 | 38.9 | YR | |||||||||||||||||||||||||
| 250.0 | q2w | easi75 | 16 | 31 | c31t3 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | 45.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 16 | WK | EASI 75 | 60.6 | percent | 34.7 | 38.9 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 98 | 75 | 100 | 100 | 100 | 100 | 100 | 67 | 67 | 100 | 85 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 250 | every4weeks | easi75 | 16 | 0 | c23t0 | test | Double-Blind | TRUE | lebrikizumab | Interleukin-13 Inhibitor | 250 | mg | SC | Every 4 weeks | 80 | 80 | 45 | mITT | Pairwise Cochran-Mantel-Haenszel tests | MCMC | 16 | WK | EASI-75 | Percent | 56.1 | Percent | pvalue two-sided | 41.2 | 40.2 | YR | |||||||||||||||||||||||||
| 125.0 | q4w | easi75 | 16 | 23 | c23t0 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | 32.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 16 | WK | EASI 75 | 43.3 | percent | 37.0 | 36.7 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 98 | 50 | 100 | 100 | 25 | 100 | 0 | 33 | 0 | 100 | 85 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 25 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 25 | 25 | 100 | |||||||
| 125 | every4weeks | easi75 | 16 | 8 | c22t8 | test | Double-Blind | TRUE | lebrikizumab | Interleukin-13 Inhibitor | 125 | mg | SC | Every 4 weeks | 73 | 73 | 43 | mITT | Pairwise Cochran-Mantel-Haenszel tests | MCMC | 16 | WK | EASI-75 | Percent | 43.3 | Percent | pvalue | 37.0 | 36.7 | YR | |||||||||||||||||||||||||
| 125.0 | q4w | easi75 | 12 | 22 | c22t8 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | 32.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 12 | WK | EASI 75 | 43.312999999999995 | percent | 37.0 | 36.7 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 98 | 75 | 100 | 100 | 25 | 100 | 100 | 67 | 33 | 100 | 85 | 100 | 50 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 36 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | q2w | easi75 | 16 | 6 | c19t6 | test | Double-Blind | TRUE | Placebo | SC | Q2W | 52 | 52 | 13 | mITT | Pairwise Cochran-Mantel-Haenszel tests | MCMC | 16 | wk | EASI-75 | Percent | 24.3 | percent | pvalue two-sided | 53.8 | 42.2 | YR | ||||||||||||||||||||||||||||
| 0.0 | q2w | easi75 | 16 | 19 | c19t6 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | 13.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 16 | WK | EASI 75 | 24.3 | percent | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 67 | 67 | 100 | 85 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| lebrikizumab | 250 | q2w | easi50 | 16 | 4 | c15t4 | test | Double-Blind | TRUE | lebrikizumab | Interleukin-13 Inhibitor | 250 | mg | SC | Q2W | 75 | 75 | 60 | mITT | Pairwise Cochran-Mantel-Haenszel tests | MCMC | 16 | wk | EASI-50 | Percent | 81.0 | Percent | pvalue <.001 | 34.7 | 38.9 | YR | ||||||||||||||||||||||||
| 250.0 | q2w | easi50 | 16 | 15 | c15t4 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | 61.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 16 | WK | EASI 50 | 81.0 | percent | 34.7 | 38.9 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 98 | 75 | 100 | 100 | 100 | 100 | 100 | 67 | 33 | 100 | 85 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | 0.0 | q2w | easi90 | 8 | 33 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | 2.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 8 | WK | EASI 90 | 3.822 | percent | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||
| 4 | 32 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | 0.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 4 | WK | EASI 90 | 0.0 | percent | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||||||
| 16 | 35 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | 6.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 16 | WK | EASI 90 | 11.4 | percent | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||||||
| 12 | 34 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | 3.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 12 | WK | EASI 90 | 5.096 | percent | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||||||
| easi75 | 8 | 17 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | 8.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 8 | WK | EASI 75 | 15.924 | percent | 53.8 | 42.2 | YR | ||||||||||||||||||||||||||||||
| 4 | 16 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | 1.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 4 | WK | EASI 75 | 2.548 | percent | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||||||
| 12 | 18 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | 8.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 12 | WK | EASI 75 | 15.924 | percent | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||||||
| easi50 | 8 | 1 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | 18.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 8 | WK | EASI 50 | 33.758 | percent | 53.8 | 42.2 | YR | ||||||||||||||||||||||||||||||
| 4 | 0 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | 14.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 4 | WK | EASI 50 | 26.115 | percent | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||||||
| 12 | 2 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | 18.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 12 | WK | EASI 50 | 34.394999999999996 | percent | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||||||
| easi | 8 | 50 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | mITT | ANCOVA | MCMC | 8 | WK | EASI | Mean | 28.9 | 0-72 score | 11.8 | SD | Mean | -31.3 | 53.8 | 42.2 | YR | ||||||||||||||||||||||||||
| 4 | 49 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | mITT | ANCOVA | MCMC | 4 | WK | EASI | Mean | 28.9 | 0-72 score | 11.8 | SD | Mean | -25.4 | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||
| 16 | 52 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | mITT | ANCOVA | MCMC | 16 | WK | EASI | Mean | 28.9 | 0-72 score | 11.8 | SD | Mean | -40.6 | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||
| 12 | 51 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | mITT | ANCOVA | MCMC | 12 | WK | EASI | Mean | 28.9 | 0-72 score | 11.8 | SD | Mean | -34.0 | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||
| 0 | 48 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 52 | 52.0 | mITT | ANCOVA | MCMC | 0 | WK | EASI | Mean | 28.9 | 0-72 score | 11.8 | SD | Mean | 0.0 | 53.8 | 42.2 | YR | |||||||||||||||||||||||||||
| lebrikizumab | 500.0 | q4w | easi | 0 | 58 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 500.0 | MG | SC | Q4W | 80 | 80.0 | mITT | ANCOVA | MCMC | 0 | WK | EASI | Mean | 26.2 | 0-72 score | 10.1 | SD | Mean | 0.0 | 41.2 | 40.2 | YR | |||||||||||||||||||||||
| q2w | easi | 0 | 63 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 500.0 | MG | SC | Q2W | 75 | 75.0 | mITT | ANCOVA | MCMC | 0 | WK | EASI | Mean | 25.5 | 0-72 score | 11.2 | SD | Mean | 0.0 | 34.7 | 38.9 | YR | |||||||||||||||||||||||||
| 250.0 | q4w | easi90 | 8 | 41 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | 20.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 8 | WK | EASI 90 | 25.478 | percent | 41.2 | 40.2 | YR | ||||||||||||||||||||||||||||
| 4 | 40 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | 6.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 4 | WK | EASI 90 | 7.644 | percent | 41.2 | 40.2 | YR | |||||||||||||||||||||||||||||||
| 16 | 43 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | 29.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 16 | WK | EASI 90 | 36.1 | percent | 41.2 | 40.2 | YR | |||||||||||||||||||||||||||||||
| 12 | 42 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | 22.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 12 | WK | EASI 90 | 28.026 | percent | 41.2 | 40.2 | YR | |||||||||||||||||||||||||||||||
| easi75 | 8 | 25 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | 31.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 8 | WK | EASI 75 | 38.217 | percent | 41.2 | 40.2 | YR | ||||||||||||||||||||||||||||||
| 4 | 24 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | 18.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 4 | WK | EASI 75 | 22.93 | percent | 41.2 | 40.2 | YR | |||||||||||||||||||||||||||||||
| 16 | 27 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | 45.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 16 | WK | EASI 75 | 56.1 | percent | 41.2 | 40.2 | YR | |||||||||||||||||||||||||||||||
| 12 | 26 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | 38.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 12 | WK | EASI 75 | 47.771 | percent | 41.2 | 40.2 | YR | |||||||||||||||||||||||||||||||
| easi50 | 8 | 9 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | 54.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 8 | WK | EASI 50 | 67.516 | percent | 41.2 | 40.2 | YR | ||||||||||||||||||||||||||||||
| 4 | 8 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | 36.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 4 | WK | EASI 50 | 44.586 | percent | 41.2 | 40.2 | YR | |||||||||||||||||||||||||||||||
| 16 | 11 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | 62.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 16 | WK | EASI 50 | 77.0 | percent | 41.2 | 40.2 | YR | |||||||||||||||||||||||||||||||
| 12 | 10 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | 59.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 12 | WK | EASI 50 | 73.88600000000001 | percent | 41.2 | 40.2 | YR | |||||||||||||||||||||||||||||||
| easi | 8 | 60 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | mITT | ANCOVA | MCMC | 8 | WK | EASI | Mean | 26.2 | 0-72 score | 10.1 | SD | Mean | -61.2 | 41.2 | 40.2 | YR | ||||||||||||||||||||||||||
| 4 | 59 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | mITT | ANCOVA | MCMC | 4 | WK | EASI | Mean | 26.2 | 0-72 score | 10.1 | SD | Mean | -46.5 | 41.2 | 40.2 | YR | |||||||||||||||||||||||||||
| 16 | 62 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | mITT | ANCOVA | MCMC | 16 | WK | EASI | Mean | 26.2 | 0-72 score | 10.1 | SD | Mean | -69.7 | 41.2 | 40.2 | YR | |||||||||||||||||||||||||||
| 12 | 61 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 80 | 80.0 | mITT | ANCOVA | MCMC | 12 | WK | EASI | Mean | 26.2 | 0-72 score | 10.1 | SD | Mean | -64.7 | 41.2 | 40.2 | YR | |||||||||||||||||||||||||||
| 0 | 53 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q4W | 73 | 73.0 | mITT | ANCOVA | MCMC | 0 | WK | EASI | Mean | 29.9 | 0-72 score | 13.5 | SD | Mean | 0.0 | 37.0 | 36.7 | YR | |||||||||||||||||||||||||||
| q2w | easi90 | 8 | 45 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | 22.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 8 | WK | EASI 90 | 29.3 | percent | 34.7 | 38.9 | YR | |||||||||||||||||||||||||||||
| 4 | 44 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | 11.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 4 | WK | EASI 90 | 14.65 | percent | 34.7 | 38.9 | YR | |||||||||||||||||||||||||||||||
| 12 | 46 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | 27.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 12 | WK | EASI 90 | 35.669 | percent | 34.7 | 38.9 | YR | |||||||||||||||||||||||||||||||
| easi75 | 8 | 29 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | 33.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 8 | WK | EASI 75 | 43.949 | percent | 34.7 | 38.9 | YR | ||||||||||||||||||||||||||||||
| 4 | 28 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | 22.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 4 | WK | EASI 75 | 29.937 | percent | 34.7 | 38.9 | YR | |||||||||||||||||||||||||||||||
| 12 | 30 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | 49.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 12 | WK | EASI 75 | 65.60600000000001 | percent | 34.7 | 38.9 | YR | |||||||||||||||||||||||||||||||
| easi50 | 8 | 13 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | 52.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 8 | WK | EASI 50 | 68.79 | percent | 34.7 | 38.9 | YR | ||||||||||||||||||||||||||||||
| 4 | 12 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | 39.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 4 | WK | EASI 50 | 52.23 | percent | 34.7 | 38.9 | YR | |||||||||||||||||||||||||||||||
| 12 | 14 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | 62.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 12 | WK | EASI 50 | 82.16600000000001 | percent | 34.7 | 38.9 | YR | |||||||||||||||||||||||||||||||
| easi | 8 | 65 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | mITT | ANCOVA | MCMC | 8 | WK | EASI | Mean | 25.5 | 0-72 score | 11.2 | SD | Mean | -64.1 | 34.7 | 38.9 | YR | ||||||||||||||||||||||||||
| 4 | 64 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | mITT | ANCOVA | MCMC | 4 | WK | EASI | Mean | 25.5 | 0-72 score | 11.2 | SD | Mean | -50.4 | 34.7 | 38.9 | YR | |||||||||||||||||||||||||||
| 16 | 67 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | mITT | ANCOVA | MCMC | 16 | WK | EASI | Mean | 25.5 | 0-72 score | 11.2 | SD | Mean | -72.8 | 34.7 | 38.9 | YR | |||||||||||||||||||||||||||
| 12 | 66 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 250.0 | MG | SC | Q2W | 75 | 75.0 | mITT | ANCOVA | MCMC | 12 | WK | EASI | Mean | 25.5 | 0-72 score | 11.2 | SD | Mean | -73.5 | 34.7 | 38.9 | YR | |||||||||||||||||||||||||||
| 125.0 | q4w | easi90 | 8 | 37 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | 12.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 8 | WK | EASI 90 | 16.561 | percent | 37.0 | 36.7 | YR | ||||||||||||||||||||||||||||
| 4 | 36 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | 2.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 4 | WK | EASI 90 | 3.185 | percent | 37.0 | 36.7 | YR | |||||||||||||||||||||||||||||||
| easi75 | 8 | 21 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | 22.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 8 | WK | EASI 75 | 29.937 | percent | 37.0 | 36.7 | YR | ||||||||||||||||||||||||||||||
| 4 | 20 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | 12.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 4 | WK | EASI 75 | 16.561 | percent | 37.0 | 36.7 | YR | |||||||||||||||||||||||||||||||
| easi50 | 8 | 5 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | 41.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 8 | WK | EASI 50 | 56.687999999999995 | percent | 37.0 | 36.7 | YR | ||||||||||||||||||||||||||||||
| 4 | 4 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | 30.0 | mITT | Cochran Mantel Haenszel Test | MCMC | 4 | WK | EASI 50 | 41.402 | percent | 37.0 | 36.7 | YR | |||||||||||||||||||||||||||||||
| easi | 8 | 55 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | mITT | ANCOVA | MCMC | 8 | WK | EASI | Mean | 29.9 | 0-72 score | 13.5 | SD | Mean | -53.9 | 37.0 | 36.7 | YR | ||||||||||||||||||||||||||
| 4 | 54 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | mITT | ANCOVA | MCMC | 4 | WK | EASI | Mean | 29.9 | 0-72 score | 13.5 | SD | Mean | -42.4 | 37.0 | 36.7 | YR | |||||||||||||||||||||||||||
| 16 | 57 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | mITT | ANCOVA | MCMC | 16 | WK | EASI | Mean | 29.9 | 0-72 score | 13.5 | SD | Mean | -61.5 | 37.0 | 36.7 | YR | |||||||||||||||||||||||||||
| 12 | 56 | control | Double-Blind | True | lebrikizumab | Interleukin 13 inhibitors | 125.0 | MG | SC | Q4W | 73 | 73.0 | mITT | ANCOVA | MCMC | 12 | WK | EASI | Mean | 29.9 | 0-72 score | 13.5 | SD | Mean | -62.5 | 37.0 | 36.7 | YR |
305_debruin_2018¶
Control rows matched by test output: 8 of 132
Literature data accuracy: 85.40%
Clinical data accuracy: 5.58%
Clinical data accuracy (drop unmatched): 92.04%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| placebo | placebo | easi75 | 16 | 6 | c6t6 | test | Double-Blind | TRUE | Placebo | Placebo | SC | Placebo | 108 | 108 | 32 | FAS | Cochran-Mantel-Haenszel test | NRI | 16 | WK | EASI-75 | Percent | 29.6 | Percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||
| 0.0 | qw | easi75 | 16 | 6 | c6t6 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 32.0 | FAS | Cochran Mantel Haenszel Test | 16 | WK | EASI 75 | 29.6 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 0 | 100 | 100 | 75 | 67 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| dupilumab | 300 | q2w | easi90 | 16 | 2 | c62t2 | test | Double-Blind | TRUE | Dupilumab | Monoclonal antibody | 300 | mg | SC | Q2W | 107 | 107 | 49 | FAS | Nominal P < 0.001 vs. placebo + TCS | MI | 16 | WK | EASI-90 | Proportion | 45.8 | Percent | Nominal P < 0.001 vs. placebo + TCS | 60.7 | 38.0 | YR | ||||||||||||||||||||||||
| 300.0 | q2w | easi90 | 16 | 62 | c62t2 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 49.0 | FAS | Cochran Mantel Haenszel Test | 16 | WK | EASI 90 | 45.8 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 100 | 75 | 67 | 100 | 34 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 300 | qw | easi90 | 16 | 5 | c55t5 | test | Double-Blind | TRUE | Dupilumab | Monoclonal antibody | 300 | mg | SC | qw | 110 | 110 | 41 | FAS | Nominal P < 0.001 vs. placebo + TCS | 16 | WK | EASI-90 | Proportion | 37.3 | Percent | Nominal P < 0.001 vs. placebo + TCS | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| 300.0 | qw | easi90 | 16 | 55 | c55t5 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 41.0 | FAS | Cochran Mantel Haenszel Test | 16 | WK | EASI 90 | 37.3 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 100 | 75 | 67 | 100 | 34 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 300 | q2w | easi50 | 16 | 1 | c41t1 | test | Double-Blind | TRUE | Dupilumab | Monoclonal antibody | 300 | mg | SC | Q2W | 107 | 107 | 91 | FAS | Cochran-Mantel-Haenszel test | 16 | WK | EASI-50 | Percent | 85.0 | Percent | 60.7 | 38.0 | YR | |||||||||||||||||||||||||||
| 300.0 | q2w | easi50 | 16 | 41 | c41t1 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 91.0 | FAS | Cochran Mantel Haenszel Test | 16 | WK | EASI 50 | 85.0 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 100 | 75 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 300 | qw | easi50 | 16 | 4 | c34t4 | test | Double-Blind | TRUE | Dupilumab | Monoclonal antibody | 300 | mg | SC | qw | 110 | 110 | 94 | FAS | Cochran-Mantel-Haenszel test | 16 | WK | EASI-50 | Percent | 85.5 | Percent | 60.0 | 38.0 | YR | |||||||||||||||||||||||||||
| 300.0 | qw | easi50 | 16 | 34 | c34t4 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 94.0 | FAS | Cochran Mantel Haenszel Test | 16 | WK | EASI 50 | 85.5 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 100 | 75 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | placebo | easi50 | 16 | 7 | c27t7 | test | Double-Blind | TRUE | Placebo | Placebo | SC | Placebo | 108 | 107 | 47 | FAS | Cochran-Mantel-Haenszel test | 16 | WK | EASI-50 | Proportion | 43.5 | Percent | 63.0 | 37.5 | YR | |||||||||||||||||||||||||||||
| 0.0 | qw | easi50 | 16 | 27 | c27t7 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 47.0 | FAS | Cochran Mantel Haenszel Test | 16 | WK | EASI 50 | 43.5 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 0 | 100 | 100 | 50 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| dupilumab | 300 | q2w | easi75 | 16 | 0 | c20t0 | test | Double-Blind | TRUE | Dupilumab | Monoclonal antibody | 300 | mg | SC | Q2W | 107 | 107 | 67 | FAS | Cochran-Mantel-Haenszel test | 16 | WK | EASI-75 | Percent | 62.6 | Percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||
| 300.0 | q2w | easi75 | 16 | 20 | c20t0 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 67.0 | FAS | Cochran Mantel Haenszel Test | 16 | WK | EASI 75 | 62.6 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 100 | 75 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 300 | qw | easi75 | 16 | 3 | c13t3 | test | Double-Blind | TRUE | Dupilumab | Monoclonal antibody | 300 | mg | SC | qw | 110 | 110 | 65 | FAS | Cochran-Mantel-Haenszel test | NRI | 16 | WK | EASI-75 | Proportion | 59.1 | Percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| 300.0 | qw | easi75 | 16 | 13 | c13t3 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 65.0 | FAS | Cochran Mantel Haenszel Test | 16 | WK | EASI 75 | 59.1 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 100 | 75 | 67 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | 0.0 | qw | scorad | 8 | 115 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | LOCF | 8 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | -26.042 | 2.431 | SE | 63.0 | 37.5 | YR | ||||||||||||||||||||||
| 92 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | MI | 8 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | -27.694 | 2.507 | SE | 63.0 | 37.5 | YR | |||||||||||||||||||||||||||
| 6 | 114 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | LOCF | 6 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | -23.467 | 2.315 | SE | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||
| 91 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | MI | 6 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | -25.157 | 2.381 | SE | 63.0 | 37.5 | YR | |||||||||||||||||||||||||||
| 4 | 113 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | LOCF | 4 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | -19.734 | 2.199 | SE | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||
| 90 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | MI | 4 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | -20.614 | 2.256 | SE | 63.0 | 37.5 | YR | |||||||||||||||||||||||||||
| 2 | 112 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | LOCF | 2 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | -14.612 | 1.967 | SE | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||
| 89 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | MI | 2 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | -15.069 | 2.005 | SE | 63.0 | 37.5 | YR | |||||||||||||||||||||||||||
| 16 | 117 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | LOCF | 16 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | -26.5 | 2.546 | SE | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||
| 94 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 89.0 | FAS | ANCOVA | MI | 16 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | -29.5 | 2.55 | SE | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||
| 12 | 116 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | LOCF | 12 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | -26.794 | 2.547 | SE | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||
| 93 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | MI | 12 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | -29.01 | 2.507 | SE | 63.0 | 37.5 | YR | |||||||||||||||||||||||||||
| 1 | 111 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | LOCF | 1 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | -9.274 | 1.505 | SE | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||
| 88 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | MI | 1 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | -9.038 | 1.63 | SE | 63.0 | 37.5 | YR | |||||||||||||||||||||||||||
| 0 | 87 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | FAS | ANCOVA | MI | 0 | WK | SCORAD | Mean | 67.0 | 0-103 score | 12.2 | SD | LS Mean | 0.0 | 63.0 | 37.5 | YR | |||||||||||||||||||||||||||
| easi90 | 8 | 46 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 11.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 90 | 10.105 | percent | 63.0 | 37.5 | YR | |||||||||||||||||||||||||||||||
| 6 | 45 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 6.0 | FAS | Cochran Mantel Haenszel Test | 6 | WK | EASI 90 | 5.684 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| 4 | 44 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 5.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 90 | 4.632 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| 2 | 43 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 2.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 90 | 1.895 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| 16 | 48 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 13.0 | FAS | Cochran Mantel Haenszel Test | 16 | WK | EASI 90 | 12.0 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| 12 | 47 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 8.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 90 | 7.368 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| 1 | 42 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 0.0 | FAS | Cochran Mantel Haenszel Test | 1 | WK | EASI 90 | 0.0 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| easi75 | 8 | 4 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 25.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 75 | 22.998 | percent | 63.0 | 37.5 | YR | |||||||||||||||||||||||||||||||
| 6 | 3 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 18.0 | FAS | Cochran Mantel Haenszel Test | 6 | WK | EASI 75 | 16.66 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| 4 | 2 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 14.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 75 | 13.038 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| 2 | 1 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 9.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 75 | 8.149 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| 12 | 5 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 26.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 75 | 24.266 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| 1 | 0 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 3.0 | FAS | Cochran Mantel Haenszel Test | 1 | WK | EASI 75 | 2.716 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| easi50 | 8 | 25 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 44.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 50 | 40.601 | percent | 63.0 | 37.5 | YR | |||||||||||||||||||||||||||||||
| 6 | 24 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 45.0 | FAS | Cochran Mantel Haenszel Test | 6 | WK | EASI 50 | 41.981 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| 4 | 23 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 34.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 50 | 31.734 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| 2 | 22 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 22.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 50 | 20.518 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| 12 | 26 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 45.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 50 | 41.715 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| 1 | 21 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | 10.0 | FAS | Cochran Mantel Haenszel Test | 1 | WK | EASI 50 | 9.484 | percent | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||||||||
| easi | 8 | 68 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | MI | 8 | WK | EASI | Mean | 32.9 | 0-72 score | 10.8 | SD | LS Mean | -43.257 | 2.926 | SE | 63.0 | 37.5 | YR | |||||||||||||||||||||||||
| 6 | 67 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | MI | 6 | WK | EASI | Mean | 32.9 | 0-72 score | 10.8 | SD | LS Mean | -40.458 | 2.927 | SE | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||
| 4 | 66 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | MI | 4 | WK | EASI | Mean | 32.9 | 0-72 score | 10.8 | SD | LS Mean | -33.842 | 2.799 | SE | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||
| 2 | 65 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | MI | 2 | WK | EASI | Mean | 32.9 | 0-72 score | 10.8 | SD | LS Mean | -24.428 | 2.799 | SE | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||
| 16 | 70 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 89.0 | FAS | ANCOVA | MI | 16 | WK | EASI | Mean | 32.9 | 0-72 score | 10.8 | SD | LS Mean | -46.6 | 2.76 | SE | 63.0 | 37.5 | YR | |||||||||||||||||||||||||
| 12 | 69 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | MI | 12 | WK | EASI | Mean | 32.9 | 0-72 score | 10.8 | SD | LS Mean | -44.784 | 2.799 | SE | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||
| 1 | 64 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | FAS | ANCOVA | MI | 1 | WK | EASI | Mean | 32.9 | 0-72 score | 10.8 | SD | LS Mean | -14.504 | 2.163 | SE | 63.0 | 37.5 | YR | ||||||||||||||||||||||||||
| 0 | 63 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | QW | 108 | 108.0 | FAS | ANCOVA | MI | 0 | WK | EASI | Mean | 32.9 | 0-72 score | 10.8 | SD | LS Mean | 0.0 | 63.0 | 37.5 | YR | |||||||||||||||||||||||||||
| dupilumab | 600.0 | qw | scorad | 0 | 95 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 600.0 | MG | SC | QW | 110 | 110.0 | FAS | ANCOVA | MI | 0 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | 0.0 | 60.0 | 38.0 | YR | |||||||||||||||||||||||
| easi | 0 | 71 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 600.0 | MG | SC | QW | 110 | 110.0 | FAS | ANCOVA | MI | 0 | WK | EASI | Mean | 33.1 | 0-72 score | 11.02 | SD | LS Mean | 0.0 | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| q2w | scorad | 0 | 103 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 600.0 | MG | SC | Q2W | 107 | 107.0 | FAS | ANCOVA | MI | 0 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | 0.0 | 60.7 | 38.0 | YR | |||||||||||||||||||||||||
| easi | 0 | 79 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 600.0 | MG | SC | Q2W | 107 | 107.0 | FAS | ANCOVA | MI | 0 | WK | EASI | Mean | 33.3 | 0-72 score | 9.93 | SD | LS Mean | 0.0 | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||
| 300.0 | qw | scorad | 8 | 122 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | LOCF | 8 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | -52.894 | 2.431 | SE | 60.0 | 38.0 | YR | |||||||||||||||||||||||
| 100 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | MI | 8 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | -53.258 | 2.506 | SE | 60.0 | 38.0 | YR | |||||||||||||||||||||||||||
| 6 | 121 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | LOCF | 6 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | -47.309 | 2.431 | SE | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| 99 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | MI | 6 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | -47.713 | 2.381 | SE | 60.0 | 38.0 | YR | |||||||||||||||||||||||||||
| 4 | 120 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | LOCF | 4 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | -37.79 | 2.199 | SE | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| 98 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | MI | 4 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | -38.158 | 2.256 | SE | 60.0 | 38.0 | YR | |||||||||||||||||||||||||||
| 2 | 119 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | LOCF | 2 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | -26.881 | 2.315 | SE | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| 97 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | MI | 2 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | -26.598 | 2.256 | SE | 60.0 | 38.0 | YR | |||||||||||||||||||||||||||
| 16 | 124 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | LOCF | 16 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | -57.2 | 2.663 | SE | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| 102 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 104.0 | FAS | ANCOVA | MI | 16 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | -58.3 | 2.45 | SE | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| 12 | 123 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | LOCF | 12 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | -56.887 | 2.431 | SE | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| 101 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | MI | 12 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | -57.33 | 2.757 | SE | 60.0 | 38.0 | YR | |||||||||||||||||||||||||||
| 1 | 118 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | LOCF | 1 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | -12.514 | 1.621 | SE | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| 96 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | MI | 1 | WK | SCORAD | Mean | 66.0 | 0-103 score | 12.7 | SD | LS Mean | -12.297 | 1.88 | SE | 60.0 | 38.0 | YR | |||||||||||||||||||||||||||
| easi90 | 8 | 53 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 34.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 90 | 30.947 | percent | 60.0 | 38.0 | YR | |||||||||||||||||||||||||||||||
| 6 | 52 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 21.0 | FAS | Cochran Mantel Haenszel Test | 6 | WK | EASI 90 | 18.947 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 4 | 51 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 7.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 90 | 6.316 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 50 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 1.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 90 | 0.842 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 54 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 43.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 90 | 38.947 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 1 | 49 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 0.0 | FAS | Cochran Mantel Haenszel Test | 1 | WK | EASI 90 | 0.0 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| easi75 | 8 | 11 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 58.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 75 | 52.515 | percent | 60.0 | 38.0 | YR | |||||||||||||||||||||||||||||||
| 6 | 10 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 48.0 | FAS | Cochran Mantel Haenszel Test | 6 | WK | EASI 75 | 43.642 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 4 | 9 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 26.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 75 | 23.541 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 8 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 5.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 75 | 4.346 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 12 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 69.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 75 | 62.656 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 1 | 7 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 0.0 | FAS | Cochran Mantel Haenszel Test | 1 | WK | EASI 75 | 0.0 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| easi50 | 8 | 32 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 87.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 50 | 78.973 | percent | 60.0 | 38.0 | YR | |||||||||||||||||||||||||||||||
| 6 | 31 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 81.0 | FAS | Cochran Mantel Haenszel Test | 6 | WK | EASI 50 | 73.571 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 4 | 30 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 66.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 50 | 60.029 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 29 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 39.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 50 | 35.441 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 33 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 93.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 50 | 84.35 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 1 | 28 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 110.0 | 13.0 | FAS | Cochran Mantel Haenszel Test | 1 | WK | EASI 50 | 11.81 | percent | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| easi | 8 | 76 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | MI | 8 | WK | EASI | Mean | 33.1 | 0-72 score | 11.02 | SD | LS Mean | -72.01 | 2.799 | SE | 60.0 | 38.0 | YR | |||||||||||||||||||||||||
| 6 | 75 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | MI | 6 | WK | EASI | Mean | 33.1 | 0-72 score | 11.02 | SD | LS Mean | -66.921 | 2.926 | SE | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| 4 | 74 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | MI | 4 | WK | EASI | Mean | 33.1 | 0-72 score | 11.02 | SD | LS Mean | -55.471 | 2.672 | SE | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| 2 | 73 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | MI | 2 | WK | EASI | Mean | 33.1 | 0-72 score | 11.02 | SD | LS Mean | -39.949 | 2.672 | SE | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| 16 | 78 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | 105.0 | FAS | ANCOVA | MI | 16 | WK | EASI | Mean | 33.1 | 0-72 score | 11.02 | SD | LS Mean | -78.2 | 2.55 | SE | 60.0 | 38.0 | YR | |||||||||||||||||||||||||
| 12 | 77 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | MI | 12 | WK | EASI | Mean | 33.1 | 0-72 score | 11.02 | SD | LS Mean | -77.354 | 2.545 | SE | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| 1 | 72 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | QW | 110 | FAS | ANCOVA | MI | 1 | WK | EASI | Mean | 33.1 | 0-72 score | 11.02 | SD | LS Mean | -20.611 | 1.909 | SE | 60.0 | 38.0 | YR | ||||||||||||||||||||||||||
| q2w | scorad | 8 | 129 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | LOCF | 8 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | -54.514 | 2.431 | SE | 60.7 | 38.0 | YR | ||||||||||||||||||||||||
| 108 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | MI | 8 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | -54.762 | 2.506 | SE | 60.7 | 38.0 | YR | |||||||||||||||||||||||||||
| 6 | 128 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | LOCF | 6 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | -49.161 | 2.315 | SE | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||
| 107 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | MI | 6 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | -49.467 | 2.381 | SE | 60.7 | 38.0 | YR | |||||||||||||||||||||||||||
| 4 | 127 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | LOCF | 4 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | -41.725 | 2.431 | SE | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||
| 106 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | MI | 4 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | -41.667 | 2.256 | SE | 60.7 | 38.0 | YR | |||||||||||||||||||||||||||
| 2 | 126 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | LOCF | 2 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | -28.733 | 1.852 | SE | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||
| 105 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | MI | 2 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | -29.104 | 2.13 | SE | 60.7 | 38.0 | YR | |||||||||||||||||||||||||||
| 16 | 131 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | LOCF | 16 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | -61.9 | 2.662 | SE | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||
| 110 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 103.0 | FAS | ANCOVA | MI | 16 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | -62.4 | 2.48 | SE | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||
| 12 | 130 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | LOCF | 12 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | -60.128 | 2.546 | SE | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||
| 109 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | MI | 12 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | -60.338 | 2.506 | SE | 60.7 | 38.0 | YR | |||||||||||||||||||||||||||
| 1 | 125 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | LOCF | 1 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | -13.672 | 1.505 | SE | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||
| 104 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | MI | 1 | WK | SCORAD | Mean | 68.6 | 0-103 score | 11.91 | SD | LS Mean | -13.55 | 1.629 | SE | 60.7 | 38.0 | YR | |||||||||||||||||||||||||||
| easi90 | 8 | 60 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 29.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 90 | 26.947 | percent | 60.7 | 38.0 | YR | |||||||||||||||||||||||||||||||
| 6 | 59 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 15.0 | FAS | Cochran Mantel Haenszel Test | 6 | WK | EASI 90 | 14.105 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 4 | 58 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 8.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 90 | 7.579 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 57 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 1.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 90 | 0.842 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 61 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 38.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 90 | 35.79 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 1 | 56 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 0.0 | FAS | Cochran Mantel Haenszel Test | 1 | WK | EASI 90 | 0.0 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| easi75 | 8 | 18 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 59.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 75 | 55.05 | percent | 60.7 | 38.0 | YR | |||||||||||||||||||||||||||||||
| 6 | 17 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 44.0 | FAS | Cochran Mantel Haenszel Test | 6 | WK | EASI 75 | 40.926 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 4 | 16 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 32.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 75 | 29.698 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 15 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 10.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 75 | 9.054 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 19 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 69.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 75 | 64.467 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 1 | 14 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 0.0 | FAS | Cochran Mantel Haenszel Test | 1 | WK | EASI 75 | 0.0 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| easi50 | 8 | 39 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 85.0 | FAS | Cochran Mantel Haenszel Test | 8 | WK | EASI 50 | 79.36 | percent | 60.7 | 38.0 | YR | |||||||||||||||||||||||||||||||
| 6 | 38 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 78.0 | FAS | Cochran Mantel Haenszel Test | 6 | WK | EASI 50 | 72.602 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 4 | 37 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 68.0 | FAS | Cochran Mantel Haenszel Test | 4 | WK | EASI 50 | 63.517 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 36 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 36.0 | FAS | Cochran Mantel Haenszel Test | 2 | WK | EASI 50 | 33.309 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 40 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 94.0 | FAS | Cochran Mantel Haenszel Test | 12 | WK | EASI 50 | 87.645 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| 1 | 35 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 107.0 | 8.0 | FAS | Cochran Mantel Haenszel Test | 1 | WK | EASI 50 | 7.352 | percent | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||||||||
| easi | 8 | 84 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | MI | 8 | WK | EASI | Mean | 33.3 | 0-72 score | 9.93 | SD | LS Mean | -73.537 | 2.799 | SE | 60.7 | 38.0 | YR | |||||||||||||||||||||||||
| 6 | 83 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | MI | 6 | WK | EASI | Mean | 33.3 | 0-72 score | 9.93 | SD | LS Mean | -67.176 | 2.799 | SE | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||
| 4 | 82 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | MI | 4 | WK | EASI | Mean | 33.3 | 0-72 score | 9.93 | SD | LS Mean | -58.524 | 2.799 | SE | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||
| 2 | 81 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | MI | 2 | WK | EASI | Mean | 33.3 | 0-72 score | 9.93 | SD | LS Mean | -39.44 | 2.799 | SE | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||
| 16 | 86 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | 103.0 | FAS | ANCOVA | MI | 16 | WK | EASI | Mean | 33.3 | 0-72 score | 9.93 | SD | LS Mean | -79.8 | 2.59 | SE | 60.7 | 38.0 | YR | |||||||||||||||||||||||||
| 12 | 85 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | MI | 12 | WK | EASI | Mean | 33.3 | 0-72 score | 9.93 | SD | LS Mean | -78.88 | 2.672 | SE | 60.7 | 38.0 | YR | ||||||||||||||||||||||||||
| 1 | 80 | control | Double-Blind | True | dupilumab | Interleukin 4R alpha inhibitors | 300.0 | MG | SC | Q2W | 107 | FAS | ANCOVA | MI | 1 | WK | EASI | Mean | 33.3 | 0-72 score | 9.93 | SD | LS Mean | -18.83 | 2.418 | SE | 60.7 | 38.0 | YR |
544_cefalu_2015¶
Control rows matched by test output: 8 of 8
Literature data accuracy: 75.33%
Clinical data accuracy: 58.71%
Clinical data accuracy (drop unmatched): 58.71%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| dapagliflozin | 10mg | oncedaily | hba1c | 24 | 4 | c7t4 | test | Double-Blind | TRUE | Dapagliflozin | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | 10 mg | mg | Oral | Once-Daily | 455 | 451 | FAS | ANCOVA | LOCF | 24 | WK | HbA1c | Mean | 8.18 | percent | 0.84 | SD | Adjusted Mean | -0.46 | percent | -0.50 | -0.33 | Adjusted Mean | -0.38 | percent | -0.46 | -0.30 | 62.8 | YR | |||||||||||||||
| 10 | qd | hba1c | 24.0 | 7 | c7t4 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 220 | FAS | LOCF | 24.0 | WK | HbA1c | Mean | 8.05 | percent | 0.81 | SD | LS Mean | -0.47 | percent | 95%CI | -0.59 | -0.36 | LS Mean | 7.55 | percent | LS Mean | -5.86 | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 20 | 57 | 50 | 100 | 17 | 0 | 0 | 0 | 100 | 100 | 0 | 100 | 67 | 100 | 100 | 100 | 50 | 100 | 75 | 100 | 100 | 100 | 60 | 75 | 100 | 100 | 0 | 75 | 75 | 60 | 25 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | |||||||
| placebo | oncedaily | hba1c | 24 | 7 | c6t7 | test | Double-Blind | TRUE | Placebo | Once-daily | 459 | 451 | FAS | ANCOVA | LOCF | 24 | WK | HbA1c | Mean | 8.08 | percent | 0.80 | SD | Adjusted Mean | 0.08 | percent | 0.01 | 0.16 | Adjusted Mean | 0.08 | percent | 0.01 | 0.16 | 68.6 | 63.0 | YR | |||||||||||||||||||
| 0 | qd | hba1c | 24.0 | 6 | c6t7 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 217 | FAS | LOCF | 24.0 | WK | HbA1c | Mean | 7.99 | percent | 0.76 | SD | LS Mean | -0.02 | percent | 95%CI | -0.13 | 0.1 | LS Mean | 8.0 | percent | LS Mean | -0.249 | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 17 | 0 | 0 | 33 | 100 | 100 | 0 | 100 | 67 | 100 | 100 | 100 | 25 | 100 | 50 | 100 | 100 | 100 | 60 | 75 | 100 | 100 | 0 | 75 | 86 | 60 | 86 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| dapagliflozin | 10mg | oncedaily | hba1c | 24 | 3 | c5t3 | test | Double-Blind | TRUE | Dapagliflozin | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | 10 mg | mg | Oral | Once-Daily | 455 | 451 | FAS | ANCOVA | LOCF | 24 | WK | HbA1c | Mean | 8.18 | percent | 0.84 | SD | Adjusted Mean | -0.46 | percent | -0.50 | -0.30 | Adjusted Mean | -0.38 | percent | -0.46 | -0.30 | 62.8 | YR | |||||||||||||||
| 10 | qd | hba1c | 24.0 | 5 | c5t3 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 228 | FAS | LOCF | 24.0 | WK | HbA1c | Mean | 8.31 | percent | 0.85 | SD | LS Mean | -0.28 | percent | 95%CI | -0.39 | -0.17 | LS Mean | 7.954 | percent | LS Mean | -3.401 | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 20 | 57 | 50 | 100 | 17 | 0 | 0 | 0 | 100 | 100 | 0 | 100 | 67 | 100 | 100 | 100 | 75 | 100 | 75 | 100 | 100 | 100 | 60 | 50 | 100 | 100 | 0 | 50 | 50 | 60 | 22 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | |||||||
| placebo | oncedaily | hba1c | 24 | 6 | c4t6 | test | Double-Blind | TRUE | Placebo | Once-daily | 459 | 451 | FAS | ANCOVA | LOCF | 24 | WK | HbA1c | Mean | 8.08 | percent | 0.80 | SD | Adjusted Mean | 0.08 | percent | 0.01 | 0.16 | Adjusted Mean | 0.08 | percent | 0.01 | 0.16 | 68.6 | 63.0 | YR | |||||||||||||||||||
| 0 | qd | hba1c | 24.0 | 4 | c4t6 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 234 | FAS | LOCF | 24.0 | WK | HbA1c | Mean | 8.16 | percent | 0.83 | SD | LS Mean | 0.19 | percent | 95%CI | 0.08 | 0.29 | LS Mean | 8.424 | percent | LS Mean | 2.307 | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 17 | 0 | 0 | 33 | 100 | 100 | 0 | 100 | 67 | 100 | 100 | 100 | 50 | 100 | 75 | 100 | 100 | 100 | 60 | 50 | 100 | 100 | 0 | 75 | 50 | 60 | 44 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| dapagliflozin | 10mg | oncedaily | hba1c | 52 | 1 | c3t1 | test | Double-Blind | TRUE | Dapagliflozin | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | 10 mg | mg | Oral | Once-Daily | 455 | 188 | FAS | ANCOVA | LOCF | 52 | WK | HbA1c | Mean | 8.13 | percent | 0.81 | SD | Adjusted Mean | -0.66 | percent | -0.79 | -0.53 | -27.2 | 62.8 | YR | |||||||||||||||||||
| 10 | qd | hba1c | 0.0 | 3 | c3t1 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 220 | FAS | LOCF | 0.0 | WK | HbA1c | Mean | 8.05 | percent | 0.81 | SD | LS Mean | 0.0 | percent | Mean | 8.05 | percent | 0.81 | SD | LS Mean | 0.0 | |||||||||||||||||||
| similarity | 100 | 100 | 100 | 20 | 57 | 50 | 100 | 17 | 0 | 0 | 0 | 100 | 100 | 0 | 100 | 0 | 100 | 100 | 100 | 50 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 47 | 50 | 100 | 0 | 0 | 0 | 0 | 0 | 29 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | |||||||
| 10mg | oncedaily | hba1c | 52 | 2 | c2t2 | test | Double-Blind | TRUE | Dapagliflozin | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | 10 mg | mg | Oral | Once-Daily | 455 | 188 | FAS | ANCOVA | LOCF | 52 | WK | HbA1c | Mean | 8.13 | percent | 0.81 | SD | Adjusted Mean | -0.66 | percent | -0.79 | -0.53 | 62.8 | YR | |||||||||||||||||||||
| placebo | 0 | qd | hba1c | 0.0 | 2 | c2t2 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 217 | FAS | LOCF | 0.0 | WK | HbA1c | Mean | 7.99 | percent | 0.76 | SD | LS Mean | 0.0 | percent | Mean | 7.99 | percent | 0.76 | SD | LS Mean | 0.0 | ||||||||||||||||||
| similarity | 100 | 100 | 30 | 23 | 33 | 50 | 100 | 17 | 0 | 0 | 33 | 100 | 100 | 0 | 100 | 0 | 100 | 100 | 100 | 25 | 100 | 50 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 47 | 25 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | |||||||
| dapagliflozin | 10mg | oncedaily | hba1c | 52 | 0 | c1t0 | test | Double-Blind | TRUE | Dapagliflozin | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | 10 mg | mg | Oral | Once-Daily | 455 | 188 | FAS | ANCOVA | LOCF | 52 | WK | HbA1c | Mean | 8.13 | percent | 0.81 | SD | Adjusted Mean | -0.66 | percent | -0.79 | -0.53 | 62.8 | YR | ||||||||||||||||||||
| 10 | qd | hba1c | 0.0 | 1 | c1t0 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 228 | FAS | LOCF | 0.0 | WK | HbA1c | Mean | 8.31 | percent | 0.85 | SD | LS Mean | 0.0 | percent | Mean | 8.31 | percent | 0.85 | SD | LS Mean | 0.0 | |||||||||||||||||||
| similarity | 100 | 100 | 100 | 20 | 57 | 50 | 100 | 17 | 0 | 0 | 33 | 100 | 100 | 0 | 100 | 0 | 100 | 100 | 100 | 75 | 100 | 75 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 47 | 25 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | |||||||
| placebo | oncedaily | hba1c | 24 | 8 | c0t8 | test | Double-Blind | TRUE | Placebo | Once-daily | 459 | 451 | FAS | ANCOVA | LOCF | 24 | WK | HbA1c | Mean | 8.08 | percent | 0.80 | SD | Adjusted Mean | 0.08 | percent | 0.01 | 0.16 | Adjusted Mean | 0.08 | percent | 0.01 | 0.16 | 68.6 | 63.0 | YR | |||||||||||||||||||
| 0 | qd | hba1c | 0.0 | 0 | c0t8 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 234 | FAS | LOCF | 0.0 | WK | HbA1c | Mean | 8.16 | percent | 0.83 | SD | LS Mean | 0.0 | percent | Mean | 8.16 | percent | 0.83 | SD | LS Mean | 0.0 | |||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 17 | 0 | 0 | 33 | 100 | 100 | 0 | 100 | 0 | 100 | 100 | 100 | 50 | 100 | 75 | 100 | 100 | 100 | 60 | 86 | 100 | 100 | 100 | 0 | 0 | 47 | 50 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| dapagliflozin | 10mg | oncedaily | hba1c | 24 | 5 | test | Double-Blind | TRUE | Dapagliflozin | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | 10 mg | mg | Oral | Once-Daily | 455 | 451 | FAS | ANCOVA | LOCF | 24 | WK | HbA1c | Mean | 8.18 | percent | 0.84 | SD | Adjusted Mean | -0.46 | percent | 95% CI | -0.46 | -0.30 | Adjusted Mean | -0.38 | percent | 95% CI | -0.46 | -0.30 | 62.8 | YR |
537_jabbour_2014¶
Control rows matched by test output: 18 of 30
Literature data accuracy: 68.60%
Clinical data accuracy: 35.84%
Clinical data accuracy (drop unmatched): 59.73%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| dapagliflozin | 10 | oncedaily | hba1c | 24 | 1 | c9t1 | test | Double-Blind | TRUE | Dapagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 223 | 223 | FAS | Longitudinal repeated measures | 24 | WK | HbA1c | Mean | 7.9 | percent | 0.8 | [mmol/mol] | Adjusted mean change | -0.4 | percent | -0.5 | -0.3 | Adjusted mean | -0.4 | percent | -0.5 | -0.3 | 57.0 | 54.8 | YR | |||||||||||||||
| qd | hba1c | 24.0 | 9 | c9t1 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 94 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | LOCF | 24.0 | WK | HbA1c | Mean | 8.65 | percent | 0.55 | SD | LS Mean | -0.8 | percent | 95%CI | -0.96 | -0.65 | LS Mean | 7.865 | percent | LS Mean | -9.232 | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 0 | 0 | 0 | 100 | 100 | 77 | 0 | 67 | 100 | 100 | 100 | 29 | 100 | 57 | 0 | 100 | 100 | 44 | 67 | 100 | 100 | 0 | 57 | 57 | 60 | 25 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| placebo | oncedaily | hba1c | 24 | 13 | c8t13 | test | Double-Blind | TRUE | Placebo | Oral | Once Daily | 224 | 224 | FAS | Longitudinal repeated measures | 24 | WK | HbA1c | Mean | 8.0 | percent | 0.8 | [mmol/mol] | Adjusted mean change | 0.1 | percent | [1.0 (-0.4 to 2.3) mmol/mol] | 0.0 | 0.2 | Adjusted mean | 0.1 | percent | [1.0 (-0.4 to 2.3) mmol/mol] | 0.0 | 0.2 | 52.7 | 55.0 | YR | |||||||||||||||||
| 0 | qd | hba1c | 24.0 | 8 | c8t13 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 99 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | LOCF | 24.0 | WK | HbA1c | Mean | 8.68 | percent | 0.55 | SD | LS Mean | 0.03 | percent | 95%CI | -0.12 | 0.18 | LS Mean | 8.695 | percent | LS Mean | 0.346 | |||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 0 | 0 | 0 | 100 | 100 | 77 | 0 | 67 | 100 | 100 | 100 | 57 | 100 | 57 | 0 | 100 | 100 | 44 | 57 | 100 | 100 | 7 | 57 | 57 | 60 | 25 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| dapagliflozin | 10 | oncedaily | hba1c | 48 | 8 | c29t8 | test | Double-Blind | TRUE | Dapagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 223 | 110 | Stratum 1 (Sitagliptin monotherapy) | ANCOVA | LOCF | 48 | WK | HbA1c | Mean | 8.0 | percent | 0.8 | [mmol/mol] | Adjusted mean change | -0.4 | percent | [mmol/mol] | -0.6 | -0.3 | Adjusted mean | 0.0 | percent | [mmol/mol] | 57.0 | 54.8 | YR | ||||||||||||||
| qd | hba1c | 48.0 | 29 | c29t8 | control | Double-Blind Extension | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 39 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 48.0 | WK | HbA1c | Mean | 8.68 | percent | 0.57 | SD | LS Mean | -1.1 | percent | LS Mean | 7.564 | percent | LS Mean | -12.696 | ||||||||||||||||||||||
| similarity | 71 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 0 | 0 | 0 | 100 | 11 | 24 | 0 | 67 | 100 | 100 | 100 | 57 | 100 | 57 | 0 | 100 | 100 | 44 | 33 | 100 | 100 | 0 | 0 | 0 | 60 | 25 | 100 | 100 | 0 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| placebo | oncedaily | hba1c | 48 | 17 | c28t17 | test | Double-Blind | TRUE | Placebo | Oral | Once Daily | 224 | 224 | FAS | Longitudinal repeated measures | 48 | WK | HbA1c | Mean | 8.0 | percent | 0.8 | [mmol/mol] | Adjusted mean change | 0.4 | percent | 6.8 to 20.2 | 0.8 to 1.1 | Adjusted mean | 0.4 | percent | 0.2 to 0.5 | 4.2 to 5.9 | 52.7 | 55.0 | YR | |||||||||||||||||||
| 0 | qd | hba1c | 48.0 | 28 | c28t17 | control | Double-Blind Extension | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 43 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 48.0 | WK | HbA1c | Mean | 8.65 | percent | 0.53 | SD | LS Mean | -0.5 | percent | LS Mean | 8.164 | percent | LS Mean | -5.771 | |||||||||||||||||||||
| similarity | 71 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 0 | 0 | 40 | 100 | 100 | 77 | 100 | 67 | 100 | 100 | 100 | 57 | 100 | 57 | 0 | 100 | 100 | 44 | 67 | 100 | 100 | 100 | 0 | 0 | 60 | 25 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| dapagliflozin | 10 | oncedaily | hba1c | 48 | 7 | c27t7 | test | Double-Blind | TRUE | Dapagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 223 | 223 | FAS | Longitudinal repeated measures | 48 | WK | HbA1c | Mean | 7.9 | percent | 0.8 | [mmol/mol] | Adjusted mean change | -0.4 | percent | -0.6 | -0.3 | Adjusted mean | -0.3 | percent | -0.4 | -0.2 | 57.0 | 54.8 | YR | |||||||||||||||
| qd | hba1c | 48.0 | 27 | c27t7 | control | Double-Blind Extension | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 55 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 48.0 | WK | HbA1c | Mean | 8.62 | percent | 0.53 | SD | LS Mean | -1.2 | percent | LS Mean | 7.46 | percent | LS Mean | -13.856 | ||||||||||||||||||||||
| similarity | 71 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 0 | 0 | 0 | 100 | 100 | 77 | 100 | 67 | 100 | 100 | 100 | 29 | 100 | 57 | 0 | 100 | 100 | 44 | 33 | 100 | 100 | 100 | 0 | 0 | 60 | 29 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| placebo | oncedaily | hba1c | 48 | 16 | c26t16 | test | Double-Blind | TRUE | Placebo | Oral | Once Daily | 224 | 224 | FAS | Longitudinal repeated measures | 48 | WK | HbA1c | Mean | 8.0 | percent | 0.8 | [mmol/mol] | Adjusted mean change | 0.4 | percent | 6.8 to 20.2 | 0.8 to 1.1 | Adjusted mean | 0.4 | percent | 0.2 to 0.5 | 4.2 to 5.9 | 52.7 | 55.0 | YR | |||||||||||||||||||
| 0 | qd | hba1c | 48.0 | 26 | c26t16 | control | Double-Blind Extension | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 56 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 48.0 | WK | HbA1c | Mean | 8.7 | percent | 0.57 | SD | LS Mean | -0.4 | percent | LS Mean | 8.26 | percent | LS Mean | -4.619 | |||||||||||||||||||||
| similarity | 71 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 0 | 0 | 0 | 100 | 100 | 77 | 100 | 67 | 100 | 100 | 100 | 67 | 100 | 57 | 0 | 100 | 100 | 44 | 100 | 100 | 100 | 100 | 0 | 0 | 60 | 29 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| dapagliflozin | 10 | oncedaily | hba1c | 48 | 6 | c25t6 | test | Double-Blind | TRUE | Dapagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 223 | 223 | FAS | ANCOVA | LOCF | 48 | WK | HbA1c | Mean | 7.9 | percent | 0.8 | [mmol/mol] | Adjusted mean change | -0.4 | percent | -0.6 | -0.3 | Adjusted mean | -0.3 | percent | -0.4 | -0.2 | 57.0 | 54.8 | YR | ||||||||||||||
| qd | hba1c | 48.0 | 25 | c25t6 | control | Double-Blind Extension | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 94 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 48.0 | WK | HbA1c | Mean | 8.65 | percent | 0.55 | SD | LS Mean | -0.7 | percent | 95%CI | -1.0 | -0.5 | LS Mean | 7.965 | percent | LS Mean | -8.078 | |||||||||||||||||||
| similarity | 71 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 0 | 0 | 0 | 100 | 100 | 24 | 0 | 67 | 100 | 100 | 100 | 29 | 100 | 57 | 0 | 100 | 100 | 44 | 67 | 100 | 100 | 0 | 67 | 67 | 60 | 25 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| placebo | oncedaily | hba1c | 48 | 15 | c24t15 | test | Double-Blind | TRUE | Placebo | Oral | Once Daily | 224 | 224 | FAS | ANCOVA | LOCF | 48 | WK | HbA1c | Mean | 8.0 | percent | 0.8 | [mmol/mol] | Adjusted mean change | 0.4 | percent | 6.8 to 20.2 | 0.8 to 1.1 | Adjusted mean | 0.4 | percent | 0.2 to 0.5 | 4.2 to 5.9 | 52.7 | 55.0 | YR | ||||||||||||||||||
| 0 | qd | hba1c | 48.0 | 24 | c24t15 | control | Double-Blind Extension | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 99 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 48.0 | WK | HbA1c | Mean | 8.68 | percent | 0.55 | SD | LS Mean | 0.3 | percent | 95%CI | -0.2 | 0.7 | LS Mean | 8.965 | percent | LS Mean | 3.462 | ||||||||||||||||||
| similarity | 71 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 0 | 0 | 0 | 100 | 100 | 24 | 0 | 67 | 100 | 100 | 100 | 57 | 100 | 57 | 0 | 100 | 100 | 44 | 67 | 100 | 100 | 0 | 29 | 31 | 60 | 25 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| dapagliflozin | 10 | oncedaily | hba1c | 48 | 11 | c23t11 | test | Double-Blind | TRUE | Dapagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 223 | 113 | Stratum 2 (Sitagliptin plus metformin) | Longitudinal repeated measures | 48 | WK | HbA1c | Mean | 56.8 | years | 10.3 | SD | Adjusted mean | -0.4 | percent | -0.6 | -0.3 | Adjusted mean | -0.4 | percent | -0.6 | -0.3 | 57.0 | 54.8 | YR | |||||||||||||||
| qd | hba1c | 24.0 | 23 | c23t11 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 39 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 24.0 | WK | HbA1c | Mean | 8.68 | percent | 0.57 | SD | LS Mean | -0.9 | percent | LS Mean | 7.764 | percent | LS Mean | -10.387 | ||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 0 | 0 | 40 | 100 | 15 | 77 | 100 | 33 | 100 | 100 | 100 | 75 | 33 | 50 | 100 | 100 | 100 | 60 | 67 | 100 | 100 | 100 | 0 | 0 | 60 | 50 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| oncedaily | hba1c | 48 | 10 | c21t10 | test | Double-Blind | TRUE | Dapagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 223 | 113 | Stratum 2 (Sitagliptin plus metformin) | ANCOVA | LOCF | 48 | WK | HbA1c | Mean | 7.8 | percent | 0.8 | [62.0 (8.9)] | Adjusted mean change | -0.4 | percent | -0.6 | -0.3 | Adjusted mean | -0.4 | percent | -0.6 | -0.3 | 57.0 | 54.8 | YR | ||||||||||||||||
| qd | hba1c | 24.0 | 21 | c21t10 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 39 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | LOCF | 24.0 | WK | HbA1c | Mean | 8.68 | percent | 0.57 | SD | LS Mean | -0.8 | percent | 95%CI | -1.0 | -0.6 | LS Mean | 7.864 | percent | LS Mean | -9.233 | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 0 | 0 | 40 | 100 | 15 | 24 | 100 | 33 | 100 | 100 | 100 | 57 | 100 | 57 | 0 | 100 | 100 | 44 | 67 | 100 | 100 | 0 | 67 | 67 | 60 | 50 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| oncedaily | hba1c | 24 | 0 | c1t0 | test | Double-Blind | TRUE | Dapagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 223 | 223 | FAS | ANCOVA | LOCF | 24 | WK | HbA1c | Mean | 7.9 | percent | 0.8 | [mmol/mol] | LS Mean | -0.5 | percent | [-4.9 mmol/mol] | -0.6 | -0.4 | LS Mean | -0.5 | percent | [-4.9 mmol/mol] | -0.6 | -0.4 | 57.0 | 54.8 | YR | ||||||||||||||
| qd | hba1c | 24.0 | 1 | c1t0 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 223.0 | 223 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | LOCF | 24.0 | WK | HbA1c | Mean | 7.9 | percent | 0.806 | SD | LS Mean | -0.45 | percent | 95%CI | -0.55 | -0.35 | LS Mean | 7.485 | percent | LS Mean | -5.671 | 57.0 | 54.8 | YR | ||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 0 | 75 | 100 | 100 | 100 | 24 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 75 | 0 | 100 | 100 | 100 | 86 | 100 | 100 | 24 | 57 | 57 | 100 | 25 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| oncedaily | hba1c | 48 | 9 | c19t9 | test | Double-Blind | TRUE | Dapagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 223 | 110 | Stratum 1 (Sitagliptin monotherapy) | Longitudinal repeated measures | 48 | WK | HbA1c | Mean | 8.0 | percent | 0.8 | [mmol/mol] | Adjusted mean change | -0.4 | percent | -0.6 | -0.2 | Adjusted mean | 0.0 | percent | -0.3 | 0.3 | 57.0 | 54.8 | YR | |||||||||||||||||
| qd | hba1c | 24.0 | 19 | c19t9 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 113 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | LOCF | 24.0 | WK | HbA1c | Mean | 7.8 | percent | 0.81 | SD | LS Mean | -0.4 | percent | 95%CI | -0.6 | -0.3 | LS Mean | 7.435 | percent | LS Mean | -5.105 | 59.3 | 56.8 | YR | |||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 0 | 0 | 67 | 100 | 11 | 77 | 0 | 33 | 100 | 100 | 100 | 67 | 100 | 86 | 0 | 100 | 100 | 44 | 100 | 100 | 100 | 0 | 100 | 67 | 60 | 25 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 50 | 75 | 100 | |||||||
| oncedaily | hba1c | 24 | 5 | c17t5 | test | Double-Blind | TRUE | Dapagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 223 | 113 | Stratum 2 (Sitagliptin plus metformin) | Longitudinal repeated measures | 24 | WK | HbA1c | Mean | 7.9 | percent | 0.8 | [8.2] | Adjusted mean change | -0.4 | percent | -0.6 | -0.3 | Adjusted mean | -0.4 | percent | -0.6 | -0.3 | 57.0 | 54.8 | YR | |||||||||||||||||
| qd | hba1c | 24.0 | 17 | c17t5 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 55 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 24.0 | WK | HbA1c | Mean | 8.62 | percent | 0.53 | SD | LS Mean | -0.8 | percent | 95%CI | -1.1 | -0.5 | LS Mean | 7.86 | percent | LS Mean | -9.237 | |||||||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 0 | 0 | 0 | 100 | 15 | 77 | 100 | 67 | 100 | 100 | 100 | 29 | 100 | 57 | 0 | 100 | 100 | 44 | 67 | 100 | 100 | 0 | 33 | 67 | 60 | 29 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| oncedaily | hba1c | 24 | 4 | c15t4 | test | Double-Blind | TRUE | Dapagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 223 | 113 | Stratum 2 (Sitagliptin plus metformin) | ANCOVA | LOCF | 24 | WK | HbA1c | Mean | 7.9 | percent | 0.8 | [8.2] | Adjusted mean change | -0.4 | percent | [-4.4 (-6.3 to -2.5)] | -0.6 | -0.2 | Adjusted mean change | -0.4 | percent | [-4.7 (-6.0 to -3.3)] | -0.6 | -0.3 | 57.0 | 54.8 | YR | ||||||||||||||
| qd | hba1c | 24.0 | 15 | c15t4 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 55 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | LOCF | 24.0 | WK | HbA1c | Mean | 8.62 | percent | 0.53 | SD | LS Mean | -0.8 | percent | 95%CI | -1.0 | -0.6 | LS Mean | 7.86 | percent | LS Mean | -9.237 | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 0 | 0 | 0 | 100 | 15 | 24 | 100 | 67 | 100 | 100 | 100 | 29 | 100 | 57 | 0 | 100 | 100 | 44 | 67 | 100 | 100 | 21 | 67 | 67 | 44 | 29 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| oncedaily | hba1c | 24 | 3 | c13t3 | test | Double-Blind | TRUE | Dapagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 223 | 110 | Stratum 1 (Sitagliptin monotherapy) | Longitudinal repeated measures | 24 | WK | HbA1c | Mean | 8.0 | percent | 0.8 | [mmol/mol] | Adjusted mean | -0.4 | percent | -0.6 | -0.3 | 57.0 | 54.8 | YR | ||||||||||||||||||||||
| qd | hba1c | 24.0 | 13 | c13t3 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 110 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | LOCF | 24.0 | WK | HbA1c | Mean | 7.99 | percent | 0.8 | SD | LS Mean | -0.5 | percent | 95%CI | -0.6 | -0.3 | LS Mean | 7.53 | percent | LS Mean | -6.227 | 54.5 | 52.6 | YR | |||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 0 | 0 | 100 | 100 | 11 | 77 | 0 | 67 | 100 | 100 | 100 | 29 | 100 | 100 | 0 | 100 | 100 | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 60 | 29 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 50 | 50 | 100 | |||||||
| oncedaily | hba1c | 24 | 2 | c11t2 | test | Double-Blind | TRUE | Dapagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 223 | 110 | Stratum 1 (Sitagliptin monotherapy) | ANCOVA | LOCF | 24 | WK | HbA1c | Mean | 8.0 | percent | 0.8 | [mmol/mol] | LS Mean | -0.5 | percent | [-4.9 mmol/mol] | -0.6 | -0.3 | LS Mean | -0.5 | percent | [-4.9 mmol/mol] | -0.6 | -0.3 | 57.0 | 54.8 | YR | ||||||||||||||
| qd | hba1c | 24.0 | 11 | c11t2 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 94 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 24.0 | WK | HbA1c | Mean | 8.65 | percent | 0.55 | SD | LS Mean | -0.8 | percent | 95%CI | -1.0 | -0.6 | LS Mean | 7.865 | percent | LS Mean | -9.232 | |||||||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 0 | 0 | 0 | 100 | 11 | 24 | 0 | 67 | 100 | 100 | 100 | 57 | 100 | 57 | 0 | 100 | 100 | 100 | 67 | 100 | 100 | 24 | 67 | 67 | 100 | 50 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| placebo | oncedaily | hba1c | 24 | 14 | c10t14 | test | Double-Blind | TRUE | Placebo | Oral | Once Daily | 224 | 224 | FAS | Longitudinal repeated measures | 24 | WK | HbA1c | Mean | 8.0 | percent | 0.8 | [mmol/mol] | Adjusted mean change | 0.1 | percent | [1.0 (-0.4 to 2.3) mmol/mol] | 0.0 | 0.2 | Adjusted mean | 0.1 | percent | [1.0 (-0.4 to 2.3) mmol/mol] | 0.0 | 0.2 | 52.7 | 55.0 | YR | |||||||||||||||||
| 0 | qd | hba1c | 24.0 | 10 | c10t14 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 99 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 24.0 | WK | HbA1c | Mean | 8.68 | percent | 0.55 | SD | LS Mean | 0.2 | percent | 95%CI | -0.1 | 0.4 | LS Mean | 8.865 | percent | LS Mean | 2.308 | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 0 | 0 | 0 | 100 | 100 | 77 | 100 | 67 | 100 | 100 | 100 | 57 | 100 | 57 | 0 | 100 | 100 | 44 | 67 | 100 | 100 | 7 | 67 | 67 | 60 | 25 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| oncedaily | hba1c | 24 | 12 | c0t12 | test | Double-Blind | TRUE | Placebo | Oral | Once Daily | 224 | 224 | FAS | ANCOVA | LOCF | 24 | WK | HbA1c | Mean | 8.0 | percent | 0.8 | [mmol/mol] | Mean | 0.0 | percent | [-0.1 to 0.1] | Mean | 0.0 | percent | [-0.7 to 1.5] | 52.7 | 55.0 | YR | |||||||||||||||||||||
| 0 | qd | hba1c | 24.0 | 0 | c0t12 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 224.0 | 223 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | LOCF | 24.0 | WK | HbA1c | Mean | 7.97 | percent | 0.778 | SD | LS Mean | 0.04 | percent | 95%CI | -0.06 | 0.14 | LS Mean | 7.975 | percent | LS Mean | 0.504 | 52.7 | 55.0 | YR | |||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 0 | 75 | 67 | 100 | 100 | 24 | 100 | 67 | 100 | 100 | 100 | 29 | 100 | 75 | 0 | 100 | 100 | 73 | 86 | 100 | 100 | 13 | 0 | 0 | 73 | 25 | 100 | 100 | 0 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 22 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 43 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 24.0 | WK | HbA1c | Mean | 8.65 | percent | 0.53 | SD | LS Mean | -0.4 | percent | LS Mean | 8.264 | percent | LS Mean | -4.617 | ||||||||||||||||||||||||||
| 20 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 43 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | LOCF | 24.0 | WK | HbA1c | Mean | 8.65 | percent | 0.53 | SD | LS Mean | 0.0 | percent | 95%CI | -0.2 | 0.2 | LS Mean | 8.664 | percent | LS Mean | 0.0 | ||||||||||||||||||||||
| 18 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 113 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | LOCF | 24.0 | WK | HbA1c | Mean | 7.87 | percent | 0.75 | SD | LS Mean | 0.0 | percent | 95%CI | -0.2 | 0.1 | LS Mean | 7.835 | percent | LS Mean | 0.0 | 59.3 | 56.6 | YR | |||||||||||||||||||
| 16 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 56 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 24.0 | WK | HbA1c | Mean | 8.7 | percent | 0.57 | SD | LS Mean | 0.2 | percent | 95%CI | -0.1 | 0.6 | LS Mean | 8.86 | percent | LS Mean | 2.309 | |||||||||||||||||||||||
| 14 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 56 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | LOCF | 24.0 | WK | HbA1c | Mean | 8.7 | percent | 0.57 | SD | LS Mean | 0.1 | percent | 95%CI | -0.2 | 0.3 | LS Mean | 8.76 | percent | LS Mean | 1.155 | ||||||||||||||||||||||
| 12 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 111 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | LOCF | 24.0 | WK | HbA1c | Mean | 8.07 | percent | 0.8 | SD | LS Mean | 0.1 | percent | 95%CI | -0.1 | 0.3 | LS Mean | 8.13 | percent | LS Mean | 1.245 | 45.9 | 53.3 | YR | |||||||||||||||||||
| 0.0 | 6 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 43 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 0.0 | WK | HbA1c | Mean | 8.65 | percent | 0.53 | SD | LS Mean | 0.0 | percent | Mean | 8.65 | percent | 0.53 | SD | LS Mean | 0.0 | |||||||||||||||||||||||
| 4 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 56 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 0.0 | WK | HbA1c | Mean | 8.7 | percent | 0.57 | SD | LS Mean | 0.0 | percent | Mean | 8.7 | percent | 0.57 | SD | LS Mean | 0.0 | ||||||||||||||||||||||||
| 2 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 99 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 0.0 | WK | HbA1c | Mean | 8.68 | percent | 0.55 | SD | LS Mean | 0.0 | percent | Mean | 8.68 | percent | 0.55 | SD | LS Mean | 0.0 | ||||||||||||||||||||||||
| dapagliflozin | 10 | qd | hba1c | 0.0 | 7 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 39 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 0.0 | WK | HbA1c | Mean | 8.68 | percent | 0.57 | SD | LS Mean | 0.0 | percent | Mean | 8.68 | percent | 0.57 | SD | LS Mean | 0.0 | |||||||||||||||||||
| 5 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 55 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 0.0 | WK | HbA1c | Mean | 8.62 | percent | 0.53 | SD | LS Mean | 0.0 | percent | Mean | 8.62 | percent | 0.53 | SD | LS Mean | 0.0 | ||||||||||||||||||||||||
| 3 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 94 | FAS | ANCOVA;Longitudinal Repeated Measure Analysis | 0.0 | WK | HbA1c | Mean | 8.65 | percent | 0.55 | SD | LS Mean | 0.0 | percent | Mean | 8.65 | percent | 0.55 | SD | LS Mean | 0.0 |
286_wollenberg_2021¶
Control rows matched by test output: 15 of 178
Literature data accuracy: 74.60%
Clinical data accuracy: 6.93%
Clinical data accuracy (drop unmatched): 82.28%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| tralokinumab | 300 | q2w | easi75 | 52 | 9 | c97t9 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 603 | 74 | 38 | FAS | Cochran -Mantel -Haenszel test, stratified by region and baseline IGA | NRI | 52 | WK | EASI-75 | Percent | 51 | Percent | 95% CI | 13.7 | 46.4 | 58.2 | 37.0 | YR | ||||||||||||||||||||||
| 300.0 | q2w | easi75 | 2 | 97 | c97t9 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 28.0 | FAS | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 75 | 4.672 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 33 | 0 | 33 | 100 | 60 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 25 | 75 | 100 | |||||||
| placebo | q2w | easi75 | 16 | 2 | c96t2 | test | Double-Blind | TRUE | Placebo | SC | Q2W | 199 | 197 | 25 | FAS | Repeated-measurements model | 16 | WK | EASI-75 | Adjusted mean change (SE) | -9.0 | 1.05 | SE | -8.8 | -4.1 | 61.8 | 37.0 | YR | |||||||||||||||||||||||||||
| 0.0 | q2w | easi75 | 16 | 96 | c96t2 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 23.0 | FAS | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 75 | 11.4 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 33 | 25 | 33 | 100 | 40 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 29 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 50 | 75 | 100 | |||||||
| tralokinumab | 300 | q2w | easi75 | 52 | 6 | c8t6 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 68 | 47 | 28 | FAS | Repeated-measurements model on postbaseline data: change =(Treatment9Week) +(Baseline measure 9Week) +Region +Baseline IGA | 52 | WK | EASI-75 | n/N(%) | 60 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||
| 300.0 | q2w | easi75 | 2 | 8 | c8t6 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 28.0 | FAS | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 75 | 4.672 | percent | 58.2 | 37.0 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 40 | 0 | 67 | 100 | 28 | 0 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 29 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | q2w | easi75 | 16 | 1 | c7t1 | test | Double-Blind | TRUE | Placebo | SC | Q2W | 199 | 197 | 25 | FAS | Cochran -Mantel -Haenszel test | NRI | 16 | WK | EASI-75 | Percent | 12.7 | Percent | 95% CI | 6.5 | 17.7 | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||
| 0.0 | q2w | easi75 | 16 | 7 | c7t1 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 25.0 | FAS | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 75 | 12.7 | percent | 61.8 | 37.0 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 50 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| tralokinumab | 300 | q2w | easi90 | 16 | 13 | c50t13 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 603 | 601 | 87 | FAS | Cochran -Mantel -Haenszel test, stratified by region and baseline IGA | NRI | 16 | WK | EASI-90 | n/N(%) | 14.5 | percent | 10.3 | 14.1 | 58.2 | 37.0 | YR | |||||||||||||||||||||||
| 300.0 | q2w | easi90 | 16 | 50 | c50t13 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 88.0 | FAS | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 90 | 14.512 | percent | 58.2 | 37.0 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 100 | 50 | 33 | 100 | 60 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 80 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | q2w | easi90 | 16 | 4 | c42t4 | test | Double-Blind | TRUE | Placebo | SC | Q2W | 199 | 197 | 8 | FAS | Cochran -Mantel -Haenszel test, stratified by region and baseline IGA | NRI | 16 | WK | EASI-90 | n/N(%) | 4.1 | percent | 61.8 | 37.0 | YR | |||||||||||||||||||||||||||||
| 0.0 | q2w | easi90 | 16 | 42 | c42t4 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 8.0 | FAS | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 90 | 4.095 | percent | 61.8 | 37.0 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 50 | 50 | 100 | 60 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 50 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| tralokinumab | 300 | q2w | easi50 | 16 | 11 | c34t11 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 603 | 601 | 250 | FAS | Cochran -Mantel -Haenszel test, stratified by region and baseline IGA | NRI | 16 | WK | EASI-50 | n/N(%) | 41.6 | percent | 13.3 | 26.8 | 58.2 | 37.0 | YR | |||||||||||||||||||||||
| 300.0 | q2w | easi50 | 16 | 34 | c34t11 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 251.0 | FAS | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 50 | 41.672 | percent | 58.2 | 37.0 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 100 | 50 | 50 | 100 | 60 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 80 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | q2w | easi50 | 16 | 3 | c26t3 | test | Double-Blind | TRUE | Placebo | SC | Q2W | 199 | 197 | 42 | FAS | Cochran -Mantel -Haenszel test, stratified by region and baseline IGA | NRI | 16 | WK | EASI-50 | n/N(%) | 21.3 | percent | 13.3 | 26.8 | 61.8 | 37.0 | YR | |||||||||||||||||||||||||||
| 0.0 | q2w | easi50 | 16 | 26 | c26t3 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 42.0 | FAS | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 50 | 21.268 | percent | 61.8 | 37.0 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 50 | 67 | 100 | 60 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 60 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| tralokinumab | 300 | every4weeks | easi75 | 52 | 14 | c17t14 | test | Double-Blind | TRUE | tralokinumab | Monoclonal Antibody | 300 | mg | SC | Every 4 Weeks | 89 | 74 | 38 | FAS | Cochran -Mantel -Haenszel test, stratified by region and baseline IGA | NRI | 52 | WK | EASI-75 | Percent | 51 | Percent | 95% CI | 17.3 | 50.0 | |||||||||||||||||||||||||
| 300.0 | q4w | easi75 | 52 | 17 | c17t14 | control | Open-Label | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q4W | 78 | 57.0 | 28.0 | FAS | Cochran Mantel Haenszel Test | NRI | 52 | WK | EASI 75 | 49.0 | percent | ||||||||||||||||||||||||||||||
| similarity | 45 | 100 | 100 | 36 | 75 | 100 | 100 | 25 | 100 | 50 | 33 | 33 | 100 | 60 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 300 | q2w | easi75 | 52 | 0 | c16t0 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 35 | 30 | 10 | FAS | Cochran -Mantel -Haenszel test, stratified by region and baseline IGA | NRI | 52 | WK | EASI-75 | n/N(%) | 33 | percent | 21.2 | 42.6 | 56.7 | 30.0 | YR | ||||||||||||||||||||||||
| 300.0 | q2w | easi75 | 52 | 16 | c16t0 | control | Open-Label | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 71 | 47.0 | 28.0 | FAS | Cochran Mantel Haenszel Test | NRI | 52 | WK | EASI 75 | 60.0 | percent | ||||||||||||||||||||||||||||||
| similarity | 45 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 0 | 33 | 33 | 100 | 60 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| 300 | q2w | easi75 | 16 | 7 | c15t7 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 603 | 591 | 196 | FAS | Cochran -Mantel -Haenszel test, stratified by region and baseline IGA | NRI | 16 | WK | EASI-75 | Percent | 33.2 | Percent | 95% CI | 15.8 | 27.3 | 58.2 | 37.0 | YR | |||||||||||||||||||||||
| 300.0 | q2w | easi75 | 16 | 15 | c15t7 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 151.0 | FAS | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 75 | 25.0 | percent | 58.2 | 37.0 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 100 | 0 | 25 | 100 | 60 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 25 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 300 | q2w | easi75 | 52 | 10 | c13t10 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 603 | 74 | 38 | FAS | Repeated-measurements model on postbaseline data: change =(Treatment9Week) +(Baseline measure 9Week) +Region +Baseline IGA | 52 | WK | EASI-75 | Adjusted mean change (SE) | 51.0 | percent | 58.2 | 37.0 | YR | |||||||||||||||||||||||||||
| 300.0 | q2w | easi75 | 12 | 13 | c13t10 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 163.0 | FAS | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 75 | 27.009 | percent | 58.2 | 37.0 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 100 | 0 | 29 | 100 | 28 | 0 | 50 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 40 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 300 | q2w | easi50 | 16 | 12 | c123t12 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 603 | 601 | 250 | FAS | Mantel -Haenszel risk difference, stratified by region and baseline IGA | NRI | 16 | WK | EASI-50 | Percent | 41.6 | percent | 13.3 | 26.8 | 58.2 | 37.0 | YR | ||||||||||||||||||||||||
| 300.0 | q2w | easi50 | 16 | 123 | c123t12 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 296.0 | FAS | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 50 | 49.971 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 33 | 25 | 25 | 100 | 45 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 40 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 25 | 75 | 100 | |||||||
| 300 | q2w | easi75 | 52 | 5 | c105t5 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 68 | 77 | 43 | FAS | Cochran -Mantel -Haenszel test, stratified by region and baseline IGA | NRI | 52 | WK | EASI-75 | Percent | 56 | Percent | 95% CI | 17.3 | 50.0 | 58.2 | 37.0 | YR | |||||||||||||||||||||||
| 300.0 | q2w | easi75 | 52 | 105 | c105t5 | control | Open-Label | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 91 | 77.0 | 43.0 | FAS | Cochran Mantel Haenszel Test | NRI | 52 | WK | EASI 75 | 56.0 | percent | ||||||||||||||||||||||||||||||
| similarity | 45 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 0 | 67 | 67 | 100 | 60 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 67 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| 300 | q2w | easi75 | 16 | 8 | c104t8 | test | Double-Blind | TRUE | Tralokinumab | Monoclonal Antibody | 300 | mg | SC | Q2W | 603 | 601 | 150 | FAS | Repeated-measurements model on postbaseline data: change =(Treatment9Week) +(Baseline measure 9Week) +Region +Baseline IGA | 16 | WK | EASI-75 | LSMean | 25.0 | percent | 95% CI | 6.5 | 17.7 | 58.2 | 37.0 | YR | ||||||||||||||||||||||||
| 300.0 | q2w | easi75 | 16 | 104 | c104t8 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 197.0 | FAS | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 75 | 33.2 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 36 | 75 | 100 | 100 | 100 | 100 | 33 | 25 | 25 | 100 | 28 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 25 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 25 | 75 | 100 | |||||||
| 600.0 | q2w | scorad | 0 | 168 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 600.0 | MG | SC | Q2W | 591 | 591.0 | FAS | OC | 0 | WK | SCORAD | Mean | 70.0 | 0-103 score | 13.4 | SD | LS Mean | 0.0 | 0-103 score | Mean | 70.0 | 0-103 score | 13.4 | SD | 60.5 | 34.0 | YR | |||||||||||||||||||
| 79 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 600.0 | MG | SC | Q2W | 601 | 601.0 | FAS | OC | 0 | WK | SCORAD | Mean | 70.3 | 0-103 score | 13.0 | SD | LS Mean | 0.0 | 0-103 score | Mean | 70.3 | 0-103 score | 13.0 | SD | 58.2 | 37.0 | YR | |||||||||||||||||||||||
| easi | 0 | 149 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 600.0 | MG | SC | Q2W | 591 | 591.0 | FAS | OC | 0 | WK | EASI | Mean | 32.1 | 0-72 score | 14.3 | SD | Mean | 0.0 | 0-72 score | LS Mean | 0.0 | 60.5 | 34.0 | YR | ||||||||||||||||||||||||
| 60 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 600.0 | MG | SC | Q2W | 601 | 601.0 | FAS | OC | 0 | WK | EASI | Mean | 32.2 | 0-72 score | 13.7 | SD | Mean | 0.0 | 0-72 score | LS Mean | 0.0 | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||
| 300.0 | q4w | easi75 | 52 | 106 | control | Open-Label | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q4W | 90 | 74.0 | 38.0 | FAS | Cochran Mantel Haenszel Test | NRI | 52 | WK | EASI 75 | 51.0 | percent | |||||||||||||||||||||||||||||||
| q2w | scorad | 8 | 172 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 569.0 | FAS | OC | 8 | WK | SCORAD | Mean | 70.0 | 0-103 score | 13.4 | SD | LS Mean | -25.0 | 0-103 score | 0.76 | SE | Mean | 44.0 | 0-103 score | 19.8 | SD | 60.5 | 34.0 | YR | ||||||||||||||||||
| 83 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 570.0 | FAS | OC | 8 | WK | SCORAD | Mean | 70.3 | 0-103 score | 13.0 | SD | LS Mean | -22.8 | 0-103 score | 0.81 | SE | Mean | 44.4 | 0-103 score | 19.1 | SD | 58.2 | 37.0 | YR | |||||||||||||||||||||
| 6 | 171 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 574.0 | FAS | OC | 6 | WK | SCORAD | Mean | 70.0 | 0-103 score | 13.4 | SD | LS Mean | -22.4 | 0-103 score | 0.72 | SE | Mean | 46.9 | 0-103 score | 19.3 | SD | 60.5 | 34.0 | YR | ||||||||||||||||||||
| 82 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 579.0 | FAS | OC | 6 | WK | SCORAD | Mean | 70.3 | 0-103 score | 13.0 | SD | LS Mean | -21.2 | 0-103 score | 0.73 | SE | Mean | 46.7 | 0-103 score | 18.8 | SD | 58.2 | 37.0 | YR | |||||||||||||||||||||
| 4 | 170 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 574.0 | FAS | OC | 4 | WK | SCORAD | Mean | 70.0 | 0-103 score | 13.4 | SD | LS Mean | -18.0 | 0-103 score | 0.62 | SE | Mean | 50.9 | 0-103 score | 18.4 | SD | 60.5 | 34.0 | YR | ||||||||||||||||||||
| 81 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 588.0 | FAS | OC | 4 | WK | SCORAD | Mean | 70.3 | 0-103 score | 13.0 | SD | LS Mean | -17.0 | 0-103 score | 0.65 | SE | Mean | 51.1 | 0-103 score | 17.8 | SD | 58.2 | 37.0 | YR | |||||||||||||||||||||
| 2 | 169 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 587.0 | FAS | OC | 2 | WK | SCORAD | Mean | 70.0 | 0-103 score | 13.4 | SD | LS Mean | -10.8 | 0-103 score | 0.49 | SE | Mean | 58.3 | 0-103 score | 17.2 | SD | 60.5 | 34.0 | YR | ||||||||||||||||||||
| 80 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 591.0 | FAS | OC | 2 | WK | SCORAD | Mean | 70.3 | 0-103 score | 13.0 | SD | LS Mean | -10.6 | 0-103 score | 0.53 | SE | Mean | 58.2 | 0-103 score | 16.3 | SD | 58.2 | 37.0 | YR | |||||||||||||||||||||
| 16 | 177 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 564.0 | FAS | OC | 16 | WK | SCORAD | Mean | 70.0 | 0-103 score | 13.4 | SD | Mean | 41.1 | 0-103 score | 21.9 | SD | 60.5 | 34.0 | YR | |||||||||||||||||||||||||
| 176 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 555.0 | FAS | OC | 16 | WK | SCORAD | Mean | 70.0 | 0-103 score | 13.4 | SD | LS Mean | -28.1 | 0-103 score | 0.92 | SE | Mean | 40.9 | 0-103 score | 21.8 | SD | 60.5 | 34.0 | YR | |||||||||||||||||||||
| 88 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 561.0 | FAS | OC | 16 | WK | SCORAD | Mean | 70.3 | 0-103 score | 13.0 | SD | Mean | 42.2 | 0-103 score | 20.7 | SD | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||
| 87 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 547.0 | FAS | OC | 16 | WK | SCORAD | Mean | 70.3 | 0-103 score | 13.0 | SD | LS Mean | -25.2 | 0-103 score | 0.94 | SE | Mean | 42.1 | 0-103 score | 20.7 | SD | 58.2 | 37.0 | YR | |||||||||||||||||||||
| 14 | 175 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 549.0 | FAS | OC | 14 | WK | SCORAD | Mean | 70.0 | 0-103 score | 13.4 | SD | LS Mean | -29.0 | 0-103 score | 0.87 | SE | Mean | 40.2 | 0-103 score | 20.8 | SD | 60.5 | 34.0 | YR | ||||||||||||||||||||
| 86 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 545.0 | FAS | OC | 14 | WK | SCORAD | Mean | 70.3 | 0-103 score | 13.0 | SD | LS Mean | -25.9 | 0-103 score | 0.91 | SE | Mean | 41.1 | 0-103 score | 19.7 | SD | 58.2 | 37.0 | YR | |||||||||||||||||||||
| 12 | 174 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 561.0 | FAS | OC | 12 | WK | SCORAD | Mean | 70.0 | 0-103 score | 13.4 | SD | LS Mean | -27.7 | 0-103 score | 0.83 | SE | Mean | 41.2 | 0-103 score | 19.9 | SD | 60.5 | 34.0 | YR | ||||||||||||||||||||
| 85 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 560.0 | FAS | OC | 12 | WK | SCORAD | Mean | 70.3 | 0-103 score | 13.0 | SD | LS Mean | -25.3 | 0-103 score | 0.84 | SE | Mean | 42.1 | 0-103 score | 19.7 | SD | 58.2 | 37.0 | YR | |||||||||||||||||||||
| 10 | 173 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 560.0 | FAS | OC | 10 | WK | SCORAD | Mean | 70.0 | 0-103 score | 13.4 | SD | LS Mean | -27.1 | 0-103 score | 0.78 | SE | Mean | 41.5 | 0-103 score | 19.2 | SD | 60.5 | 34.0 | YR | ||||||||||||||||||||
| 84 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 564.0 | FAS | OC | 10 | WK | SCORAD | Mean | 70.3 | 0-103 score | 13.0 | SD | LS Mean | -24.9 | 0-103 score | 0.83 | SE | Mean | 42.7 | 0-103 score | 19.4 | SD | 58.2 | 37.0 | YR | |||||||||||||||||||||
| easi90 | 8 | 135 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 61.0 | FAS | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 90 | 10.345 | percent | 60.5 | 34.0 | YR | ||||||||||||||||||||||||||||||
| 46 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 52.0 | FAS | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 90 | 8.549 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 6 | 134 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 53.0 | FAS | Cochran Mantel Haenszel Test | NRI | 6 | WK | EASI 90 | 8.98 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 45 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 38.0 | FAS | Cochran Mantel Haenszel Test | NRI | 6 | WK | EASI 90 | 6.322 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 4 | 133 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 27.0 | FAS | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 90 | 4.598 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 44 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 22.0 | FAS | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 90 | 3.592 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 132 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 8.0 | FAS | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 90 | 1.293 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 43 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 3.0 | FAS | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 90 | 0.503 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 16 | 139 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 109.0 | FAS | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 90 | 18.391 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 14 | 138 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 101.0 | FAS | Cochran Mantel Haenszel Test | NRI | 14 | WK | EASI 90 | 17.026 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 49 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 71.0 | FAS | Cochran Mantel Haenszel Test | NRI | 14 | WK | EASI 90 | 11.782 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 137 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 86.0 | FAS | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 90 | 14.583 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 48 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 68.0 | FAS | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 90 | 11.207 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 10 | 136 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 68.0 | FAS | Cochran Mantel Haenszel Test | NRI | 10 | WK | EASI 90 | 11.422 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 47 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 69.0 | FAS | Cochran Mantel Haenszel Test | NRI | 10 | WK | EASI 90 | 11.494 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| easi75 | 8 | 100 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 155.0 | FAS | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 75 | 26.097 | percent | 60.5 | 34.0 | YR | ||||||||||||||||||||||||||||||
| 11 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 135.0 | FAS | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 75 | 22.336 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 6 | 99 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 116.0 | FAS | Cochran Mantel Haenszel Test | NRI | 6 | WK | EASI 75 | 19.487 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 10 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 115.0 | FAS | Cochran Mantel Haenszel Test | NRI | 6 | WK | EASI 75 | 19.145 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 4 | 98 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 81.0 | FAS | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 75 | 13.675 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 9 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 73.0 | FAS | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 75 | 12.08 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 14 | 103 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 193.0 | FAS | Cochran Mantel Haenszel Test | NRI | 14 | WK | EASI 75 | 32.593 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 14 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 160.0 | FAS | Cochran Mantel Haenszel Test | NRI | 14 | WK | EASI 75 | 26.553 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 102 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 184.0 | FAS | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 75 | 31.111 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 10 | 101 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 158.0 | FAS | Cochran Mantel Haenszel Test | NRI | 10 | WK | EASI 75 | 26.667 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 12 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 162.0 | FAS | Cochran Mantel Haenszel Test | NRI | 10 | WK | EASI 75 | 26.895 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| easi50 | 8 | 119 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 269.0 | FAS | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 50 | 45.303 | percent | 60.5 | 34.0 | YR | ||||||||||||||||||||||||||||||
| 30 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 245.0 | FAS | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 50 | 40.634 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 6 | 118 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 253.0 | FAS | Cochran Mantel Haenszel Test | NRI | 6 | WK | EASI 50 | 42.709 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 29 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 240.0 | FAS | Cochran Mantel Haenszel Test | NRI | 6 | WK | EASI 50 | 39.77 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 4 | 117 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 188.0 | FAS | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 50 | 31.643 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 28 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 199.0 | FAS | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 50 | 33.026 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 116 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 104.0 | FAS | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 50 | 17.464 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 27 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 103.0 | FAS | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 50 | 17.118 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 14 | 122 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 305.0 | FAS | Cochran Mantel Haenszel Test | NRI | 14 | WK | EASI 50 | 51.355 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 33 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 265.0 | FAS | Cochran Mantel Haenszel Test | NRI | 14 | WK | EASI 50 | 43.919 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 121 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 307.0 | FAS | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 50 | 51.7 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 32 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 266.0 | FAS | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 50 | 44.092 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 10 | 120 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 593 | 593.0 | 301.0 | FAS | Cochran Mantel Haenszel Test | NRI | 10 | WK | EASI 50 | 50.836 | percent | 60.5 | 34.0 | YR | |||||||||||||||||||||||||||||||
| 31 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 603 | 603.0 | 262.0 | FAS | Cochran Mantel Haenszel Test | NRI | 10 | WK | EASI 50 | 43.401 | percent | 58.2 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| easi | 8 | 153 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 570.0 | FAS | OC | 8 | WK | EASI | Mean | 32.1 | 0-72 score | 14.3 | SD | Mean | -16.0 | 0-72 score | 12.4 | SD | LS Mean | -50.122 | 1.463 | SE | 60.5 | 34.0 | YR | ||||||||||||||||||||
| 64 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 570.0 | FAS | OC | 8 | WK | EASI | Mean | 32.2 | 0-72 score | 13.7 | SD | Mean | -16.6 | 0-72 score | 13.1 | SD | LS Mean | -47.561 | 1.555 | SE | 58.2 | 37.0 | YR | ||||||||||||||||||||||
| 6 | 152 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 577.0 | FAS | OC | 6 | WK | EASI | Mean | 32.1 | 0-72 score | 14.3 | SD | Mean | -14.3 | 0-72 score | 12.2 | SD | LS Mean | -45.0 | 1.463 | SE | 60.5 | 34.0 | YR | |||||||||||||||||||||
| 63 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 579.0 | FAS | OC | 6 | WK | EASI | Mean | 32.2 | 0-72 score | 13.7 | SD | Mean | -15.1 | 0-72 score | 12.2 | SD | LS Mean | -44.268 | 1.463 | SE | 58.2 | 37.0 | YR | ||||||||||||||||||||||
| 4 | 151 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 574.0 | FAS | OC | 4 | WK | EASI | Mean | 32.1 | 0-72 score | 14.3 | SD | Mean | -11.8 | 0-72 score | 10.9 | SD | LS Mean | -36.585 | 1.463 | SE | 60.5 | 34.0 | YR | |||||||||||||||||||||
| 62 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 588.0 | FAS | OC | 4 | WK | EASI | Mean | 32.2 | 0-72 score | 13.7 | SD | Mean | -12.4 | 0-72 score | 11.8 | SD | LS Mean | -35.671 | 1.372 | SE | 58.2 | 37.0 | YR | ||||||||||||||||||||||
| 2 | 150 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 587.0 | FAS | OC | 2 | WK | EASI | Mean | 32.1 | 0-72 score | 14.3 | SD | Mean | -7.2 | 0-72 score | 9.6 | SD | LS Mean | -21.951 | 1.098 | SE | 60.5 | 34.0 | YR | |||||||||||||||||||||
| 61 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 593.0 | FAS | OC | 2 | WK | EASI | Mean | 32.2 | 0-72 score | 13.7 | SD | Mean | -7.7 | 0-72 score | 10.3 | SD | LS Mean | -21.951 | 1.281 | SE | 58.2 | 37.0 | YR | ||||||||||||||||||||||
| 16 | 157 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 555.0 | FAS | OC | 16 | WK | EASI | Mean | 32.1 | 0-72 score | 14.3 | SD | Mean | -17.8 | 0-72 score | 13.0 | SD | LS Mean | -57.073 | 1.829 | SE | 60.5 | 34.0 | YR | |||||||||||||||||||||
| 68 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 547.0 | FAS | OC | 16 | WK | EASI | Mean | 32.2 | 0-72 score | 13.7 | SD | Mean | -17.7 | 0-72 score | 13.3 | SD | LS Mean | -51.402 | 2.012 | SE | 58.2 | 37.0 | YR | ||||||||||||||||||||||
| 14 | 156 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 549.0 | FAS | OC | 14 | WK | EASI | Mean | 32.1 | 0-72 score | 14.3 | SD | Mean | -18.4 | 0-72 score | 13.1 | SD | LS Mean | -57.805 | 1.646 | SE | 60.5 | 34.0 | YR | |||||||||||||||||||||
| 67 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 546.0 | FAS | OC | 14 | WK | EASI | Mean | 32.2 | 0-72 score | 13.7 | SD | Mean | -18.5 | 0-72 score | 13.5 | SD | LS Mean | -52.5 | 1.646 | SE | 58.2 | 37.0 | YR | ||||||||||||||||||||||
| 12 | 155 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 561.0 | FAS | OC | 12 | WK | EASI | Mean | 32.1 | 0-72 score | 14.3 | SD | Mean | -18.0 | 0-72 score | 12.5 | SD | LS Mean | -55.976 | 1.646 | SE | 60.5 | 34.0 | YR | |||||||||||||||||||||
| 66 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 561.0 | FAS | OC | 12 | WK | EASI | Mean | 32.2 | 0-72 score | 13.7 | SD | Mean | -17.8 | 0-72 score | 13.3 | SD | LS Mean | -52.134 | 1.646 | SE | 58.2 | 37.0 | YR | ||||||||||||||||||||||
| 10 | 154 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 591 | 560.0 | FAS | OC | 10 | WK | EASI | Mean | 32.1 | 0-72 score | 14.3 | SD | Mean | -17.2 | 0-72 score | 12.1 | SD | LS Mean | -54.146 | 1.646 | SE | 60.5 | 34.0 | YR | |||||||||||||||||||||
| 65 | control | Double-Blind | True | tralokinumab | Interleukin 13 inhibitors | 300.0 | MG | SC | Q2W | 601 | 564.0 | FAS | OC | 10 | WK | EASI | Mean | 32.2 | 0-72 score | 13.7 | SD | Mean | -17.4 | 0-72 score | 13.0 | SD | LS Mean | -49.939 | 1.646 | SE | 58.2 | 37.0 | YR | ||||||||||||||||||||||
| placebo | 0.0 | q2w | scorad | 8 | 162 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 185.0 | FAS | OC | 8 | WK | SCORAD | Mean | 70.5 | 0-103 score | 12.2 | SD | LS Mean | -10.8 | 0-103 score | 1.41 | SE | Mean | 55.9 | 0-103 score | 19.8 | SD | 56.7 | 30.0 | YR | ||||||||||||||||
| 73 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 185.0 | FAS | OC | 8 | WK | SCORAD | Mean | 71.7 | 0-103 score | 12.5 | SD | LS Mean | -12.9 | 0-103 score | 1.52 | SE | Mean | 53.2 | 0-103 score | 19.2 | SD | 61.8 | 37.0 | YR | |||||||||||||||||||||
| 6 | 161 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 187.0 | FAS | OC | 6 | WK | SCORAD | Mean | 70.5 | 0-103 score | 12.2 | SD | LS Mean | -9.0 | 0-103 score | 1.31 | SE | Mean | 58.1 | 0-103 score | 17.9 | SD | 56.7 | 30.0 | YR | ||||||||||||||||||||
| 72 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 186.0 | FAS | OC | 6 | WK | SCORAD | Mean | 71.7 | 0-103 score | 12.5 | SD | LS Mean | -11.4 | 0-103 score | 1.36 | SE | Mean | 55.0 | 0-103 score | 17.8 | SD | 61.8 | 37.0 | YR | |||||||||||||||||||||
| 4 | 160 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 189.0 | FAS | OC | 4 | WK | SCORAD | Mean | 70.5 | 0-103 score | 12.2 | SD | LS Mean | -6.9 | 0-103 score | 1.11 | SE | Mean | 60.6 | 0-103 score | 16.9 | SD | 56.7 | 30.0 | YR | ||||||||||||||||||||
| 71 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 188.0 | FAS | OC | 4 | WK | SCORAD | Mean | 71.7 | 0-103 score | 12.5 | SD | LS Mean | -7.5 | 0-103 score | 1.19 | SE | Mean | 59.9 | 0-103 score | 17.9 | SD | 61.8 | 37.0 | YR | |||||||||||||||||||||
| 2 | 159 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 194.0 | FAS | OC | 2 | WK | SCORAD | Mean | 70.5 | 0-103 score | 12.2 | SD | LS Mean | -3.9 | 0-103 score | 0.84 | SE | Mean | 64.8 | 0-103 score | 14.7 | SD | 56.7 | 30.0 | YR | ||||||||||||||||||||
| 70 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 193.0 | FAS | OC | 2 | WK | SCORAD | Mean | 71.7 | 0-103 score | 12.5 | SD | LS Mean | -5.0 | 0-103 score | 0.92 | SE | Mean | 63.8 | 0-103 score | 17.7 | SD | 61.8 | 37.0 | YR | |||||||||||||||||||||
| 16 | 167 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 181.0 | FAS | OC | 16 | WK | SCORAD | Mean | 70.5 | 0-103 score | 12.2 | SD | Mean | 53.3 | 0-103 score | 23.1 | SD | 56.7 | 30.0 | YR | |||||||||||||||||||||||||
| 166 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 175.0 | FAS | OC | 16 | WK | SCORAD | Mean | 70.5 | 0-103 score | 12.2 | SD | LS Mean | -14.0 | 0-103 score | 1.79 | SE | Mean | 53.8 | 0-103 score | 23.2 | SD | 56.7 | 30.0 | YR | |||||||||||||||||||||
| 78 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 182.0 | FAS | OC | 16 | WK | SCORAD | Mean | 71.7 | 0-103 score | 12.5 | SD | Mean | 51.6 | 0-103 score | 18.6 | SD | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||
| 77 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 178.0 | FAS | OC | 16 | WK | SCORAD | Mean | 71.7 | 0-103 score | 12.5 | SD | LS Mean | -14.7 | 0-103 score | 1.8 | SE | Mean | 51.4 | 0-103 score | 18.6 | SD | 61.8 | 37.0 | YR | |||||||||||||||||||||
| 14 | 165 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 177.0 | FAS | OC | 14 | WK | SCORAD | Mean | 70.5 | 0-103 score | 12.2 | SD | LS Mean | -13.5 | 0-103 score | 1.67 | SE | Mean | 52.6 | 0-103 score | 21.9 | SD | 56.7 | 30.0 | YR | ||||||||||||||||||||
| 76 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 176.0 | FAS | OC | 14 | WK | SCORAD | Mean | 71.7 | 0-103 score | 12.5 | SD | LS Mean | -15.2 | 0-103 score | 1.75 | SE | Mean | 50.6 | 0-103 score | 19.1 | SD | 61.8 | 37.0 | YR | |||||||||||||||||||||
| 12 | 164 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 176.0 | FAS | OC | 12 | WK | SCORAD | Mean | 70.5 | 0-103 score | 12.2 | SD | LS Mean | -12.2 | 0-103 score | 1.59 | SE | Mean | 52.2 | 0-103 score | 20.4 | SD | 56.7 | 30.0 | YR | ||||||||||||||||||||
| 75 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 177.0 | FAS | OC | 12 | WK | SCORAD | Mean | 71.7 | 0-103 score | 12.5 | SD | LS Mean | -16.2 | 0-103 score | 1.62 | SE | Mean | 49.2 | 0-103 score | 17.9 | SD | 61.8 | 37.0 | YR | |||||||||||||||||||||
| 10 | 163 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 182.0 | FAS | OC | 10 | WK | SCORAD | Mean | 70.5 | 0-103 score | 12.2 | SD | LS Mean | -12.3 | 0-103 score | 1.47 | SE | Mean | 53.9 | 0-103 score | 21.2 | SD | 56.7 | 30.0 | YR | ||||||||||||||||||||
| 74 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 180.0 | FAS | OC | 10 | WK | SCORAD | Mean | 71.7 | 0-103 score | 12.5 | SD | LS Mean | -15.9 | 0-103 score | 1.58 | SE | Mean | 50.0 | 0-103 score | 18.9 | SD | 61.8 | 37.0 | YR | |||||||||||||||||||||
| 0 | 158 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | FAS | OC | 0 | WK | SCORAD | Mean | 70.5 | 0-103 score | 12.2 | SD | LS Mean | 0.0 | 0-103 score | Mean | 70.5 | 0-103 score | 12.2 | SD | 56.7 | 30.0 | YR | ||||||||||||||||||||||
| 69 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 197.0 | FAS | OC | 0 | WK | SCORAD | Mean | 71.7 | 0-103 score | 12.5 | SD | LS Mean | 0.0 | 0-103 score | Mean | 71.7 | 0-103 score | 12.5 | SD | 61.8 | 37.0 | YR | |||||||||||||||||||||||
| easi90 | 8 | 127 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 4.0 | FAS | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 90 | 2.011 | percent | 56.7 | 30.0 | YR | ||||||||||||||||||||||||||||||
| 38 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 5.0 | FAS | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 90 | 2.514 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 6 | 126 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 1.0 | FAS | Cochran Mantel Haenszel Test | NRI | 6 | WK | EASI 90 | 0.575 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 37 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 3.0 | FAS | Cochran Mantel Haenszel Test | NRI | 6 | WK | EASI 90 | 1.437 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 4 | 125 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 0.0 | FAS | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 90 | 0.0 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 36 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 4.0 | FAS | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 90 | 1.94 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 124 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 0.0 | FAS | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 90 | 0.0 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 35 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 4.0 | FAS | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 90 | 1.94 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 16 | 131 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 11.0 | FAS | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 90 | 5.46 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 14 | 130 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 8.0 | FAS | Cochran Mantel Haenszel Test | NRI | 14 | WK | EASI 90 | 3.879 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 41 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 9.0 | FAS | Cochran Mantel Haenszel Test | NRI | 14 | WK | EASI 90 | 4.526 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 129 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 6.0 | FAS | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 90 | 2.945 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 40 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 7.0 | FAS | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 90 | 3.52 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 10 | 128 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 6.0 | FAS | Cochran Mantel Haenszel Test | NRI | 10 | WK | EASI 90 | 2.945 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 39 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 6.0 | FAS | Cochran Mantel Haenszel Test | NRI | 10 | WK | EASI 90 | 3.017 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| easi75 | 8 | 92 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 14.0 | FAS | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 75 | 6.838 | percent | 56.7 | 30.0 | YR | ||||||||||||||||||||||||||||||
| 3 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 25.0 | FAS | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 75 | 12.65 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 6 | 91 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 9.0 | FAS | Cochran Mantel Haenszel Test | NRI | 6 | WK | EASI 75 | 4.444 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 2 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 20.0 | FAS | Cochran Mantel Haenszel Test | NRI | 6 | WK | EASI 75 | 10.143 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 52 | 107 | control | Open-Label | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 46 | 42.0 | 9.0 | FAS | Cochran Mantel Haenszel Test | NRI | 52 | WK | EASI 75 | 21.0 | percent | ||||||||||||||||||||||||||||||||||
| 18 | control | Open-Label | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 36 | 30.0 | 10.0 | FAS | Cochran Mantel Haenszel Test | NRI | 52 | WK | EASI 75 | 33.0 | percent | |||||||||||||||||||||||||||||||||||
| 4 | 90 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 6.0 | FAS | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 75 | 2.849 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 1 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 15.0 | FAS | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 75 | 7.407 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 89 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 2.0 | FAS | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 75 | 0.912 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 0 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 9.0 | FAS | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 75 | 4.558 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 14 | 95 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 24.0 | FAS | Cochran Mantel Haenszel Test | NRI | 14 | WK | EASI 75 | 11.966 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 6 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 23.0 | FAS | Cochran Mantel Haenszel Test | NRI | 14 | WK | EASI 75 | 11.738 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 94 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 17.0 | FAS | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 75 | 8.433 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 5 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 29.0 | FAS | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 75 | 14.701 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 10 | 93 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 18.0 | FAS | Cochran Mantel Haenszel Test | NRI | 10 | WK | EASI 75 | 8.889 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 4 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 28.0 | FAS | Cochran Mantel Haenszel Test | NRI | 10 | WK | EASI 75 | 14.131 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| easi50 | 8 | 111 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 34.0 | FAS | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 50 | 16.772 | percent | 56.7 | 30.0 | YR | ||||||||||||||||||||||||||||||
| 22 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 42.0 | FAS | Cochran Mantel Haenszel Test | NRI | 8 | WK | EASI 50 | 21.268 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 6 | 110 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 34.0 | FAS | Cochran Mantel Haenszel Test | NRI | 6 | WK | EASI 50 | 16.772 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 21 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 42.0 | FAS | Cochran Mantel Haenszel Test | NRI | 6 | WK | EASI 50 | 21.095 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 4 | 109 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 20.0 | FAS | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 50 | 10.029 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 20 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 32.0 | FAS | Cochran Mantel Haenszel Test | NRI | 4 | WK | EASI 50 | 16.081 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 2 | 108 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 11.0 | FAS | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 50 | 5.706 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 19 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 19.0 | FAS | Cochran Mantel Haenszel Test | NRI | 2 | WK | EASI 50 | 9.51 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 16 | 115 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 40.0 | FAS | Cochran Mantel Haenszel Test | NRI | 16 | WK | EASI 50 | 20.058 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 14 | 114 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 39.0 | FAS | Cochran Mantel Haenszel Test | NRI | 14 | WK | EASI 50 | 19.366 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 25 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 46.0 | FAS | Cochran Mantel Haenszel Test | NRI | 14 | WK | EASI 50 | 22.997 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 12 | 113 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 40.0 | FAS | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 50 | 19.712 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 24 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 49.0 | FAS | Cochran Mantel Haenszel Test | NRI | 12 | WK | EASI 50 | 24.726 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| 10 | 112 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | 37.0 | FAS | Cochran Mantel Haenszel Test | NRI | 10 | WK | EASI 50 | 18.501 | percent | 56.7 | 30.0 | YR | |||||||||||||||||||||||||||||||
| 23 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 199 | 199.0 | 53.0 | FAS | Cochran Mantel Haenszel Test | NRI | 10 | WK | EASI 50 | 26.801 | percent | 61.8 | 37.0 | YR | ||||||||||||||||||||||||||||||||
| easi | 8 | 144 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 185.0 | FAS | OC | 8 | WK | EASI | Mean | 32.6 | 0-72 score | 13.9 | SD | Mean | -8.5 | 0-72 score | 12.8 | SD | LS Mean | -19.39 | 2.927 | SE | 56.7 | 30.0 | YR | ||||||||||||||||||||
| 55 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 185.0 | FAS | OC | 8 | WK | EASI | Mean | 32.9 | 0-72 score | 13.9 | SD | Mean | -11.6 | 0-72 score | 13.6 | SD | LS Mean | -27.988 | 2.927 | SE | 61.8 | 37.0 | YR | ||||||||||||||||||||||
| 6 | 143 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 187.0 | FAS | OC | 6 | WK | EASI | Mean | 32.6 | 0-72 score | 13.9 | SD | Mean | -7.2 | 0-72 score | 12.7 | SD | LS Mean | -16.098 | 2.744 | SE | 56.7 | 30.0 | YR | |||||||||||||||||||||
| 54 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 186.0 | FAS | OC | 6 | WK | EASI | Mean | 32.9 | 0-72 score | 13.9 | SD | Mean | -10.1 | 0-72 score | 13.5 | SD | LS Mean | -24.329 | 2.652 | SE | 61.8 | 37.0 | YR | ||||||||||||||||||||||
| 4 | 142 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 189.0 | FAS | OC | 4 | WK | EASI | Mean | 32.6 | 0-72 score | 13.9 | SD | Mean | -5.5 | 0-72 score | 10.9 | SD | LS Mean | -10.61 | 2.561 | SE | 56.7 | 30.0 | YR | |||||||||||||||||||||
| 53 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 188.0 | FAS | OC | 4 | WK | EASI | Mean | 32.9 | 0-72 score | 13.9 | SD | Mean | -7.8 | 0-72 score | 13.0 | SD | LS Mean | -18.11 | 2.561 | SE | 61.8 | 37.0 | YR | ||||||||||||||||||||||
| 2 | 141 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 194.0 | FAS | OC | 2 | WK | EASI | Mean | 32.6 | 0-72 score | 13.9 | SD | Mean | -3.4 | 0-72 score | 9.3 | SD | LS Mean | -7.317 | 2.012 | SE | 56.7 | 30.0 | YR | |||||||||||||||||||||
| 52 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 194.0 | FAS | OC | 2 | WK | EASI | Mean | 32.9 | 0-72 score | 13.9 | SD | Mean | -5.0 | 0-72 score | 12.2 | SD | LS Mean | -9.878 | 2.104 | SE | 61.8 | 37.0 | YR | ||||||||||||||||||||||
| 16 | 148 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 176.0 | FAS | OC | 16 | WK | EASI | Mean | 32.6 | 0-72 score | 13.9 | SD | Mean | -9.5 | 0-72 score | 14.0 | SD | LS Mean | -22.317 | 3.476 | SE | 56.7 | 30.0 | YR | |||||||||||||||||||||
| 59 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 178.0 | FAS | OC | 16 | WK | EASI | Mean | 32.9 | 0-72 score | 13.9 | SD | Mean | -12.3 | 0-72 score | 13.9 | SD | LS Mean | -28.537 | 3.659 | SE | 61.8 | 37.0 | YR | ||||||||||||||||||||||
| 14 | 147 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 177.0 | FAS | OC | 14 | WK | EASI | Mean | 32.6 | 0-72 score | 13.9 | SD | Mean | -10.1 | 0-72 score | 14.2 | SD | LS Mean | -21.585 | 3.293 | SE | 56.7 | 30.0 | YR | |||||||||||||||||||||
| 58 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 176.0 | FAS | OC | 14 | WK | EASI | Mean | 32.9 | 0-72 score | 13.9 | SD | Mean | -13.0 | 0-72 score | 14.0 | SD | LS Mean | -32.927 | 3.293 | SE | 61.8 | 37.0 | YR | ||||||||||||||||||||||
| 12 | 146 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 176.0 | FAS | OC | 12 | WK | EASI | Mean | 32.6 | 0-72 score | 13.9 | SD | Mean | -11.1 | 0-72 score | 13.6 | SD | LS Mean | -21.585 | 3.11 | SE | 56.7 | 30.0 | YR | |||||||||||||||||||||
| 57 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 177.0 | FAS | OC | 12 | WK | EASI | Mean | 32.9 | 0-72 score | 13.9 | SD | Mean | -13.5 | 0-72 score | 13.8 | SD | LS Mean | -34.207 | 3.293 | SE | 61.8 | 37.0 | YR | ||||||||||||||||||||||
| 10 | 145 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 182.0 | FAS | OC | 10 | WK | EASI | Mean | 32.6 | 0-72 score | 13.9 | SD | Mean | -9.6 | 0-72 score | 13.2 | SD | LS Mean | -21.585 | 3.11 | SE | 56.7 | 30.0 | YR | |||||||||||||||||||||
| 56 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 181.0 | FAS | OC | 10 | WK | EASI | Mean | 32.9 | 0-72 score | 13.9 | SD | Mean | -12.5 | 0-72 score | 13.7 | SD | LS Mean | -32.561 | 3.201 | SE | 61.8 | 37.0 | YR | ||||||||||||||||||||||
| 0 | 140 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 201 | 201.0 | FAS | OC | 0 | WK | EASI | Mean | 32.6 | 0-72 score | 13.9 | SD | Mean | 0.0 | 0-72 score | LS Mean | 0.0 | 56.7 | 30.0 | YR | |||||||||||||||||||||||||
| 51 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG | SC | Q2W | 197 | 197.0 | FAS | OC | 0 | WK | EASI | Mean | 32.9 | 0-72 score | 13.9 | SD | Mean | 0.0 | 0-72 score | LS Mean | 0.0 | 61.8 | 37.0 | YR |
1227_list_2009¶
Control rows matched by test output: 7 of 14
Literature data accuracy: 76.27%
Clinical data accuracy: 33.31%
Clinical data accuracy (drop unmatched): 66.61%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| dapagliflozin | 20mg | oncedaily | hba1c | 12 | 5 | c9t5 | test | Double-Blind | TRUE | Dapagliflozin | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | 20 mg | mg | Oral | Once Daily | 54 | 54 | ITT | ANCOVA | LOCF | 12 | WK | HbA1c | Mean | 7.9 | percent | 0.9 | SD | LS Mean | -0.90 | percent | 0.10 | SE | LS Mean | -2.6 | mmHg | 11.1 | SD | 56 | 53 | YR | ||||||||||||||
| 20.0 | qd | hba1c | 12.0 | 9 | c9t5 | control | Double-Blind | True | dapagliflozin | SGLT2 | 20.0 | MG/DAY | ORAL | QD | TAB | 59.0 | 59 | Treated | ANCOVA | LOCF | 12.0 | WK | HbA1c | Mean | 7.7 | percent | 0.9 | SD | LS Mean | -0.55 | percent | 0.09 | SE | -0.73 | -0.37 | LS Mean | 7.244 | percent | LS Mean | -7.057 | 54.0 | 55.0 | YR | ||||||||||||
| similarity | 100 | 100 | 100 | 20 | 44 | 50 | 100 | 17 | 0 | 33 | 50 | 100 | 40 | 100 | 100 | 67 | 100 | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 50 | 100 | 75 | 100 | 0 | 0 | 100 | 50 | 0 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 33 | 33 | 100 | |||||||
| 10mg | oncedaily | hba1c | 12 | 6 | c7t6 | test | Double-Blind | TRUE | Dapagliflozin | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | 10 mg | mg | Oral | Once Daily | 56 | 56 | ITT | ANCOVA | LOCF | 12 | WK | HbA1c | Mean | 7.8 | percent | 1.0 | SD | LS Mean | -0.90 | percent | 0.10 | SE | LS Mean | -0.90 | percent | 0.10 | SE | 45 | 53 | YR | |||||||||||||||
| 10.0 | qd | hba1c | 12.0 | 7 | c7t6 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10.0 | MG/DAY | ORAL | QD | TAB | 47.0 | 47 | Treated | ANCOVA | LOCF | 12.0 | WK | HbA1c | Mean | 8.0 | percent | 0.8 | SD | LS Mean | -0.85 | percent | 0.11 | SE | -1.071 | -0.629 | LS Mean | 6.944 | percent | LS Mean | -10.906 | 53.0 | 54.0 | YR | ||||||||||||
| similarity | 100 | 100 | 100 | 20 | 44 | 50 | 100 | 17 | 0 | 0 | 0 | 100 | 40 | 100 | 100 | 67 | 100 | 100 | 100 | 67 | 100 | 67 | 100 | 100 | 100 | 100 | 50 | 100 | 75 | 100 | 0 | 0 | 100 | 44 | 100 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 33 | 33 | 100 | |||||||
| 50 | oncedaily | hba1c | 12 | 2 | c5t2 | test | Double-Blind | TRUE | Dapagliflozin | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | 50 | mg | Oral | Once Daily | 57 | 57 | 38 | ITT | ANCOVA | LOCF | 12 | WK | HbA1c | Mean | 7.6 | percent | 0.8 | SD | LS Mean | -0.90 | percent | LS Mean | 48 | 54 | YR | ||||||||||||||||||||
| 5.0 | qd | hba1c | 12.0 | 5 | c5t2 | control | Double-Blind | True | dapagliflozin | SGLT2 | 5.0 | MG/DAY | ORAL | QD | TAB | 58.0 | 58 | Treated | ANCOVA | LOCF | 12.0 | WK | HbA1c | Mean | 8.0 | percent | 0.9 | SD | LS Mean | -0.72 | percent | 0.09 | SE | -0.9 | -0.54 | LS Mean | 7.074 | percent | LS Mean | -9.238 | 48.0 | 55.0 | YR | ||||||||||||
| similarity | 100 | 100 | 100 | 20 | 40 | 50 | 100 | 17 | 0 | 33 | 50 | 0 | 40 | 100 | 100 | 67 | 100 | 100 | 100 | 33 | 100 | 67 | 100 | 100 | 100 | 100 | 50 | 100 | 0 | 0 | 0 | 0 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 67 | 33 | 100 | |||||||
| 2.5 | oncedaily | hba1c | 12 | 1 | c3t1 | test | Double-Blind | TRUE | Dapagliflozin | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | 2.5 | mg | Oral | Once Daily | 47 | 47 | ITT | ANCOVA | LOCF | 12 | WK | HbA1c | Mean | 8.0 | percent | 0.8 | SD | LS Mean | -0.85 | percent | 0.11 | LS Mean | -0.85 | percent | 0.11 | 53 | 54 | YR | |||||||||||||||||
| qd | hba1c | 12.0 | 3 | c3t1 | control | Double-Blind | True | dapagliflozin | SGLT2 | 2.5 | MG/DAY | ORAL | QD | TAB | 59.0 | 59 | Treated | ANCOVA | LOCF | 12.0 | WK | HbA1c | Mean | 7.6 | percent | 0.7 | SD | LS Mean | -0.71 | percent | 0.09 | SE | -0.89 | -0.53 | LS Mean | 7.084 | percent | LS Mean | -9.11 | 49.0 | 55.0 | YR | |||||||||||||
| similarity | 100 | 100 | 100 | 20 | 100 | 50 | 100 | 17 | 0 | 0 | 0 | 100 | 40 | 100 | 100 | 67 | 100 | 100 | 100 | 33 | 100 | 67 | 100 | 100 | 100 | 100 | 50 | 100 | 50 | 0 | 0 | 0 | 100 | 44 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 33 | 100 | |||||||
| placebo | oncedaily | hba1c | 12 | 3 | c1t3 | test | Double-Blind | TRUE | Placebo | Once-daily | 59 | 59 | ITT | ANCOVA | LOCF | 12 | WK | HbA1c | Mean | 7.6 | percent | 0.7 | SD | Adjusted Mean | -0.18 | percent | 0.10 | SE | Adjusted Mean | -0.18 | percent | 0.10 | SE | 49 | 55 | YR | |||||||||||||||||||
| 0.0 | qd | hba1c | 12.0 | 1 | c1t3 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | TAB | 54.0 | 54 | Treated | ANCOVA | LOCF | 12.0 | WK | HbA1c | Mean | 7.9 | percent | 0.9 | SD | LS Mean | -0.18 | percent | 0.1 | SE | -0.38 | 0.02 | LS Mean | 7.614 | percent | LS Mean | -2.31 | 56.0 | 53.0 | YR | ||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 17 | 0 | 33 | 50 | 100 | 40 | 100 | 100 | 67 | 100 | 100 | 100 | 33 | 100 | 67 | 100 | 100 | 100 | 60 | 100 | 100 | 86 | 100 | 0 | 0 | 60 | 22 | 100 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 33 | 100 | |||||||
| metformin | 750 | forcetitratedatweek2to1,500mg | hba1c | 12 | 4 | c13t4 | test | Double-Blind | TRUE | Metformin | Biguanide | 750 | mg | Oral | Force-titrated at week 2 to 1,500 mg | XR | 58 | 58 | ITT | ANCOVA | LOCF | 12 | WK | HbA1c | Mean | 8.0 | percent | 0.9 | SD | LS Mean | -0.73 | percent | LS Mean | -0.73 | percent | 48 | 55 | YR | |||||||||||||||||
| 1500.0 | qd | hba1c | 12.0 | 13 | c13t4 | control | Double-Blind | True | metformin | Biguanides | 1500.0 | MG/DAY | ORAL | QD | TAB-XR | 56.0 | 56 | Treated | ANCOVA | LOCF | 12.0 | WK | HbA1c | Mean | 7.6 | percent | 0.8 | SD | LS Mean | -0.73 | percent | 0.1 | SE | -0.93 | -0.53 | LS Mean | 7.064 | percent | LS Mean | -9.367 | 48.0 | 54.0 | YR | ||||||||||||
| similarity | 100 | 100 | 100 | 95 | 44 | 50 | 100 | 5 | 50 | 33 | 50 | 100 | 40 | 100 | 100 | 67 | 100 | 100 | 100 | 33 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 67 | 33 | 100 | |||||||
| dapagliflozin | 5mg | oncedaily | hba1c | 12 | 0 | c11t0 | test | Double-Blind | TRUE | Dapagliflozin | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | 5 mg | mg | Oral | Once Daily | 59 | 59 | ITT | ANCOVA | LOCF | 12 | WK | HbA1c | Mean | 7.7 | percent | 0.9 | SD | LS Mean | -0.55 | percent | 0.09 | LS Mean | -0.55 | percent | 0.09 | 54 | 55 | YR | ||||||||||||||||
| 50.0 | qd | hba1c | 12.0 | 11 | c11t0 | control | Double-Blind | True | dapagliflozin | SGLT2 | 50.0 | MG/DAY | ORAL | QD | TAB | 56.0 | 56 | Treated | ANCOVA | LOCF | 12.0 | WK | HbA1c | Mean | 7.8 | percent | 1.0 | SD | LS Mean | -0.9 | percent | 0.1 | SE | -1.1 | -0.7 | LS Mean | 6.894 | percent | LS Mean | -11.548 | 45.0 | 53.0 | YR | ||||||||||||
| similarity | 100 | 100 | 100 | 20 | 25 | 50 | 100 | 17 | 0 | 33 | 50 | 100 | 40 | 100 | 100 | 67 | 100 | 100 | 100 | 67 | 100 | 67 | 100 | 100 | 100 | 100 | 57 | 100 | 57 | 0 | 0 | 0 | 100 | 22 | 100 | 0 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 33 | 33 | 100 | |||||||
| placebo | 0.0 | qd | hba1c | 0.0 | 0 | control | Double-Blind | True | placebo | Placebo | 0.0 | MG/DAY | ORAL | QD | TAB | 54.0 | 54 | Treated | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 7.9 | percent | 0.9 | SD | LS Mean | 0.0 | percent | Mean | 7.9 | percent | 0.9 | SD | LS Mean | 0.0 | 56.0 | 53.0 | YR | ||||||||||||||
| metformin | 750.0 | qd | hba1c | 0.0 | 12 | control | Double-Blind | True | metformin | Biguanides | 750.0 | MG/DAY | ORAL | QD | TAB-XR | 56.0 | 56 | Treated | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 7.6 | percent | 0.8 | SD | LS Mean | 0.0 | percent | Mean | 7.6 | percent | 0.8 | SD | LS Mean | 0.0 | 48.0 | 54.0 | YR | ||||||||||||||
| dapagliflozin | 50.0 | qd | hba1c | 0.0 | 10 | control | Double-Blind | True | dapagliflozin | SGLT2 | 50.0 | MG/DAY | ORAL | QD | TAB | 56.0 | 56 | Treated | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 7.8 | percent | 1.0 | SD | LS Mean | 0.0 | percent | Mean | 7.8 | percent | 1.0 | SD | LS Mean | 0.0 | 45.0 | 53.0 | YR | ||||||||||||||
| 5.0 | qd | hba1c | 0.0 | 4 | control | Double-Blind | True | dapagliflozin | SGLT2 | 5.0 | MG/DAY | ORAL | QD | TAB | 58.0 | 58 | Treated | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 8.0 | percent | 0.9 | SD | LS Mean | 0.0 | percent | Mean | 8.0 | percent | 0.9 | SD | LS Mean | 0.0 | 48.0 | 55.0 | YR | |||||||||||||||
| 20.0 | qd | hba1c | 0.0 | 8 | control | Double-Blind | True | dapagliflozin | SGLT2 | 20.0 | MG/DAY | ORAL | QD | TAB | 59.0 | 59 | Treated | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 7.7 | percent | 0.9 | SD | LS Mean | 0.0 | percent | Mean | 7.7 | percent | 0.9 | SD | LS Mean | 0.0 | 54.0 | 55.0 | YR | |||||||||||||||
| 2.5 | qd | hba1c | 0.0 | 2 | control | Double-Blind | True | dapagliflozin | SGLT2 | 2.5 | MG/DAY | ORAL | QD | TAB | 59.0 | 59 | Treated | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 7.6 | percent | 0.7 | SD | LS Mean | 0.0 | percent | Mean | 7.6 | percent | 0.7 | SD | LS Mean | 0.0 | 49.0 | 55.0 | YR | |||||||||||||||
| 10.0 | qd | hba1c | 0.0 | 6 | control | Double-Blind | True | dapagliflozin | SGLT2 | 10.0 | MG/DAY | ORAL | QD | TAB | 47.0 | 47 | Treated | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 8.0 | percent | 0.8 | SD | LS Mean | 0.0 | percent | Mean | 8.0 | percent | 0.8 | SD | LS Mean | 0.0 | 53.0 | 54.0 | YR |
341_wilding_2013¶
Control rows matched by test output: 10 of 18
Literature data accuracy: 77.53%
Clinical data accuracy: 34.40%
Clinical data accuracy (drop unmatched): 61.92%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| placebo;canagliflozin100mg;canagliflozin300mg | 100;300 | oncedaily | hba1c | 52 | 4 | c7t4 | test | Double-Blind | TRUE | Placebo;Canagliflozin 100 mg;Canagliflozin 300 mg | Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor | 100;300 | mg | Oral | Once Daily | 156;157;156 | 156 | mITT | ANCOVA | LOCF | 52 | WK | HbA1c | Mean | 8.1 | percent | 0.9 | SD | LS Mean | -0.13 | percent | LS Mean | -0.13 | percent | 48.7;48.4;55.8 | 56.8;57.4;56.1 | YR | ||||||||||||||||||
| canagliflozin | 100 | qam | hba1c | 0.0 | 7 | c7t4 | control | Double-Blind | True | canagliflozin | SGLT2 | 100 | MG/DAY | ORAL | QAM | CAP | 31 | mITT | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 9.6 | percent | 0.4 | SD | LS Mean | 0.0 | percent | Mean | 9.6 | percent | 0.4 | SD | LS Mean | 0.0 | |||||||||||||||||
| similarity | 100 | 100 | 42 | 19 | 60 | 50 | 100 | 15 | 0 | 0 | 40 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 33 | 100 | 67 | 100 | 100 | 100 | 100 | 57 | 100 | 100 | 100 | 100 | 100 | 73 | 29 | 100 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| placebo;canagliflozin100mg;canagliflozin300mg | 100;300 | oncedaily | hba1c | 52 | 3 | c4t3 | test | Double-Blind | TRUE | Placebo;Canagliflozin 100 mg;Canagliflozin 300 mg | Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor | 100;300 | mg | Oral | Once Daily | 156;157;156 | 150 | mITT | ANCOVA | LOCF | 52 | WK | HbA1c | Mean | 8.1 | percent | 0.9 | SD | LS Mean | -0.13 | percent | LS Mean | -0.13 | percent | 48.7;48.4;55.8 | 56.8;57.4;56.1 | YR | ||||||||||||||||||
| canagliflozin | 100 | qam | hba1c | 0.0 | 4 | c4t3 | control | Double-Blind | True | canagliflozin | SGLT2 | 100 | MG/DAY | ORAL | QAM | CAP | 51 | mITT | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 8.4 | percent | 0.3 | SD | LS Mean | 0.0 | percent | Mean | 8.4 | percent | 0.3 | SD | LS Mean | 0.0 | |||||||||||||||||
| similarity | 100 | 100 | 42 | 19 | 60 | 50 | 100 | 15 | 0 | 0 | 40 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 67 | 100 | 67 | 100 | 100 | 100 | 100 | 57 | 100 | 100 | 100 | 100 | 100 | 73 | 29 | 100 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| placebo;canagliflozin100mg;canagliflozin300mg | 100;300 | oncedaily | hba1c | 26 | 7 | c2t7 | test | Double-Blind | TRUE | Placebo;Canagliflozin 100 mg;Canagliflozin 300 mg | Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor | 100;300 | mg | Oral | Once Daily | 156;157;156 | 150 | mITT | ANCOVA | LOCF | 26 | WK | HbA1c | Mean | 8.1 | percent | 0.9 | SD | LS Mean | -0.13 | percent | LS Mean | -0.13 | percent | 48.7;48.4;55.8 | 56.8;57.4;56.1 | YR | ||||||||||||||||||
| canagliflozin | 300 | qam | hba1c | 0.0 | 2 | c2t7 | control | Double-Blind | True | canagliflozin | SGLT2 | 300 | MG/DAY | ORAL | QAM | CAP | 74 | mITT | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 7.4 | percent | 0.3 | SD | LS Mean | 0.0 | percent | Mean | 7.4 | percent | 0.3 | SD | LS Mean | 0.0 | |||||||||||||||||
| similarity | 100 | 100 | 42 | 19 | 60 | 50 | 100 | 15 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 33 | 100 | 67 | 100 | 100 | 100 | 100 | 57 | 100 | 100 | 100 | 100 | 100 | 73 | 29 | 100 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| placebo;canagliflozin100mg;canagliflozin300mg | 100;300 | oncedaily | hba1c | 52 | 2 | c1t2 | test | Double-Blind | TRUE | Placebo;Canagliflozin 100 mg;Canagliflozin 300 mg | Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor | 100;300 | mg | Oral | Once Daily | 156;157;156 | 150 | mITT | ANCOVA | LOCF | 52 | WK | HbA1c | Mean | 130.1 | mmHg | 13.7 | SD | LS Mean | 0.1 | mmHg | 1.0 | SE | LS Mean | 0.1 | mmHg | 1.0 | SE | 48.7;48.4;55.8 | 56.8;57.4;56.1 | YR | ||||||||||||||
| canagliflozin | 100 | qam | hba1c | 0.0 | 1 | c1t2 | control | Double-Blind | True | canagliflozin | SGLT2 | 100 | MG/DAY | ORAL | QAM | CAP | 73 | mITT | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 7.3 | percent | 0.4 | SD | LS Mean | 0.0 | percent | Mean | 7.3 | percent | 0.4 | SD | LS Mean | 0.0 | |||||||||||||||||
| similarity | 100 | 100 | 42 | 19 | 60 | 50 | 100 | 15 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 25 | 0 | 29 | 100 | 100 | 100 | 100 | 67 | 0 | 0 | 0 | 100 | 100 | 73 | 33 | 0 | 67 | 50 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| placebo;canagliflozin100mg;canagliflozin300mg | 100;300 | oncedaily | hba1c | 26 | 6 | c17t6 | test | Double-Blind | TRUE | Placebo;Canagliflozin 100 mg;Canagliflozin 300 mg | Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor | 100;300 | mg | Oral | Once Daily | 156;157;156 | 150 | mITT | ANCOVA | LOCF | 26 | WK | HbA1c | Mean | 8.1 | percent | 0.9 | SD | LS Mean | -0.13 | percent | LS Mean | -0.13 | percent | 48.7;48.4;55.8 | 56.8;57.4;56.1 | YR | ||||||||||||||||||
| canagliflozin | 300 | qam | hba1c | 26.0 | 17 | c17t6 | control | Double-Blind | True | canagliflozin | SGLT2 | 300 | MG/DAY | ORAL | QAM | CAP | 29 | mITT | LOCF | 26.0 | WK | HbA1c | Mean | 9.6 | percent | 0.5 | SD | LS Mean | -1.59 | percent | 0.24 | SE | -2.081 | -1.099 | LS Mean | 7.978 | percent | LS Mean | -16.618 | ||||||||||||||||
| similarity | 100 | 100 | 42 | 19 | 60 | 50 | 100 | 15 | 0 | 0 | 0 | 100 | 100 | 0 | 100 | 67 | 100 | 100 | 100 | 33 | 100 | 67 | 100 | 100 | 100 | 100 | 25 | 100 | 0 | 0 | 0 | 0 | 100 | 22 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| placebo;canagliflozin100mg;canagliflozin300mg | 100;300 | oncedaily | hba1c | 26 | 5 | c16t5 | test | Double-Blind | TRUE | Placebo;Canagliflozin 100 mg;Canagliflozin 300 mg | Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor | 100;300 | mg | Oral | Once Daily | 156;157;156 | 150 | mITT | ANCOVA | LOCF | 26 | WK | HbA1c | Mean | 8.1 | percent | 0.9 | SD | LS Mean | -0.13 | percent | LS Mean | -0.13 | percent | 48.7;48.4;55.8 | 56.8;57.4;56.1 | YR | ||||||||||||||||||
| canagliflozin | 100 | qam | hba1c | 26.0 | 16 | c16t5 | control | Double-Blind | True | canagliflozin | SGLT2 | 100 | MG/DAY | ORAL | QAM | CAP | 31 | mITT | ANCOVA | LOCF | 26.0 | WK | HbA1c | Mean | 9.6 | percent | 0.4 | SD | LS Mean | -1.55 | percent | 0.22 | SE | -1.999 | -1.101 | LS Mean | 8.018 | percent | LS Mean | -16.2 | |||||||||||||||
| similarity | 100 | 100 | 42 | 19 | 60 | 50 | 100 | 15 | 0 | 0 | 40 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | 100 | 33 | 100 | 67 | 100 | 100 | 100 | 100 | 25 | 100 | 0 | 0 | 0 | 0 | 100 | 44 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| 300 | oncedaily | hba1c | 52 | 0 | c14t0 | test | Double-Blind | TRUE | Canagliflozin | Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor | 300 | mg | Oral | Once Daily | 156 | 156 | mITT | Least Square Means | LOCF | 52 | WK | HbA1c | Mean | 8.1 | percent | 0.9 | SD | LS Mean | -0.97 | percent | -1.17 | -0.77 | 55.8 | 56.1 | YR | ||||||||||||||||||||
| qam | hba1c | 26.0 | 14 | c14t0 | control | Double-Blind | True | canagliflozin | SGLT2 | 300 | MG/DAY | ORAL | QAM | CAP | 49 | mITT | ANCOVA | LOCF | 26.0 | WK | HbA1c | Mean | 8.4 | percent | 0.3 | SD | LS Mean | -1.3 | percent | 0.12 | SE | -1.541 | -1.059 | LS Mean | 7.1 | percent | LS Mean | -15.476 | |||||||||||||||||
| similarity | 100 | 100 | 100 | 19 | 100 | 50 | 100 | 15 | 0 | 0 | 0 | 100 | 100 | 25 | 100 | 33 | 100 | 100 | 100 | 67 | 100 | 67 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 57 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| 100 | oncedaily | hba1c | 52 | 8 | c13t8 | test | Double-Blind | TRUE | Canagliflozin | Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor | 100 | mg | Oral | Once Daily | 157 | 157 | mITT | Least Square Means | LOCF | 52 | WK | HbA1c | Mean | 8.1 | percent | 0.9 | SD | LS Mean | -0.75 | percent | -0.95 | -0.55 | 48.4 | 57.4 | YR | ||||||||||||||||||||
| qam | hba1c | 26.0 | 13 | c13t8 | control | Double-Blind | True | canagliflozin | SGLT2 | 100 | MG/DAY | ORAL | QAM | CAP | 51 | mITT | ANCOVA | LOCF | 26.0 | WK | HbA1c | Mean | 8.4 | percent | 0.3 | SD | LS Mean | -1.02 | percent | 0.13 | SE | -1.281 | -0.759 | LS Mean | 7.38 | percent | LS Mean | -12.143 | |||||||||||||||||
| similarity | 100 | 100 | 100 | 19 | 100 | 50 | 100 | 15 | 0 | 0 | 40 | 100 | 100 | 25 | 100 | 33 | 100 | 100 | 100 | 67 | 100 | 67 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 50 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| 300 | oncedaily | hba1c | 26 | 1 | c11t1 | test | Double-Blind | TRUE | Canagliflozin | Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor | 300 | mg | Oral | Once Daily | 156 | 156 | mITT | Least Square Means | LOCF | 26 | WK | HbA1c | Mean | 8.1 | percent | 0.9 | SD | LS Mean | -1.06 | percent | LS Mean | -1.06 | percent | 55.8 | 56.1 | YR | |||||||||||||||||||
| qam | hba1c | 26.0 | 11 | c11t1 | control | Double-Blind | True | canagliflozin | SGLT2 | 300 | MG/DAY | ORAL | QAM | CAP | 74 | mITT | ANCOVA | LOCF | 26.0 | WK | HbA1c | Mean | 7.4 | percent | 0.3 | SD | LS Mean | -0.67 | percent | 0.09 | SE | -0.849 | -0.491 | LS Mean | 6.697 | percent | LS Mean | -9.095 | |||||||||||||||||
| similarity | 100 | 100 | 100 | 19 | 100 | 50 | 100 | 15 | 0 | 0 | 0 | 100 | 100 | 25 | 100 | 67 | 100 | 100 | 100 | 33 | 100 | 67 | 100 | 100 | 100 | 100 | 50 | 100 | 0 | 0 | 0 | 0 | 100 | 44 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| 100 | oncedaily | hba1c | 26 | 9 | c10t9 | test | Double-Blind | TRUE | Canagliflozin | Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor | 100 | mg | Oral | Once Daily | 157 | 157 | mITT | Least Square Means | LOCF | 26 | WK | HbA1c | Mean | 8.1 | percent | 0.9 | SD | LS Mean | -0.85 | percent | LS Mean | -0.85 | percent | 48.4 | 57.4 | YR | |||||||||||||||||||
| qam | hba1c | 26.0 | 10 | c10t9 | control | Double-Blind | True | canagliflozin | SGLT2 | 100 | MG/DAY | ORAL | QAM | CAP | 73 | mITT | ANCOVA | LOCF | 26.0 | WK | HbA1c | Mean | 7.3 | percent | 0.4 | SD | LS Mean | -0.47 | percent | 0.09 | SE | -0.649 | -0.291 | LS Mean | 6.897 | percent | LS Mean | -6.38 | |||||||||||||||||
| similarity | 100 | 100 | 100 | 19 | 100 | 50 | 100 | 15 | 0 | 0 | 40 | 100 | 100 | 25 | 100 | 67 | 100 | 100 | 100 | 33 | 100 | 67 | 100 | 100 | 100 | 100 | 50 | 100 | 0 | 0 | 0 | 0 | 100 | 44 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | |||||||
| placebo | 0 | qam | hba1c | 26.0 | 15 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QAM | CAP | 28 | mITT | ANCOVA | LOCF | 26.0 | WK | HbA1c | Mean | 9.5 | percent | 0.7 | SD | LS Mean | -0.44 | percent | 0.22 | SE | -0.891 | 0.011 | LS Mean | 9.128 | percent | LS Mean | -4.599 | ||||||||||||||||
| 12 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QAM | CAP | 48 | mITT | ANCOVA | LOCF | 26.0 | WK | HbA1c | Mean | 8.4 | percent | 0.3 | SD | LS Mean | -0.12 | percent | 0.12 | SE | -0.361 | 0.121 | LS Mean | 8.28 | percent | LS Mean | -1.429 | |||||||||||||||||||||
| 9 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QAM | CAP | 74 | mITT | ANCOVA | LOCF | 26.0 | WK | HbA1c | Mean | 7.4 | percent | 0.3 | SD | LS Mean | -0.02 | percent | 0.1 | SE | -0.219 | 0.179 | LS Mean | 7.347 | percent | LS Mean | -0.271 | |||||||||||||||||||||
| 0.0 | 6 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QAM | CAP | 28 | mITT | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 9.5 | percent | 0.7 | SD | LS Mean | 0.0 | percent | Mean | 9.5 | percent | 0.7 | SD | LS Mean | 0.0 | ||||||||||||||||||||||
| 3 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QAM | CAP | 48 | mITT | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 8.4 | percent | 0.3 | SD | LS Mean | 0.0 | percent | Mean | 8.4 | percent | 0.3 | SD | LS Mean | 0.0 | |||||||||||||||||||||||
| 0 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QAM | CAP | 74 | mITT | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 7.4 | percent | 0.3 | SD | LS Mean | 0.0 | percent | Mean | 7.4 | percent | 0.3 | SD | LS Mean | 0.0 | |||||||||||||||||||||||
| canagliflozin | 300 | qam | hba1c | 0.0 | 8 | control | Double-Blind | True | canagliflozin | SGLT2 | 300 | MG/DAY | ORAL | QAM | CAP | 29 | mITT | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 9.6 | percent | 0.5 | SD | LS Mean | 0.0 | percent | Mean | 9.6 | percent | 0.5 | SD | LS Mean | 0.0 | ||||||||||||||||||
| 5 | control | Double-Blind | True | canagliflozin | SGLT2 | 300 | MG/DAY | ORAL | QAM | CAP | 49 | mITT | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 8.4 | percent | 0.3 | SD | LS Mean | 0.0 | percent | Mean | 8.4 | percent | 0.3 | SD | LS Mean | 0.0 |
432_devineni_2012¶
Control rows matched by test output: 6 of 6
Literature data accuracy: 60.53%
Clinical data accuracy: 62.83%
Clinical data accuracy (drop unmatched): 62.83%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| canagliflozin | 300 | twicedaily | hba1c | 1 | 3 | c5t3 | test | Double-Blind | TRUE | Canagliflozin | SGLT2 inhibitor | 300 | mg | Oral | Twice Daily | 10 | 10 | FAS | ANCOVA | -1 | days | HbA1c | Mean | 8.42 | percent | 1.02 | s.d. | LSMean | -0.92 | percent | -0.92 | -0.17 | 30 | 42.7 | YR | ||||||||||||||||||||
| 600 | bid | hba1c | 3.8571429 | 5 | c5t3 | control | Double-Blind | True | canagliflozin | SGLT2 | 600 | MG/DAY | SC | BID | 10.0 | 10 | CO | 3.8571429 | WK | HbA1c | Mean | 8.42 | percent | 1.02 | SD | Mean | -0.92 | percent | 0.66 | SD | -1.385 | -0.455 | Mean | 7.5 | percent | Mean | -10.926 | 30.0 | 42.7 | YR | |||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 67 | 50 | 0 | 14 | 100 | 67 | 100 | 100 | 0 | 0 | 100 | 20 | 0 | 100 | 100 | 100 | 100 | 100 | 40 | 100 | 100 | 80 | 100 | 100 | 0 | 0 | 22 | 44 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | |||||||
| 100 | qd | hba1c | 27 | 4 | c4t4 | test | Double-Blind | TRUE | Canagliflozin | SGLT2 inhibitor | 100 | mg | Oral | QD | 10 | 10 | FAS | ANCOVA | 27 | days | HbA1c | Mean | 8.38 | percent | 0.88 | SD | LSMean | -0.73 | percent | -0.74 | -0.003 | 70 | 50.5 | YR | |||||||||||||||||||||
| 600 | bid | hba1c | 0.0 | 4 | c4t4 | control | Double-Blind | True | canagliflozin | SGLT2 | 600 | MG/DAY | SC | BID | 10.0 | 10 | CO | 0.0 | WK | HbA1c | Mean | 8.42 | percent | 1.02 | SD | Mean | 0.0 | percent | Mean | 8.42 | percent | 1.02 | SD | Mean | 0.0 | 30.0 | 42.7 | YR | |||||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 67 | 50 | 0 | 40 | 100 | 67 | 100 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 100 | 50 | 100 | 50 | 100 | 100 | 100 | 80 | 57 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 33 | 25 | 100 | |||||||
| 300 | twicedaily | hba1c | 27 | 2 | c3t2 | test | Double-Blind | TRUE | Canagliflozin | SGLT2 inhibitor | 300 | mg | Oral | Twice Daily | 10 | 10 | FAS | ANCOVA | 27 | days | HbA1c | Mean | 8.42 | percent | 1.02 | s.d. | LSMean | -0.92 | percent | -0.92 | -0.17 | LSMean | 30 | 42.7 | YR | ||||||||||||||||||||
| 100 | qam | hba1c | 3.8571429 | 3 | c3t2 | control | Double-Blind | True | canagliflozin | SGLT2 | 100 | MG/DAY | SC | QAM | 10.0 | 10 | CO | 3.8571429 | WK | HbA1c | Mean | 8.38 | percent | 0.88 | SD | Mean | -0.73 | percent | 0.5 | SD | -1.082 | -0.378 | Mean | 7.65 | percent | Mean | -8.711 | 70.0 | 50.5 | YR | |||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 67 | 50 | 0 | 14 | 100 | 67 | 100 | 100 | 0 | 0 | 100 | 18 | 0 | 100 | 100 | 50 | 100 | 50 | 40 | 100 | 100 | 80 | 50 | 100 | 0 | 0 | 44 | 67 | 80 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 33 | 25 | 100 | |||||||
| qd | hba1c | 1 | 5 | c2t5 | test | Double-Blind | TRUE | Canagliflozin | SGLT2 inhibitor | 100 | mg | Oral | QD | 10 | 10 | FAS | ANCOVA | -1 | days | HbA1c | Mean | 8.38 | percent | 0.88 | s.d. | LSMean | -0.73 | percent | -0.74 | -0.003 | 70 | 50.5 | YR | ||||||||||||||||||||||
| qam | hba1c | 0.0 | 2 | c2t5 | control | Double-Blind | True | canagliflozin | SGLT2 | 100 | MG/DAY | SC | QAM | 10.0 | 10 | CO | 0.0 | WK | HbA1c | Mean | 8.38 | percent | 0.88 | SD | Mean | 0.0 | percent | Mean | 8.38 | percent | 0.88 | SD | Mean | 0.0 | 70.0 | 50.5 | YR | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 0 | 40 | 100 | 67 | 100 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 40 | 100 | 100 | 80 | 57 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | |||||||
| placebo | hba1c | 27 | 1 | c1t1 | test | Double-Blind | TRUE | Placebo | 9 | 7 | FAS | ANCOVA | 27 | days | HbA1c | Mean | 7.99 | percent | 0.52 | SD | LSMean | -0.19 | percent | 56 | 52.8 | YR | |||||||||||||||||||||||||||||
| 0 | hba1c | 3.8571429 | 1 | c1t1 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | SC | 7.0 | 7 | CO | 3.8571429 | WK | HbA1c | Mean | 7.99 | percent | 0.52 | SD | Mean | -0.19 | percent | 0.49 | SD | -0.628 | 0.248 | Mean | 7.8 | percent | Mean | -2.378 | 56.0 | 52.8 | YR | |||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 0 | 100 | 100 | 0 | 0 | 100 | 18 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 80 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | |||||||
| hba1c | 1 | 0 | c0t0 | test | Double-Blind | TRUE | Placebo | 9 | 7 | FAS | ANCOVA | -1 | HbA1c | Mean | 7.99 | percent | 0.52 | SD | LSMean | -0.19 | percent | 56 | 52.8 | YR | |||||||||||||||||||||||||||||||
| 0 | hba1c | 0.0 | 0 | c0t0 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | SC | 7.0 | 7 | CO | 0.0 | WK | HbA1c | Mean | 7.99 | percent | 0.52 | SD | Mean | 0.0 | percent | Mean | 7.99 | percent | 0.52 | SD | Mean | 0.0 | 56.0 | 52.8 | YR | |||||||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 0 | 100 | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 80 | 57 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 67 | 100 | 100 |
678_rosenstock_2015¶
Control rows matched by test output: 6 of 6
Literature data accuracy: 81.33%
Clinical data accuracy: 72.19%
Clinical data accuracy (drop unmatched): 72.19%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| empagliflozin | 25 | oncedaily | hba1c | 78 | 0 | c5t0 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 25 | mg | Oral | Once Daily | 155 | 110 | FAS-18 completers | ANCOVA | LOCF | 78 | WK | HbA1c | Mean | 8.3 | percent | 0.1 | SE | Adjusted Mean | -0.6 | percent | 0.1 | SE | -0.9 | -0.4 | Mean | 7.6 | percent | 0.1 | SE | 58.8 | YR | |||||||||||||
| qd | hba1c | 78.0 | 5 | c5t0 | control | Double-Blind | True | empagliflozin | SGLT2 | 25 | MG/DAY | ORAL | QD | 155.0 | 110 | FAS | ANCOVA | LOCF | 78.0 | WK | HbA1c | Mean | 8.34 | percent | 0.08 | SE | Mean | -0.68 | percent | 0.09 | SE | -0.858 | -0.502 | Mean | 7.6 | percent | 0.1 | SE | 7.402 | 7.798 | Mean | -8.193 | 60.0 | 59.9 | YR | ||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 100 | 75 | 100 | 100 | 30 | 100 | 100 | 67 | 100 | 100 | 100 | 86 | 100 | 57 | 100 | 100 | 100 | 47 | 86 | 100 | 57 | 100 | 50 | 50 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 50 | 100 | |||||||
| oncedaily | hba1c | 18 | 3 | c4t3 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 25 | mg | Oral | Once Daily | 155 | 117 | FAS-18 completers | ANCOVA | LOCF | 18 | WK | HbA1c | Mean | 8.3 | percent | 0.1 | SE | Adjusted Mean | -0.7 | percent | 0.1 | SE | -0.9 | -0.5 | Mean | 7.6 | percent | 0.1 | SE | 58.8 | YR | |||||||||||||||
| qd | hba1c | 18.0 | 4 | c4t3 | control | Double-Blind | True | empagliflozin | SGLT2 | 25 | MG/DAY | ORAL | QD | 155.0 | 117 | FAS | ANCOVA | LOCF | 18.0 | WK | HbA1c | Mean | 8.34 | percent | 0.08 | SE | Mean | -0.75 | percent | 0.08 | SE | -0.908 | -0.592 | Mean | 7.6 | percent | 0.1 | SE | 7.402 | 7.798 | Mean | -9.036 | 60.0 | 59.9 | YR | ||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 100 | 75 | 100 | 100 | 30 | 100 | 100 | 67 | 100 | 100 | 100 | 86 | 100 | 57 | 100 | 100 | 100 | 47 | 86 | 100 | 57 | 100 | 75 | 75 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 50 | 100 | |||||||
| 10 | oncedaily | hba1c | 78 | 12 | c3t12 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once Daily | 169 | 127 | FAS-18 completers | ANCOVA | LOCF | 78 | WK | HbA1c | Mean | 8.3 | percent | 0.1 | SE | Adjusted Mean | -0.5 | percent | 0.1 | SE | -0.7 | -0.2 | 7.8 | percent | 58.8 | YR | |||||||||||||||||
| qd | hba1c | 78.0 | 3 | c3t12 | control | Double-Blind | True | empagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | 169.0 | 127 | FAS | ANCOVA | LOCF | 78.0 | WK | HbA1c | Mean | 8.26 | percent | 0.07 | SE | Mean | -0.51 | percent | 0.09 | SE | -0.688 | -0.332 | Mean | 7.8 | percent | 0.1 | SE | 7.602 | 7.998 | Mean | -6.145 | 55.0 | 58.6 | YR | ||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 100 | 75 | 100 | 100 | 30 | 100 | 100 | 67 | 100 | 100 | 100 | 57 | 100 | 57 | 100 | 100 | 100 | 47 | 86 | 100 | 57 | 100 | 50 | 75 | 0 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 75 | 100 | |||||||
| oncedaily | hba1c | 18 | 15 | c2t15 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once Daily | 169 | 132 | FAS-18 completers | ANCOVA | LOCF | 18 | WK | HbA1c | Mean | 8.3 | percent | 0.1 | SE | Adjusted Mean | -0.6 | percent | 0.1 | SE | -0.8 | -0.4 | Mean | 7.7 | percent | 0.1 | SE | 58.8 | YR | |||||||||||||||
| qd | hba1c | 18.0 | 2 | c2t15 | control | Double-Blind | True | empagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | 169.0 | 132 | FAS | ANCOVA | LOCF | 18.0 | WK | HbA1c | Mean | 8.26 | percent | 0.07 | SE | Mean | -0.58 | percent | 0.07 | SE | -0.718 | -0.442 | Mean | 7.7 | percent | 0.1 | SE | 7.502 | 7.898 | Mean | -6.988 | 55.0 | 58.6 | YR | ||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 100 | 75 | 100 | 100 | 30 | 100 | 100 | 67 | 100 | 100 | 100 | 57 | 100 | 57 | 100 | 100 | 100 | 47 | 57 | 100 | 57 | 100 | 75 | 75 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 75 | 100 | |||||||
| placebo | oncedaily | hba1c | 78 | 6 | c1t6 | test | Double-Blind | TRUE | Placebo | Once Daily | 170 | 112 | FAS-18 completers | ANCOVA | LOCF | 78 | WK | HbA1c | Mean | 8.1 | percent | 0.1 | SE | Adjusted Mean | 0.0 | percent | 0.1 | SE | Mean | 8.1 | percent | 0.1 | SE | 58.8 | YR | ||||||||||||||||||||
| 0 | qd | hba1c | 78.0 | 1 | c1t6 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | 170.0 | 112 | FAS | ANCOVA | LOCF | 78.0 | WK | HbA1c | Mean | 8.1 | percent | 0.07 | SE | Mean | -0.05 | percent | 0.1 | SE | -0.248 | 0.148 | Mean | 8.1 | percent | 0.1 | SE | 7.902 | 8.298 | Mean | -0.617 | 53.0 | 58.1 | YR | |||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 17 | 100 | 75 | 100 | 100 | 30 | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 57 | 100 | 100 | 100 | 47 | 86 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 50 | 100 | |||||||
| oncedaily | hba1c | 18 | 9 | c0t9 | test | Double-Blind | TRUE | Placebo | Once Daily | 170 | 125 | FAS-18 completers | ANCOVA | LOCF | 18 | WK | HbA1c | Mean | 8.1 | percent | 0.1 | SE | Adjusted Mean | 0.0 | percent | 0.1 | SE | 8.1 | percent | 58.8 | YR | ||||||||||||||||||||||||
| 0 | qd | hba1c | 18.0 | 0 | c0t9 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | 170.0 | 125 | FAS | ANCOVA | LOCF | 18.0 | WK | HbA1c | Mean | 8.1 | percent | 0.07 | SE | Mean | 0.03 | percent | 0.07 | SE | -0.109 | 0.169 | Mean | 8.1 | percent | 0.1 | SE | 7.902 | 8.298 | Mean | 0.37 | 53.0 | 58.1 | YR | |||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 17 | 100 | 75 | 100 | 100 | 30 | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 57 | 100 | 100 | 100 | 47 | 86 | 100 | 57 | 100 | 0 | 0 | 0 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 50 | 100 | |||||||
| oncedaily | hba1c | 78 | 8 | test | Double-Blind | TRUE | Placebo | Once Daily | 170 | 112 | FAS | MMRM | OC | 78 | WK | HbA1c | Mean | 8.1 | percent | 0.1 | SE | Mean | 0.0 | percent | 0.1 | SE | Mean | 8.1 | percent | 0.1 | SE | 58.8 | YR | ||||||||||||||||||||||
| 7 | test | Double-Blind | TRUE | Placebo | Once Daily | 170 | 112 | FAS-78 completers | ANCOVA | LOCF | 78 | WK | HbA1c | Mean | 8.1 | percent | 0.1 | SE | Mean | 0.0 | percent | 0.1 | SE | Mean | 8.1 | percent | 0.1 | SE | 58.8 | YR | |||||||||||||||||||||||||
| 18 | 11 | test | Double-Blind | TRUE | Placebo | Once Daily | 170 | 125 | FAS | MMRM | OC | 18 | WK | HbA1c | Mean | 8.1 | percent | 0.1 | SE | Adjusted Mean | 0.0 | percent | 0.1 | SE | 8.1 | percent | 58.8 | YR | |||||||||||||||||||||||||||
| 10 | test | Double-Blind | TRUE | Placebo | Once Daily | 170 | 125 | FAS-78 completers | ANCOVA | LOCF | 18 | WK | HbA1c | Mean | 8.1 | percent | 0.1 | SE | Adjusted Mean | 0.0 | percent | 0.1 | SE | 8.1 | percent | 0.1 | SE | 58.8 | YR | ||||||||||||||||||||||||||
| empagliflozin | 25 | oncedaily | hba1c | 78 | 2 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 25 | mg | Oral | Once Daily | 155 | 110 | FAS | MMRM | OC | 78 | WK | HbA1c | Mean | 8.3 | percent | 0.1 | SE | LSMean | -0.6 | percent | 0.1 | SE | -0.9 | -0.4 | LSMean | 7.6 | percent | 58.8 | YR | ||||||||||||||||
| 1 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 25 | mg | Oral | Once Daily | 155 | 110 | FAS-78 completers | ANCOVA | LOCF | 78 | WK | HbA1c | Mean | 8.3 | percent | 0.1 | SE | Mean | -0.6 | percent | 0.1 | SE | -0.9 | -0.4 | Mean | 7.6 | percent | 0.1 | SE | 58.8 | YR | |||||||||||||||||||
| 18 | 5 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 25 | mg | Oral | Once Daily | 155 | 117 | FAS | MMRM | OC | 18 | WK | HbA1c | Mean | 8.3 | percent | 0.1 | SE | Adjusted Mean | -0.7 | percent | 0.1 | SE | Mean | 7.6 | percent | 0.1 | SE | 58.8 | YR | ||||||||||||||||||||
| 4 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 25 | mg | Oral | Once Daily | 155 | 117 | FAS-78 completers | ANCOVA | LOCF | 18 | WK | HbA1c | Mean | 8.3 | percent | 0.1 | SE | Adjusted Mean | -0.7 | percent | 0.1 | SE | -0.9 | -0.5 | Mean | 7.6 | percent | 0.1 | SE | 58.8 | YR | |||||||||||||||||||
| 10 | oncedaily | hba1c | 78 | 14 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once Daily | 169 | 127 | FAS | MMRM | OC | 78 | WK | HbA1c | Mean | 8.3 | percent | 0.1 | SE | LSMean | -0.5 | percent | 0.1 | SE | -0.7 | -0.2 | LSMean | 7.8 | percent | 58.8 | YR | |||||||||||||||||
| 13 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once Daily | 169 | 127 | FAS-78 completers | ANCOVA | LOCF | 78 | WK | HbA1c | Mean | 8.3 | percent | 0.1 | SE | Mean | -0.5 | percent | 0.1 | SE | -0.7 | -0.2 | Mean | 7.8 | percent | 0.1 | SE | 58.8 | YR | |||||||||||||||||||
| 18 | 17 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once Daily | 169 | 132 | FAS | MMRM | OC | 18 | WK | HbA1c | Mean | 8.3 | percent | 0.1 | SE | Adjusted Mean | -0.6 | percent | 0.1 | SE | -0.8 | -0.4 | 58.8 | YR | |||||||||||||||||||||||
| 16 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once Daily | 169 | 117 | FAS-78 completers | ANCOVA | LOCF | 18 | WK | HbA1c | Mean | 8.3 | percent | 0.1 | SE | Adjusted Mean | -0.7 | percent | 0.1 | SE | -0.9 | -0.5 | 7.6 | percent | 58.8 | YR |
566_fadini_2017¶
Control rows matched by test output: 2 of 4
Literature data accuracy: 63.60%
Clinical data accuracy: 36.63%
Clinical data accuracy (drop unmatched): 73.26%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| dapagliflozin | 10 | daily | hba1c | 12 | 0 | c3t0 | test | Single-Blind | TRUE | Dapagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Daily | 15 | 16 | 6 | PP | Least Square Means | 12 | WK | HbA1c | Mean | 8.2 | percent | 0.2 | SE | LSMean | -0.9 | percent | 0.2 | SE | LSMean | 7.3 | percent | 0.4 | SE | 68.8 | 66.3 | YR | ||||||||||||||
| qam | hba1c | 12.0 | 3 | c3t0 | control | Single-Blind | True | dapagliflozin | SGLT2 | 10 | MG | ORAL | QAM | TAB | 17.0 | 17 | CO | Student T Test | 12.0 | WK | HbA1c | Mean | 8.2 | percent | 0.2 | SE | Mean | -0.9 | percent | 0.2 | SE | -1.322 | -0.478 | Mean | 7.3 | percent | 0.4 | SE | 6.456 | 8.144 | Mean | -10.976 | 68.8 | 66.3 | YR | ||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 100 | 100 | 25 | 0 | 33 | 50 | 0 | 0 | 38 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 80 | 100 | 100 | 100 | 100 | 0 | 0 | 80 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | hba1c | 12 | 1 | c1t1 | test | Single-Blind | TRUE | Placebo | 16 | 16 | CO | Paired Student's t test | 12 | WK | HbA1c | Mean | 8.2 | percent | 0.2 | SE | Mean | 0.4 | percent | 0.2 | SE | Mean | 8.6 | percent | 0.4 | SE | 66.7 | 61.0 | YR | ||||||||||||||||||||||
| 0 | qam | hba1c | 12.0 | 1 | c1t1 | control | Single-Blind | True | placebo | Placebo | 0 | MG | ORAL | QAM | TAB | 16.0 | 16 | CO | Student T Test | 12.0 | WK | HbA1c | Mean | 8.2 | percent | 0.2 | SE | Mean | 0.4 | percent | 0.2 | SE | -0.024 | 0.824 | Mean | 8.6 | percent | 0.4 | SE | 7.752 | 9.448 | Mean | 4.878 | 66.7 | 61.0 | YR | |||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 67 | 100 | 100 | 100 | 76 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 0.0 | 0 | control | Single-Blind | True | placebo | Placebo | 0 | MG | ORAL | QAM | TAB | 16.0 | 16 | CO | Student T Test | 0.0 | WK | HbA1c | Mean | 8.2 | percent | 0.2 | SE | Mean | 0.0 | percent | Mean | 8.2 | percent | 0.2 | SE | Mean | 0.0 | 66.7 | 61.0 | YR | |||||||||||||||||||
| dapagliflozin | 10 | qam | hba1c | 0.0 | 2 | control | Single-Blind | True | dapagliflozin | SGLT2 | 10 | MG | ORAL | QAM | TAB | 17.0 | 17 | CO | Student T Test | 0.0 | WK | HbA1c | Mean | 8.2 | percent | 0.2 | SE | Mean | 0.0 | percent | Mean | 8.2 | percent | 0.2 | SE | Mean | 0.0 | 68.8 | 66.3 | YR |
705_roden_2015¶
Control rows matched by test output: 4 of 4
Literature data accuracy: 67.40%
Clinical data accuracy: 77.33%
Clinical data accuracy (drop unmatched): 77.33%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| sitagliptin | 100 | oncedaily | hba1c | 76 | 6 | c3t6 | test | Double-Blind | TRUE | Sitagliptin | DPP-4 inhibitor | 100 | mg | Oral | Once daily | 223 | 223 | FAS | ANCOVA | LOCF | 76 | WK | HbA1c | Mean | 7.85 | percent | 0.79 | SD | Adjusted Mean | -0.53 | percent | 0.06 | SE | Adjusted Mean | 7.34 | percent | 0.06 | SE | 63.2 | 55.1 | YR | ||||||||||||||
| qd | hba1c | 76.0 | 3 | c3t6 | control | Double-Blind Extension | True | sitagliptin | DPP4 | 100 | MG/DAY | ORAL | QD | TAB | 223.0 | 223 | FAS | ANCOVA | LOCF | 76.0 | WK | HbA1c | Mean | 7.85 | percent | 0.79 | SD | LS Mean | -0.53 | percent | 0.06 | SE | -0.648 | -0.412 | LS Mean | 7.34 | percent | 0.06 | SE | 7.222 | 7.458 | LS Mean | -6.732 | 63.2 | 55.1 | YR | |||||||||
| similarity | 71 | 100 | 100 | 32 | 100 | 50 | 100 | 17 | 0 | 75 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 60 | 100 | 100 | 100 | 100 | 0 | 0 | 60 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| empagliflozin | 25mg | oncedaily | hba1c | 76 | 0 | c2t0 | test | Double-Blind | TRUE | Empagliflozin | SGLT2 inhibitor | 25mg | mg | Oral | Once daily | 224 | 224 | FAS | ANCOVA | LOCF | 76 | WK | HbA1c | Mean | 7.86 | percent | 0.85 | SD | Adjusted Mean | -0.76 | percent | 0.06 | SE | -1.04 | -0.73 | Adjusted Mean | 7.12 | percent | 0.06 | SE | 64.7 | 53.8 | YR | ||||||||||||
| 25 | qd | hba1c | 76.0 | 2 | c2t0 | control | Double-Blind Extension | True | empagliflozin | SGLT2 | 25 | MG/DAY | ORAL | QD | TAB | 224.0 | 224 | FAS | ANCOVA | LOCF | 76.0 | WK | HbA1c | Mean | 7.86 | percent | 0.85 | SD | LS Mean | -0.76 | percent | 0.06 | SE | -0.878 | -0.642 | LS Mean | 7.12 | percent | 0.06 | SE | 7.002 | 7.238 | LS Mean | -9.654 | 64.7 | 53.8 | YR | ||||||||
| similarity | 71 | 100 | 100 | 50 | 67 | 50 | 100 | 17 | 0 | 75 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 60 | 100 | 100 | 100 | 100 | 44 | 44 | 60 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| 10 | oncedaily | hba1c | 76 | 3 | c1t3 | test | Double-Blind | TRUE | Empagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 224 | 224 | FAS | ANCOVA | LOCF | 76 | WK | HbA1c | Mean | 7.87 | percent | 0.88 | SD | Adjusted Mean | -0.65 | percent | 0.06 | SE | -0.94 | -0.63 | Adjusted Mean | 7.22 | percent | 0.06 | SE | 63.4 | 56.2 | YR | |||||||||||||
| qd | hba1c | 76.0 | 1 | c1t3 | control | Double-Blind Extension | True | empagliflozin | SGLT2 | 10 | MG/DAY | ORAL | QD | TAB | 224.0 | 224 | FAS | ANCOVA | LOCF | 76.0 | WK | HbA1c | Mean | 7.87 | percent | 0.88 | SD | LS Mean | -0.65 | percent | 0.06 | SE | -0.768 | -0.532 | LS Mean | 7.22 | percent | 0.06 | SE | 7.102 | 7.338 | LS Mean | -8.256 | 63.4 | 56.2 | YR | |||||||||
| similarity | 71 | 100 | 100 | 50 | 100 | 50 | 100 | 17 | 0 | 75 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 60 | 100 | 100 | 100 | 100 | 44 | 67 | 60 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| placebo | oncedaily | hba1c | 76 | 7 | c0t7 | test | Double-Blind | TRUE | Placebo | Once daily | 228 | 228 | FAS | ANCOVA | LOCF | 76 | WK | HbA1c | Mean | 7.91 | percent | 0.78 | SD | Adjusted Mean | 0.13 | percent | 0.06 | SE | Adjusted Mean | 8.01 | percent | 0.06 | SE | 53.9 | 54.9 | YR | |||||||||||||||||||
| 0 | qd | hba1c | 76.0 | 0 | c0t7 | control | Double-Blind Extension | True | placebo | Placebo | 0 | MG/DAY | ORAL | QD | TAB | 228.0 | 228 | FAS | ANCOVA | LOCF | 76.0 | WK | HbA1c | Mean | 7.91 | percent | 0.78 | SD | LS Mean | 0.13 | percent | 0.06 | SE | 0.012 | 0.248 | LS Mean | 8.01 | percent | 0.06 | SE | 7.892 | 8.128 | LS Mean | 1.651 | 53.9 | 54.9 | YR | ||||||||
| similarity | 71 | 100 | 100 | 0 | 0 | 0 | 0 | 17 | 0 | 75 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 60 | 100 | 100 | 100 | 100 | 0 | 0 | 60 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| empagliflozin | 25mg | oncedaily | hba1c | 76 | 2 | test | Double-Blind | TRUE | Empagliflozin | SGLT2 inhibitor | 25mg | mg | Oral | Once daily | 224 | 224 | FAS-completers | MMRM | OC | 76 | WK | HbA1c | Mean | 7.86 | percent | 0.85 | SD | LS Mean | -0.76 | percent | 0.06 | SE | -1.04 | -0.73 | LS Mean | 7.12 | percent | 0.06 | SE | 64.7 | 53.8 | YR | |||||||||||||
| 1 | test | Double-Blind | TRUE | Empagliflozin | SGLT2 inhibitor | 25mg | mg | Oral | Once daily | 224 | 224 | FAS | MMRM | OC | 76 | WK | HbA1c | Mean | 7.86 | percent | 0.85 | SD | LS Mean | -0.76 | percent | -1.04 | -0.73 | LS Mean | 7.12 | percent | 64.7 | 53.8 | YR | ||||||||||||||||||||||
| 10 | oncedaily | hba1c | 76 | 5 | test | Double-Blind | TRUE | Empagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 224 | 224 | FAS-completers | MMRM | OC | 76 | WK | HbA1c | Mean | 7.87 | percent | 0.88 | SD | LS Mean | -0.65 | percent | 0.06 | SE | -0.94 | -0.63 | LS Mean | 7.22 | percent | 0.06 | SE | 63.4 | 56.2 | YR | ||||||||||||||
| 4 | test | Double-Blind | TRUE | Empagliflozin | SGLT2 inhibitor | 10 | mg | Oral | Once daily | 224 | 224 | FAS | MMRM | OC | 76 | WK | HbA1c | Mean | 7.87 | percent | 0.88 | SD | LS Mean | -0.65 | percent | -0.94 | -0.63 | LS Mean | 7.22 | percent | 63.4 | 56.2 | YR |
2069_hattori_2018¶
Control rows matched by test output: 2 of 4
Literature data accuracy: 73.60%
Clinical data accuracy: 40.70%
Clinical data accuracy (drop unmatched): 81.41%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| empagliflozin | 10 | oncedaily | hba1c | 12 | 0 | c3t0 | test | Open-Label | TRUE | Empagliflozin | Sodium-glucose cotransporter-2 (SGLT2) inhibitor | 10 | mg | Oral | Once daily | 58 | 58 | ITT | 12 | WK | HbA1c | Mean | 7.37 | percent | 1.34 | SD | Mean | -0.49 | percent | 1.1 | SD | Mean | 6.97 | percent | 0.94 | SD | Mean | -5.4 | 38-74 | YR | |||||||||||||||
| qd | hba1c | 12.0 | 3 | c3t0 | control | Open-Label | True | empagliflozin | SGLT2 | 10 | MG/DAY | QD | 58.0 | 58 | 12.0 | WK | HbA1c | Mean | 7.37 | percent | 1.34 | SD | Mean | -0.49 | percent | 1.1 | SD | Mean | 6.97 | percent | 0.94 | SD | Mean | -5.4 | |||||||||||||||||||||
| similarity | 100 | 100 | 100 | 20 | 100 | 50 | 0 | 17 | 100 | 67 | 100 | 100 | 0 | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | |||||||
| oncedaily | hba1c | 0 | 1 | c2t1 | test | Open-Label | TRUE | Empagliflozin | Sodium-glucose cotransporter-2 (SGLT2) inhibitor | 10 | mg | Oral | Once daily | 58 | 58 | ITT | 0 | WK | HbA1c | Mean | 7.37 | percent | 1.34 | SD | Mean | -0.49 | percent | 1.1 | SD | Mean | 6.97 | percent | 0.94 | SD | Mean | -5.4 | 38-74 | YR | |||||||||||||||||
| qd | hba1c | 0.0 | 2 | c2t1 | control | Open-Label | True | empagliflozin | SGLT2 | 10 | MG/DAY | QD | 58.0 | 58 | 0.0 | WK | HbA1c | Mean | 7.37 | percent | 1.34 | SD | Mean | 0.0 | percent | Mean | 7.37 | percent | 1.34 | SD | Mean | 0.0 | |||||||||||||||||||||||
| similarity | 100 | 100 | 100 | 20 | 100 | 50 | 0 | 17 | 100 | 67 | 100 | 100 | 0 | 100 | 100 | 50 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 57 | 100 | 0 | 0 | 100 | 100 | 100 | 50 | 100 | 50 | 100 | 100 | 100 | 100 | 33 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | |||||||
| placebo | 0 | qd | hba1c | 12.0 | 1 | control | Open-Label | True | placebo | Placebo | 0 | MG/DAY | QD | 51.0 | 51 | 12.0 | WK | HbA1c | Mean | 6.91 | percent | 0.61 | SD | Mean | 0.07 | percent | 0.37 | SD | Mean | 6.95 | percent | 0.58 | SD | Mean | 0.5 | ||||||||||||||||||||
| 0.0 | 0 | control | Open-Label | True | placebo | Placebo | 0 | MG/DAY | QD | 51.0 | 51 | 0.0 | WK | HbA1c | Mean | 6.91 | percent | 0.61 | SD | Mean | 0.0 | percent | Mean | 6.91 | percent | 0.61 | SD | Mean | 0.0 |
1027_kashiwagi_2015¶
Control rows matched by test output: 2 of 2
Literature data accuracy: 72.33%
Clinical data accuracy: 72.22%
Clinical data accuracy (drop unmatched): 72.22%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| ipragliflozin;placebo | oncedaily;oncedaily | hba1c | 24 | 1 | c1t1 | test | Double-Blind | TRUE | Ipragliflozin; Placebo | SGLT2 inhibitor | Oral; Oral | Once daily; Once daily | 112; 56 | 56 | FAS | ANCOVA | LOCF | 24 | WK | HbA1c | Mean | 8.38 | percent | 0.738 | SD | Mean | -0.87 | percent | 0.655 | SD | -1.501 | -1.095 | Mean | 7.38 | percent | 0.712 | SD | 58.9; 58.9 | 56.2; 57.7 | years; years | |||||||||||||||
| ipragliflozin | 50 | qd | hba1c | 24.0 | 1 | c1t1 | control | Double-Blind | True | ipragliflozin | SGLT2 | 50 | MG/DAY | QD | 112.0 | 112 | FAS | LOCF | 24.0 | WK | HbA1c | Mean | 8.25 | percent | 0.719 | SD | Mean | -0.87 | percent | 0.655 | SD | -0.993 | -0.747 | Mean | 7.38 | percent | 0.712 | SD | 7.247 | 7.513 | Mean | -10.545 | 58.9 | 56.2 | YR | ||||||||||
| similarity | 100 | 100 | 76 | 50 | 0 | 0 | 0 | 9 | 100 | 55 | 0 | 100 | 100 | 0 | 100 | 67 | 100 | 100 | 100 | 50 | 100 | 60 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 20 | 40 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 62 | 62 | 31 | |||||||
| placebo | oncedaily | hba1c | 24 | 3 | c0t3 | test | Double-Blind | TRUE | Placebo | Once daily | 56 | 56 | FAS | ANCOVA | LOCF | 24 | WK | HbA1c | Mean | 8.38 | percent | 0.738 | SD | Mean | 0.38 | percent | 0.703 | SD | Mean | 8.76 | percent | 0.912 | SD | 58.9 | 57.7 | YR | |||||||||||||||||||
| 0 | qd | hba1c | 24.0 | 0 | c0t3 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | QD | 56.0 | 56 | FAS | LOCF | 24.0 | WK | HbA1c | Mean | 8.38 | percent | 0.738 | SD | Mean | 0.38 | percent | 0.703 | SD | 0.192 | 0.568 | Mean | 8.76 | percent | 0.912 | SD | 8.516 | 9.004 | Mean | 4.535 | 58.9 | 57.7 | YR | |||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 17 | 100 | 67 | 100 | 100 | 100 | 0 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| oncedaily | hba1c | 0 | 2 | test | Double-Blind | TRUE | Placebo | Once daily | 56 | 56 | FAS | ANCOVA | LOCF | 0 | HbA1c | Mean | 8.38 | percent | 0.738 | SD | Mean | 0.38 | percent | 0.703 | SD | Mean | 8.76 | percent | 0.912 | SD | 58.9 | 57.7 | YR | ||||||||||||||||||||||
| ipragliflozin;placebo | oncedaily;oncedaily | hba1c | 0 | 0 | test | Double-Blind | TRUE | Ipragliflozin; Placebo | SGLT2 inhibitor | Oral; Oral | Once daily; Once daily | 112; 56 | 56 | FAS | ANCOVA | LOCF | 0 | HbA1c | Mean | 8.38 | percent | 0.738 | SD | Mean | 0.38 | percent | 0.703 | SD | 58.9; 58.9 | 56.2; 57.7 | years; years |
1783_pratley_2018¶
Control rows matched by test output: 5 of 5
Literature data accuracy: 72.53%
Clinical data accuracy: 75.96%
Clinical data accuracy (drop unmatched): 75.96%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| ertugliflozin;sitagliptin | 15;100 | oncedaily;oncedaily | hba1c | 52 | 13 | c4t13 | test | Double-Blind | TRUE | ertugliflozin;sitagliptin | SGLT2 inhibitor;DPP-4 inhibitor | 15;100 | mg;mg | Oral;Oral | Once daily;Once daily | 244 | 244 | mITT | Least Square Means | MMRM | 52 | WK | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LSMean | -1.4 | percent | -1.5 | -1.3 | LSMean | 7.0 | percent | 6.9 | 7.1 | 51.6 | 55.1 | YR | ||||||||||||||
| qd;qd | hba1c | 52.0 | 4 | c4t13 | control | Double-Blind Extension | True | ertugliflozin;sitagliptin | SGLT2;DPP4 | 15;100 | MG/DAY;MG/DAY | ORAL | QD;QD | TAB;TAB | 244.0 | 244 | Treated | Constrained Longitudinal Data Analysis | 52.0 | WK | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LS Mean | -1.4 | percent | 95%CI | -1.5 | -1.3 | LS Mean | 7.18 | percent | LS Mean | -16.317 | 51.639 | 55.1 | YR | |||||||||||||||
| similarity | 71 | 100 | 100 | 44 | 100 | 56 | 62 | 23 | 0 | 75 | 100 | 100 | 36 | 29 | 0 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 92 | 100 | 100 | 100 | 0 | 100 | 100 | 92 | 57 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 80 | 100 | 100 | |||||||
| 5;100 | oncedaily;oncedaily | hba1c | 52 | 10 | c3t10 | test | Double-Blind | TRUE | ertugliflozin; sitagliptin | SGLT2 inhibitor; DPP-4 inhibitor | 5; 100 | mg; mg | Oral; Oral | Once daily; Once daily | 243 | 243 | mITT | Least Square Means | MMRM | 52 | WK | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LSMean | -1.4 | percent | -1.5 | -1.2 | LSMean | 7.0 | percent | 7.0 | 7.0 | 50.6 | 55.2 | YR | |||||||||||||||
| qd;qd | hba1c | 52.0 | 3 | c3t10 | control | Double-Blind Extension | True | ertugliflozin;sitagliptin | SGLT2;DPP4 | 5;100 | MG/DAY;MG/DAY | ORAL | QD;QD | TAB;TAB | 243.0 | 243 | Treated | Constrained Longitudinal Data Analysis | 52.0 | WK | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LS Mean | -1.4 | percent | 95%CI | -1.5 | -1.2 | LS Mean | 7.18 | percent | LS Mean | -16.317 | 50.617 | 55.2 | YR | |||||||||||||||
| similarity | 71 | 100 | 100 | 44 | 100 | 56 | 62 | 23 | 0 | 75 | 100 | 100 | 36 | 29 | 0 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 92 | 100 | 100 | 100 | 0 | 100 | 100 | 92 | 57 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 80 | 100 | 100 | |||||||
| ertugliflozin15mg | 15 | oncedaily | hba1c | 52 | 2 | c2t2 | test | Double-Blind | TRUE | ertugliflozin 15 mg | SGLT2 inhibitor | 15 | mg | Oral | Once daily | 248 | 248 | mITT | Least Square Means | MMRM | 52 | WK | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LS Mean | -0.9 | percent | -1.1 | -0.8 | LS Mean | 7.4 | percent | 7.4 | 7.4 | 54.0 | 55.3 | YR | ||||||||||||||
| ertugliflozin | 15 | qd | hba1c | 52.0 | 2 | c2t2 | control | Double-Blind Extension | True | ertugliflozin | SGLT2 | 15 | MG/DAY | ORAL | QD | TAB | 248.0 | 248 | Treated | Constrained Longitudinal Data Analysis | 52.0 | WK | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LS Mean | -0.9 | percent | 95%CI | -1.1 | -0.8 | LS Mean | 7.68 | percent | LS Mean | -10.49 | 54.032 | 55.3 | YR | |||||||||||||
| similarity | 71 | 100 | 81 | 50 | 100 | 50 | 100 | 17 | 0 | 75 | 100 | 100 | 36 | 29 | 0 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 57 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 80 | 100 | 100 | |||||||
| ertugliflozin5mg | 5 | oncedaily | hba1c | 52 | 5 | c1t5 | test | Double-Blind | TRUE | ertugliflozin 5 mg | SGLT2 inhibitor | 5 | mg | Oral | Once daily | 250 | 250 | mITT | Least Square Means | MMRM | 52 | WK | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LS Mean | -1.0 | percent | -1.1 | -0.8 | LS Mean | 7.4 | percent | 7.3 | 7.5 | 50.8 | 55.1 | YR | ||||||||||||||
| ertugliflozin | 5 | qd | hba1c | 52.0 | 1 | c1t5 | control | Double-Blind Extension | True | ertugliflozin | SGLT2 | 5 | MG/DAY | ORAL | QD | TAB | 250.0 | 250 | Treated | Constrained Longitudinal Data Analysis | 52.0 | WK | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LS Mean | -1.0 | percent | 95%CI | -1.1 | -0.8 | LS Mean | 7.58 | percent | LS Mean | -11.655 | 50.8 | 55.1 | YR | |||||||||||||
| similarity | 71 | 100 | 84 | 50 | 100 | 50 | 100 | 17 | 0 | 75 | 100 | 100 | 36 | 29 | 0 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 57 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||||
| sitagliptin | 100 | oncedaily | hba1c | 52 | 8 | c0t8 | test | Double-Blind | TRUE | sitagliptin | DPP-4 inhibitor | 100 | mg | Oral | Once daily | 247 | 247 | mITT | Least Square Means | MMRM | 52 | WK | HbA1c | Mean | 8.5 | percent | 1.0 | SD | LS Mean | -0.8 | percent | -1.0 | -0.7 | LS Mean | 7.3 | percent | 62.3 | 54.8 | YR | ||||||||||||||||
| qd | hba1c | 52.0 | 0 | c0t8 | control | Double-Blind Extension | True | sitagliptin | DPP4 | 100 | MG/DAY | ORAL | QD | TAB | 247.0 | 247 | Treated | Constrained Longitudinal Data Analysis | 52.0 | WK | HbA1c | Mean | 8.5 | percent | 1.0 | SD | LS Mean | -0.8 | percent | 95%CI | -1.0 | -0.7 | LS Mean | 7.78 | percent | LS Mean | -9.324 | 62.348 | 54.8 | YR | |||||||||||||||
| similarity | 71 | 100 | 100 | 32 | 100 | 50 | 100 | 17 | 0 | 75 | 100 | 100 | 36 | 29 | 0 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 57 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 80 | 100 | 100 | |||||||
| oncedaily | hba1c | 26 | 7 | test | Double-Blind | TRUE | sitagliptin | DPP-4 inhibitor | 100 | mg | Oral | Once daily | 247 | 247 | mITT | Least Square Means | MMRM | 26 | WK | HbA1c | Mean | 8.5 | percent | 1.0 | SD | LS Mean | -1.1 | percent | -1.2 | -0.9 | Mean | 7.3 | percent | 1.1 | SD | 62.3 | 54.8 | YR | |||||||||||||||||
| 0 | 6 | test | Double-Blind | TRUE | sitagliptin | DPP-4 inhibitor | 100 | mg | Oral | Once daily | 247 | 247 | mITT | Least Square Means | MMRM | 0 | HbA1c | Mean | 8.5 | percent | 1.0 | SD | LS Mean | -1.1 | percent | -1.2 | -0.9 | 62.3 | 54.8 | YR | |||||||||||||||||||||||||
| ertugliflozin;sitagliptin | 5;100 | oncedaily;oncedaily | hba1c | 26 | 9 | test | Double-Blind | TRUE | ertugliflozin; sitagliptin | SGLT2 inhibitor; DPP-4 inhibitor | 5; 100 | mg; mg | Oral; Oral | Once daily; Once daily | 243 | 243 | mITT | Least Square Means | MMRM | 26 | WK | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LSMean | -1.5 | percent | -1.6 | -1.4 | LSMean | 7.0 | percent | 7.0 | 7.0 | 50.6 | 55.2 | YR | |||||||||||||||
| 15;100 | oncedaily;oncedaily | hba1c | 26 | 12 | test | Double-Blind | TRUE | ertugliflozin;sitagliptin | SGLT2 inhibitor;DPP-4 inhibitor | 15;100 | mg;mg | Oral;Oral | Once daily;Once daily | 244 | 244 | mITT | Least Square Means | MMRM | 26 | WK | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LSMean | -1.5 | percent | -1.6 | -1.4 | LSMean | 7.0 | percent | 6.9 | 7.1 | 51.6 | 55.1 | YR | ||||||||||||||||
| 0 | 11 | test | Double-Blind | TRUE | ertugliflozin;sitagliptin | SGLT2 inhibitor;DPP-4 inhibitor | 15;100 | mg;mg | Oral;Oral | Once daily;Once daily | 244 | 244 | mITT | Least Square Means | MMRM | 0 | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LS Mean | 51.6 | 55.1 | YR | |||||||||||||||||||||||||||||
| ertugliflozin5mg | 5 | oncedaily | hba1c | 26 | 4 | test | Double-Blind | TRUE | ertugliflozin 5 mg | SGLT2 inhibitor | 5 | mg | Oral | Once daily | 250 | 250 | mITT | Least Square Means | MMRM | 26 | WK | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LS Mean | -1.0 | percent | 95% CI | -1.1 | -0.9 | Mean | 7.4 | percent | 0.9 | SD | 50.8 | 55.1 | YR | ||||||||||||||
| 0 | 3 | test | Double-Blind | TRUE | ertugliflozin 5 mg | SGLT2 inhibitor | 5 | mg | Oral | Once daily | 250 | 250 | mITT | Least Square Means | MMRM | 0 | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LS Mean | -1.0 | percent | -1.1 | -0.9 | 50.8 | 55.1 | YR | |||||||||||||||||||||||||
| ertugliflozin15mg | 15 | oncedaily | hba1c | 26 | 1 | test | Double-Blind | TRUE | ertugliflozin 15 mg | SGLT2 inhibitor | 15 | mg | Oral | Once daily | 248 | 248 | mITT | Least Square Means | MMRM | 26 | WK | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LS Mean | -1.1 | percent | 95% CI | -1.2 | -1.0 | Mean | 7.4 | percent | 1.0 | SD | 54.0 | 55.3 | YR | ||||||||||||||
| 0 | 0 | test | Double-Blind | TRUE | ertugliflozin 15 mg | SGLT2 inhibitor | 15 | mg | Oral | Once daily | 248 | 248 | mITT | Least Square Means | MMRM | 0 | HbA1c | Mean | 8.6 | percent | 1.0 | SD | LS Mean | -1.1 | percent | 95% CI | -1.2 | -1.0 | 54.0 | 55.3 | YR |
79_rosenstock_2013¶
Control rows matched by test output: 9 of 14
Literature data accuracy: 72.60%
Clinical data accuracy: 44.62%
Clinical data accuracy (drop unmatched): 69.41%
Test Output vs. Control Output and their Similarity¶
| Â | Â | Â | Â | Â | Â | Â | Â | ARM.BLIND | ARM.RANDFLG | ARM.TRT | ARM.TRTCLASS | ARM.DOSE | ARM.DOSEU | ARM.ROUTE | ARM.REGIMEN | ARM.FORMULATION | N.ARM | N.ARM.STATANAL | N.ARM.EVENT.SUBJ | STATANAL.POP | STATANAL.METHOD | STATANAL.IMP.METHOD | ARM.TIME1 | ARM.TIME1U | ENDPOINT | BSL.STAT | BSL.VAL | BSL.VALU | BSL.VAR | BSL.VARU | BSL.LCI | BSL.UCI | CHBSL.STAT | CHBSL.VAL | CHBSL.VALU | CHBSL.VAR | CHBSL.VARU | CHBSL.LCI | CHBSL.UCI | RSP.STAT | RSP.VAL | RSP.VALU | RSP.VAR | RSP.VARU | RSP.LCI | RSP.UCI | PCHBSL.STAT | PCHBSL.VAL | PCHBSL.VAR | PCHBSL.VARU | PCHBSL.LCI | PCHBSL.UCI | ARM.PCT.MALE | ARM.AGE | ARM.AGEU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARM.TRT | ARM.DOSE | ARM.REGIMEN | ENDPOINT | ARM.TIME1 | primary_key | match_key | sample | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
| empagliflozin | 25 | qd | hba1c | 12 | 5 | c9t5 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 25 | mg | Oral | QD | 70 | 70 | FAS | ANCOVA | LOCF | 12 | WK | HbA1c | Mean | 8.1 | percent | 0.8 | SD | LS Mean | -0.55 | percent | -0.70 | -0.40 | 47 | 59 | YR | |||||||||||||||||||
| 12.0 | 9 | c9t5 | control | Double-Blind | True | empagliflozin | SGLT2 | 25 | MG/DAY | QD | 70.0 | 70 | FAS | ANCOVA | LOCF | 12.0 | WK | HbA1c | Mean | 8.1 | percent | 0.8 | SD | LS Mean | -0.55 | percent | 95%CI | -0.7 | -0.4 | Mean | 7.421 | percent | LS Mean | -6.9 | 52.857 | 58.7 | YR | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 0 | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 73 | 22 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 25 | 33 | 100 | |||||||
| 10 | qd | hba1c | 12 | 3 | c7t3 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 10 | mg | Oral | QD | 71 | 71 | FAS | Linear ANCOVA | modified LOCF | 12 | WK | HbA1c | Mean | 7.9 | percent | 0.7 | SD | LS Mean | -0.56 | percent | 95% CI | -0.71 | -0.41 | LS Mean | -0.56 | percent | 95% CI | -0.71 | -0.41 | 41 | 60 | YR | |||||||||||||
| 12.0 | 7 | c7t3 | control | Double-Blind | True | empagliflozin | SGLT2 | 10 | MG/DAY | QD | 71.0 | 71 | FAS | ANCOVA | LOCF | 12.0 | WK | HbA1c | Mean | 7.9 | percent | 0.7 | SD | LS Mean | -0.56 | percent | 95%CI | -0.71 | -0.41 | Mean | 7.411 | percent | LS Mean | -7.025 | 46.479 | 59.0 | YR | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 0 | 100 | 100 | 67 | 100 | 100 | 100 | 63 | 47 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 73 | 22 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 25 | 33 | 100 | |||||||
| sitagliptin | 100 | qd | hba1c | 12 | 2 | c6t2 | test | Open-Label | TRUE | sitagliptin | DPP-4 inhibitor | 100 | mg | Oral | QD | 71 | 71 | Treated | ANCOVA | 12 | WK | HbA1c | Mean | 8.1 | percent | 0.9 | SD | LS Mean | -0.45 | percent | -0.65 | -0.25 | 54 | 58 | YR | ||||||||||||||||||||
| empagliflozin | 10 | qd | hba1c | 0.0 | 6 | c6t2 | control | Double-Blind | True | empagliflozin | SGLT2 | 10 | MG/DAY | QD | 71.0 | 71 | FAS | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 7.9 | percent | 0.7 | SD | LS Mean | 0.0 | percent | Mean | 7.9 | percent | 0.7 | SD | LS Mean | 0.0 | 46.479 | 59.0 | YR | |||||||||||||||
| similarity | 45 | 100 | 50 | 10 | 80 | 50 | 0 | 100 | 100 | 67 | 100 | 100 | 20 | 100 | 0 | 0 | 100 | 100 | 100 | 33 | 100 | 67 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 73 | 29 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 25 | 33 | 100 | |||||||
| 5 | qd | hba1c | 12 | 4 | c5t4 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 5 | mg | Oral | QD | 71 | 71 | FAS | Linear ANCOVA | modified LOCF | 12 | WK | HbA1c | Mean | 8.0 | percent | 0.7 | SD | LS Mean | -0.23 | percent | 95% CI | -0.39 | -0.08 | 41 | 60 | YR | |||||||||||||||||||
| 12.0 | 5 | c5t4 | control | Double-Blind | True | empagliflozin | SGLT2 | 5 | MG/DAY | QD | 71.0 | 71 | FAS | ANCOVA | LOCF | 12.0 | WK | HbA1c | Mean | 8.0 | percent | 0.7 | SD | LS Mean | -0.23 | percent | 95%CI | -0.39 | -0.08 | Mean | 7.741 | percent | LS Mean | -2.885 | 40.845 | 59.7 | YR | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 0 | 100 | 100 | 67 | 100 | 100 | 100 | 63 | 47 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 73 | 22 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 25 | 0 | 100 | |||||||
| 1 | qd | hba1c | 12 | 6 | c3t6 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 1 | mg | Oral | QD | 71 | 71 | FAS | Linear ANCOVA | modified LOCF | 12 | WK | HbA1c | Mean | 7.8 | percent | 0.7 | SD | LS Mean | -0.09 | percent | 95% CI | -0.24 | 0.07 | 58 | 57 | YR | |||||||||||||||||||
| 12.0 | 3 | c3t6 | control | Double-Blind | True | empagliflozin | SGLT2 | 1 | MG/DAY | QD | 71.0 | 71 | FAS | ANCOVA | LOCF | 12.0 | WK | HbA1c | Mean | 7.8 | percent | 0.7 | SD | LS Mean | -0.09 | percent | 95%CI | -0.24 | 0.07 | Mean | 7.881 | percent | LS Mean | -1.129 | 57.746 | 57.4 | YR | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 0 | 100 | 100 | 67 | 100 | 100 | 100 | 63 | 47 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 25 | 67 | 100 | |||||||
| placebo | qd | hba1c | 12 | 7 | c1t7 | test | Double-Blind | TRUE | Placebo | QD | 71 | 71 | FAS | linear ANCOVA | modified LOCF | 12 | WK | HbA1c | Mean | 8.0 | percent | 0.7 | SD | LS Mean | 0.15 | percent | 0.00 | 0.30 | LS Mean | 0.15 | percent | 0.00 | 0.30 | 47 | 60 | YR | |||||||||||||||||||
| 0 | qd | hba1c | 12.0 | 1 | c1t7 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | QD | 71.0 | 71 | FAS | ANCOVA | LOCF | 12.0 | WK | HbA1c | Mean | 8.0 | percent | 0.7 | SD | LS Mean | 0.15 | percent | 95%CI | 0.0 | 0.3 | Mean | 8.121 | percent | LS Mean | 1.882 | 46.479 | 59.7 | YR | |||||||||||||||
| similarity | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 67 | 100 | 100 | 100 | 63 | 47 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 86 | 86 | 73 | 22 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 50 | 0 | 100 | |||||||
| sitagliptin | 100 | qd | hba1c | 12 | 0 | c13t0 | test | Open-Label | TRUE | sitagliptin | DPP-4 inhibitor | 100 | mg | Oral | QD | 71 | 71 | 25 | FAS | Linear ANCOVA | Modified LOCF | 12 | WK | HbA1c | Mean | 8.1 | percent | 0.9 | SD | LSMean | -0.45 | percent | -0.65 | -0.25 | LSMean | 54 | 58 | YR | |||||||||||||||||
| 12.0 | 13 | c13t0 | control | Open-Label | True | sitagliptin | DPP4 | 100 | MG/DAY | QD | 71.0 | 71 | FAS | ANCOVA | LOCF | 12.0 | WK | HbA1c | Mean | 8.1 | percent | 0.9 | SD | LS Mean | -0.45 | percent | 95%CI | -0.65 | -0.25 | Mean | 7.521 | percent | LS Mean | -5.645 | 53.521 | 57.6 | YR | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 32 | 100 | 50 | 0 | 100 | 100 | 67 | 100 | 0 | 100 | 63 | 47 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 92 | 100 | 100 | 100 | 0 | 100 | 100 | 80 | 0 | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 100 | 25 | 33 | 100 | |||||||
| 12 | 1 | c12t1 | test | Open-Label | TRUE | sitagliptin | DPP-4 inhibitor | 100 | mg | Oral | QD | 71 | 71 | 24 | FAS | Logistic regression | Classical LOCF | 12 | WK | HbA1c | Mean | 8.1 | percent | 0.9 | SD | LS Mean | -0.45 | percent | -0.65 | -0.25 | 54 | 58 | YR | ||||||||||||||||||||||
| 0.0 | 12 | c12t1 | control | Open-Label | True | sitagliptin | DPP4 | 100 | MG/DAY | QD | 71.0 | 71 | FAS | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 8.1 | percent | 0.9 | SD | LS Mean | 0.0 | percent | Mean | 8.1 | percent | 0.9 | SD | LS Mean | 0.0 | 53.521 | 57.6 | YR | |||||||||||||||||||
| similarity | 100 | 100 | 100 | 32 | 100 | 50 | 0 | 100 | 100 | 67 | 100 | 0 | 100 | 16 | 44 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 73 | 29 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 25 | 33 | 100 | |||||||
| empagliflozin | 50 | qd | hba1c | 12 | 8 | c11t8 | test | Double-Blind | TRUE | empagliflozin | SGLT2 inhibitor | 50 | mg | Oral | QD | 70 | 70 | 34 | FAS | Linear ANCOVA | Modified LOCF | 12 | WK | HbA1c | Mean | 8.1 | percent | 0.8 | SD | LS Mean | -0.56 | percent | 95% CI | -0.70 | -0.40 | 53 | 59 | YR | |||||||||||||||||
| 12.0 | 11 | c11t8 | control | Double-Blind | True | empagliflozin | SGLT2 | 50 | MG/DAY | QD | 70.0 | 70 | FAS | ANCOVA | LOCF | 12.0 | WK | HbA1c | Mean | 7.9 | percent | 0.7 | SD | LS Mean | -0.49 | percent | 95%CI | -0.64 | -0.33 | Mean | 7.481 | percent | LS Mean | -6.147 | 55.714 | 55.9 | YR | ||||||||||||||||||
| similarity | 100 | 100 | 100 | 50 | 100 | 50 | 0 | 100 | 100 | 67 | 100 | 0 | 100 | 63 | 47 | 67 | 100 | 100 | 100 | 33 | 100 | 67 | 100 | 100 | 100 | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 73 | 22 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 | 25 | 67 | 100 | |||||||
| placebo | 0 | qd | hba1c | 0.0 | 0 | control | Double-Blind | True | placebo | Placebo | 0 | MG/DAY | QD | 71.0 | 71 | FAS | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 8.0 | percent | 0.7 | SD | LS Mean | 0.0 | percent | Mean | 8.0 | percent | 0.7 | SD | LS Mean | 0.0 | 46.479 | 59.7 | YR | ||||||||||||||||
| empagliflozin | 50 | qd | hba1c | 0.0 | 10 | control | Double-Blind | True | empagliflozin | SGLT2 | 50 | MG/DAY | QD | 70.0 | 70 | FAS | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 7.9 | percent | 0.7 | SD | LS Mean | 0.0 | percent | Mean | 7.9 | percent | 0.7 | SD | LS Mean | 0.0 | 55.714 | 55.9 | YR | ||||||||||||||||
| 5 | qd | hba1c | 0.0 | 4 | control | Double-Blind | True | empagliflozin | SGLT2 | 5 | MG/DAY | QD | 71.0 | 71 | FAS | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 8.0 | percent | 0.7 | SD | LS Mean | 0.0 | percent | Mean | 8.0 | percent | 0.7 | SD | LS Mean | 0.0 | 40.845 | 59.7 | YR | |||||||||||||||||
| 25 | qd | hba1c | 0.0 | 8 | control | Double-Blind | True | empagliflozin | SGLT2 | 25 | MG/DAY | QD | 70.0 | 70 | FAS | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 8.1 | percent | 0.8 | SD | LS Mean | 0.0 | percent | Mean | 8.1 | percent | 0.8 | SD | LS Mean | 0.0 | 52.857 | 58.7 | YR | |||||||||||||||||
| 1 | qd | hba1c | 0.0 | 2 | control | Double-Blind | True | empagliflozin | SGLT2 | 1 | MG/DAY | QD | 71.0 | 71 | FAS | ANCOVA | LOCF | 0.0 | WK | HbA1c | Mean | 7.8 | percent | 0.7 | SD | LS Mean | 0.0 | percent | Mean | 7.8 | percent | 0.7 | SD | LS Mean | 0.0 | 57.746 | 57.4 | YR |